The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES.
A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase.
Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY).
A glycoprotein that is important in the activation of CLASSICAL COMPLEMENT PATHWAY. C4 is cleaved by the activated COMPLEMENT C1S into COMPLEMENT C4A and COMPLEMENT C4B.
Complement activation initiated by the interaction of microbial ANTIGENS with COMPLEMENT C3B. When COMPLEMENT FACTOR B binds to the membrane-bound C3b, COMPLEMENT FACTOR D cleaves it to form alternative C3 CONVERTASE (C3BBB) which, stabilized by COMPLEMENT FACTOR P, is able to cleave multiple COMPLEMENT C3 to form alternative C5 CONVERTASE (C3BBB3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX.
A product of COMPLEMENT ACTIVATION cascade, regardless of the pathways, that forms transmembrane channels causing disruption of the target CELL MEMBRANE and cell lysis. It is formed by the sequential assembly of terminal complement components (COMPLEMENT C5B; COMPLEMENT C6; COMPLEMENT C7; COMPLEMENT C8; and COMPLEMENT C9) into the target membrane. The resultant C5b-8-poly-C9 is the "membrane attack complex" or MAC.
Complement activation initiated by the binding of COMPLEMENT C1 to ANTIGEN-ANTIBODY COMPLEXES at the COMPLEMENT C1Q subunit. This leads to the sequential activation of COMPLEMENT C1R and COMPLEMENT C1S subunits. Activated C1s cleaves COMPLEMENT C4 and COMPLEMENT C2 forming the membrane-bound classical C3 CONVERTASE (C4B2A) and the subsequent C5 CONVERTASE (C4B2A3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX.
A subcomponent of complement C1, composed of six copies of three polypeptide chains (A, B, and C), each encoded by a separate gene (C1QA; C1QB; C1QC). This complex is arranged in nine subunits (six disulfide-linked dimers of A and B, and three disulfide-linked homodimers of C). C1q has binding sites for antibodies (the heavy chain of IMMUNOGLOBULIN G or IMMUNOGLOBULIN M). The interaction of C1q and immunoglobulin activates the two proenzymes COMPLEMENT C1R and COMPLEMENT C1S, thus initiating the cascade of COMPLEMENT ACTIVATION via the CLASSICAL COMPLEMENT PATHWAY.
The larger fragment generated from the cleavage of COMPLEMENT C3 by C3 CONVERTASE. It is a constituent of the ALTERNATIVE PATHWAY C3 CONVERTASE (C3bBb), and COMPLEMENT C5 CONVERTASES in both the classical (C4b2a3b) and the alternative (C3bBb3b) pathway. C3b participates in IMMUNE ADHERENCE REACTION and enhances PHAGOCYTOSIS. It can be inactivated (iC3b) or cleaved by various proteases to yield fragments such as COMPLEMENT C3C; COMPLEMENT C3D; C3e; C3f; and C3g.
The smaller fragment generated from the cleavage of complement C3 by C3 CONVERTASE. C3a, a 77-amino acid peptide, is a mediator of local inflammatory process. It induces smooth MUSCLE CONTRACTION, and HISTAMINE RELEASE from MAST CELLS and LEUKOCYTES. C3a is considered an anaphylatoxin along with COMPLEMENT C4A; COMPLEMENT C5A; and COMPLEMENT C5A, DES-ARGININE.
C5 plays a central role in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C5 is cleaved by C5 CONVERTASE into COMPLEMENT C5A and COMPLEMENT C5B. The smaller fragment C5a is an ANAPHYLATOXIN and mediator of inflammatory process. The major fragment C5b binds to the membrane initiating the spontaneous assembly of the late complement components, C5-C9, into the MEMBRANE ATTACK COMPLEX.
Serum proteins that negatively regulate the cascade process of COMPLEMENT ACTIVATION. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host. The complement system is tightly regulated by inactivators that accelerate the decay of intermediates and certain cell surface receptors.
Molecules on the surface of some B-lymphocytes and macrophages, that recognize and combine with the C3b, C3d, C1q, and C4b components of complement.
A glycine-rich, heat-labile serum glycoprotein that contains a component of the C3 CONVERTASE ALTERNATE PATHWAY (C3bBb). Bb, a serine protease, is generated when factor B is cleaved by COMPLEMENT FACTOR D into Ba and Bb.
The minor fragment formed when C5 convertase cleaves C5 into C5a and COMPLEMENT C5B. C5a is a 74-amino-acid glycopeptide with a carboxy-terminal ARGININE that is crucial for its spasmogenic activity. Of all the complement-derived anaphylatoxins, C5a is the most potent in mediating immediate hypersensitivity (HYPERSENSITIVITY, IMMEDIATE), smooth MUSCLE CONTRACTION; HISTAMINE RELEASE; and migration of LEUKOCYTES to site of INFLAMMATION.
A 302-amino-acid fragment in the alpha chain (672-1663) of C3b. It is generated when C3b is inactivated (iC3b) and its alpha chain is cleaved by COMPLEMENT FACTOR I into C3c, and C3dg (955-1303) in the presence COMPLEMENT FACTOR H. Serum proteases further degrade C3dg into C3d (1002-1303) and C3g (955-1001).
A 63-kDa serum glycoprotein encoded by gene C9. Monomeric C9 (mC9) binds the C5b-8 complex to form C5b-9 which catalyzes the polymerization of C9 forming C5b-p9 (MEMBRANE ATTACK COMPLEX) and transmembrane channels leading to lysis of the target cell. Patients with C9 deficiency suffer from recurrent bacterial infections.
An important soluble regulator of the alternative pathway of complement activation (COMPLEMENT ACTIVATION PATHWAY, ALTERNATIVE). It is a 139-kDa glycoprotein expressed by the liver and secreted into the blood. It binds to COMPLEMENT C3B and makes iC3b (inactivated complement 3b) susceptible to cleavage by COMPLEMENT FACTOR I. Complement factor H also inhibits the association of C3b with COMPLEMENT FACTOR B to form the C3bB proenzyme, and promotes the dissociation of Bb from the C3bBb complex (COMPLEMENT C3 CONVERTASE, ALTERNATIVE PATHWAY).
The large fragment formed when COMPLEMENT C4 is cleaved by COMPLEMENT C1S. The membrane-bound C4b binds COMPLEMENT C2A, a SERINE PROTEASE, to form C4b2a (CLASSICAL PATHWAY C3 CONVERTASE) and subsequent C4b2a3b (CLASSICAL PATHWAY C5 CONVERTASE).
A component of the CLASSICAL COMPLEMENT PATHWAY. C2 is cleaved by activated COMPLEMENT C1S into COMPLEMENT C2B and COMPLEMENT C2A. C2a, the COOH-terminal fragment containing a SERINE PROTEASE, combines with COMPLEMENT C4B to form C4b2a (CLASSICAL PATHWAY C3 CONVERTASE) and subsequent C4b2a3b (CLASSICAL PATHWAY C5 CONVERTASE).
Compounds that negatively regulate the cascade process of COMPLEMENT ACTIVATION. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host.
The first complement component to act in the activation of CLASSICAL COMPLEMENT PATHWAY. It is a calcium-dependent trimolecular complex made up of three subcomponents: COMPLEMENT C1Q; COMPLEMENT C1R; and COMPLEMENT C1S at 1:2:2 ratios. When the intact C1 binds to at least two antibodies (involving C1q), C1r and C1s are sequentially activated, leading to subsequent steps in the cascade of COMPLEMENT ACTIVATION.
Serum peptides derived from certain cleaved COMPLEMENT PROTEINS during COMPLEMENT ACTIVATION. They induce smooth MUSCLE CONTRACTION; mast cell HISTAMINE RELEASE; PLATELET AGGREGATION; and act as mediators of the local inflammatory process. The order of anaphylatoxin activity from the strongest to the weakest is C5a, C3a, C4a, and C5a des-arginine.
Serine proteases that cleave COMPLEMENT C3 into COMPLEMENT C3A and COMPLEMENT C3B, or cleave COMPLEMENT C5 into COMPLEMENT C5A and COMPLEMENT C5B. These include the different forms of C3/C5 convertases in the classical and the alternative pathways of COMPLEMENT ACTIVATION. Both cleavages take place at the C-terminal of an ARGININE residue.
GPI-linked membrane proteins broadly distributed among hematopoietic and non-hematopoietic cells. CD55 prevents the assembly of C3 CONVERTASE or accelerates the disassembly of preformed convertase, thus blocking the formation of the membrane attack complex.
A 206-amino-acid fragment in the alpha chain (672-1663) of C3b. It is generated when C3b is inactivated (iC3b) and its alpha chain is cleaved by COMPLEMENT FACTOR I into C3c (749-954), and C3dg (955-1303) in the presence COMPLEMENT FACTOR H.
A 53-kDa protein that is a positive regulator of the alternate pathway of complement activation (COMPLEMENT ACTIVATION PATHWAY, ALTERNATIVE). It stabilizes the ALTERNATIVE PATHWAY C3 CONVERTASE (C3bBb) and protects it from rapid inactivation, thus facilitating the cascade of COMPLEMENT ACTIVATION and the formation of MEMBRANE ATTACK COMPLEX. Individuals with mutation in the PFC gene exhibit properdin deficiency and have a high susceptibility to infections.
Molecular sites on or in some B-lymphocytes and macrophages that recognize and combine with COMPLEMENT C3B. The primary structure of these receptors reveal that they contain transmembrane and cytoplasmic domains, with their extracellular portion composed entirely of thirty short consensus repeats each having 60 to 70 amino acids.
A screening assay for circulating COMPLEMENT PROTEINS. Diluted SERUM samples are added to antibody-coated ERYTHROCYTES and the percentage of cell lysis is measured. The values are expressed by the so called CH50, in HEMOLYTIC COMPLEMENT units per milliliter, which is the dilution of serum required to lyse 50 percent of the erythrocytes in the assay.
A serum protein that regulates the CLASSICAL COMPLEMENT ACTIVATION PATHWAY. It binds as a cofactor to COMPLEMENT FACTOR I which then hydrolyzes the COMPLEMENT C4B in the CLASSICAL PATHWAY C3 CONVERTASE (C4bC2a).
A specific mannose-binding member of the collectin family of lectins. It binds to carbohydrate groups on invading pathogens and plays a key role in the MANNOSE-BINDING LECTIN COMPLEMENT PATHWAY.
A serum protein which is important in the ALTERNATIVE COMPLEMENT ACTIVATION PATHWAY. This enzyme cleaves the COMPLEMENT C3B-bound COMPLEMENT FACTOR B to form C3bBb which is ALTERNATIVE PATHWAY C3 CONVERTASE.
Venoms from snakes of the genus Naja (family Elapidae). They contain many specific proteins that have cytotoxic, hemolytic, neurotoxic, and other properties. Like other elapid venoms, they are rich in enzymes. They include cobramines and cobralysins.
A 105-kDa serum glycoprotein with significant homology to the other late complement components, C7-C9. It is a polypeptide chain cross-linked by 32 disulfide bonds. C6 is the next complement component to bind to the membrane-bound COMPLEMENT C5B in the assembly of MEMBRANE ATTACK COMPLEX. It is encoded by gene C6.
Complement activation triggered by the interaction of microbial POLYSACCHARIDES with serum MANNOSE-BINDING LECTIN resulting in the activation of MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES. As in the classical pathway, MASPs cleave COMPLEMENT C4 and COMPLEMENT C2 to form C3 CONVERTASE (C4B2A) and the subsequent C5 CONVERTASE (C4B2A3B) leading to cleavage of COMPLEMENT C5 and assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX.
Enzymes that activate one or more COMPLEMENT PROTEINS in the complement system leading to the formation of the COMPLEMENT MEMBRANE ATTACK COMPLEX, an important response in host defense. They are enzymes in the various COMPLEMENT ACTIVATION pathways.
Small glycoproteins found on both hematopoietic and non-hematopoietic cells. CD59 restricts the cytolytic activity of homologous complement by binding to C8 and C9 and blocking the assembly of the membrane attack complex. (From Barclay et al., The Leukocyte Antigen FactsBook, 1993, p234)
Endogenous proteins that inhibit or inactivate COMPLEMENT C3B. They include COMPLEMENT FACTOR H and COMPLEMENT FACTOR I (C3b/C4b inactivator). They cleave or promote the cleavage of C3b into inactive fragments, and thus are important in the down-regulation of COMPLEMENT ACTIVATION and its cytolytic sequence.
A serine protease that is the complex of COMPLEMENT C3B and COMPLEMENT FACTOR BB. It cleaves multiple COMPLEMENT C3 into COMPLEMENT C3A (anaphylatoxin) and COMPLEMENT C3B in the ALTERNATIVE COMPLEMENT ACTIVATION PATHWAY.
The smaller fragment formed when complement C4 is cleaved by COMPLEMENT C1S. It is an anaphylatoxin that causes symptoms of immediate hypersensitivity (HYPERSENSITIVITY, IMMEDIATE) but its activity is weaker than that of COMPLEMENT C3A or COMPLEMENT C5A.
Molecular sites on or in B-lymphocytes, follicular dendritic cells, lymphoid cells, and epithelial cells that recognize and combine with COMPLEMENT C3D. Human complement receptor 2 (CR2) serves as a receptor for both C3dg and the gp350/220 glycoprotein of HERPESVIRUS 4, HUMAN, and binds the monoclonal antibody OKB7, which blocks binding of both ligands to the receptor.
A G-protein-coupled receptor that signals an increase in intracellular calcium in response to the potent ANAPHYLATOXIN peptide COMPLEMENT C5A.
A plasma serine proteinase that cleaves the alpha-chains of C3b and C4b in the presence of the cofactors COMPLEMENT FACTOR H and C4-binding protein, respectively. It is a 66-kDa glycoprotein that converts C3b to inactivated C3b (iC3b) followed by the release of two fragments, C3c (150-kDa) and C3dg (41-kDa). It was formerly called KAF, C3bINF, or enzyme 3b inactivator.
Serum proteins that inhibit, antagonize, or inactivate COMPLEMENT C1 or its subunits.
Serum serine proteases which participate in COMPLEMENT ACTIVATION. They are activated when complexed with the MANNOSE-BINDING LECTIN, therefore also known as Mannose-binding protein-Associated Serine Proteases (MASPs). They cleave COMPLEMENT C4 and COMPLEMENT C2 to form C4b2a, the CLASSICAL PATHWAY C3 CONVERTASE.
A ubiquitously expressed complement receptor that binds COMPLEMENT C3B and COMPLEMENT C4B and serves as a cofactor for their inactivation. CD46 also interacts with a wide variety of pathogens and mediates immune response.
A 150-kDa serum glycoprotein composed of three subunits with each encoded by a different gene (C8A; C8B; and C8G). This heterotrimer contains a disulfide-linked C8alpha-C8gamma heterodimer and a noncovalently associated C8beta chain. C8 is the next component to bind the C5-7 complex forming C5b-8 that binds COMPLEMENT C9 and acts as a catalyst in the polymerization of C9.
Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualized by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (hemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1.
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.
A 93-kDa serum glycoprotein encoded by C7 gene. It is a polypeptide chain with 28 disulfide bridges. In the formation of MEMBRANE ATTACK COMPLEX; C7 is the next component to bind the C5b-6 complex forming a trimolecular complex C5b-7 which is lipophilic, resembles an integral membrane protein, and serves as an anchor for the late complement components, C8 and C9.
An endogenous 105-kDa plasma glycoprotein produced primarily by the LIVER and MONOCYTES. It inhibits a broad spectrum of proteases, including the COMPLEMENT C1R and the COMPLEMENT C1S proteases of the CLASSICAL COMPLEMENT PATHWAY, and the MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES. C1-INH-deficient individuals suffer from HEREDITARY ANGIOEDEMA TYPES I AND II.
The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.
A class of C-type lectins that target the carbohydrate structures found on invading pathogens. Binding of collectins to microorganisms results in their agglutination and enhanced clearance. Collectins form trimers that may assemble into larger oligomers. Each collectin polypeptide chain consists of four regions: a relatively short N-terminal region, a collagen-like region, an alpha-helical coiled-coil region, and carbohydrate-binding region.
The larger fragment generated from the cleavage of C5 by C5 CONVERTASE that yields COMPLEMENT C5A and C5b (beta chain + alpha' chain, the residual alpha chain, bound by disulfide bond). C5b remains bound to the membrane and initiates the spontaneous assembly of the late complement components to form C5b-8-poly-C9, the MEMBRANE ATTACK COMPLEX.
A 77-kDa subcomponent of complement C1, encoded by gene C1S, is a SERINE PROTEASE existing as a proenzyme (homodimer) in the intact complement C1 complex. Upon the binding of COMPLEMENT C1Q to antibodies, the activated COMPLEMENT C1R cleaves C1s into two chains, A (heavy) and B (light, the serine protease), linked by disulfide bonds yielding the active C1s. The activated C1s, in turn, cleaves COMPLEMENT C2 and COMPLEMENT C4 to form C4b2a (CLASSICAL C3 CONVERTASE).
Proteins that bind to particles and cells to increase susceptibility to PHAGOCYTOSIS, especially ANTIBODIES bound to EPITOPES that attach to FC RECEPTORS. COMPLEMENT C3B may also participate.
A 80-kDa subcomponent of complement C1, existing as a SERINE PROTEASE proenzyme in the intact complement C1 complex. When COMPLEMENT C1Q is bound to antibodies, the changed tertiary structure causes autolytic activation of complement C1r which is cleaved into two chains, A (heavy) and B (light, the serine protease), connected by disulfide bonds. The activated C1r serine protease, in turn, activates COMPLEMENT C1S proenzyme by cleaving the Arg426-Ile427 bond. No fragment is released when either C1r or C1s is cleaved.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Zymosan is a polysaccharide derived from the cell walls of Saccharomyces cerevisiae, commonly used in research as an immunostimulant to induce inflammation and study phagocytosis, complement activation, and oxidative burst in neutrophils and macrophages.
A derivative of complement C5a, generated when the carboxy-terminal ARGININE is removed by CARBOXYPEPTIDASE B present in normal human serum. C5a des-Arg shows complete loss of spasmogenic activity though it retains some chemotactic ability (CHEMOATTRACTANTS).
Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes.
The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (PHAGOCYTES).
A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.
The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.
Group of diseases mediated by the deposition of large soluble complexes of antigen and antibody with resultant damage to tissue. Besides SERUM SICKNESS and the ARTHUS REACTION, evidence supports a pathogenic role for immune complexes in many other IMMUNE SYSTEM DISEASES including GLOMERULONEPHRITIS, systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC) and POLYARTERITIS NODOSA.
The natural bactericidal property of BLOOD due to normally occurring antibacterial substances such as beta lysin, leukin, etc. This activity needs to be distinguished from the bactericidal activity contained in a patient's serum as a result of antimicrobial therapy, which is measured by a SERUM BACTERICIDAL TEST.
Proteins that share the common characteristic of binding to carbohydrates. Some ANTIBODIES and carbohydrate-metabolizing proteins (ENZYMES) also bind to carbohydrates, however they are not considered lectins. PLANT LECTINS are carbohydrate-binding proteins that have been primarily identified by their hemagglutinating activity (HEMAGGLUTININS). However, a variety of lectins occur in animal species where they serve diverse array of functions through specific carbohydrate recognition.
Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN.
Inbred C57BL mice are a strain of laboratory mice that have been produced by many generations of brother-sister matings, resulting in a high degree of genetic uniformity and homozygosity, making them widely used for biomedical research, including studies on genetics, immunology, cancer, and neuroscience.
Antibodies produced by a single clone of cells.
Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
A syndrome that is associated with microvascular diseases of the KIDNEY, such as RENAL CORTICAL NECROSIS. It is characterized by hemolytic anemia (ANEMIA, HEMOLYTIC); THROMBOCYTOPENIA; and ACUTE RENAL FAILURE.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Abnormal immunoglobulins, especially IGG or IGM, that precipitate spontaneously when SERUM is cooled below 37 degrees Celsius. It is characteristic of CRYOGLOBULINEMIA.
Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms.
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
An adhesion-promoting leukocyte surface membrane heterodimer. The alpha subunit consists of the CD11b ANTIGEN and the beta subunit the CD18 ANTIGEN. The antigen, which is an integrin, functions both as a receptor for complement 3 and in cell-cell and cell-substrate adhesive interactions.
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.
Adverse functional, metabolic, or structural changes in ischemic tissues resulting from the restoration of blood flow to the tissue (REPERFUSION), including swelling; HEMORRHAGE; NECROSIS; and damage from FREE RADICALS. The most common instance is MYOCARDIAL REPERFUSION INJURY.
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
The clear portion of BLOOD that is left after BLOOD COAGULATION to remove BLOOD CELLS and clotting proteins.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins.
Polysaccharides consisting of mannose units.
A plasma protein that circulates in increased amounts during inflammation and after tissue damage.
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
A cluster of convoluted capillaries beginning at each nephric tubule in the kidney and held together by connective tissue.
Chronic glomerulonephritis characterized histologically by proliferation of MESANGIAL CELLS, increase in the MESANGIAL EXTRACELLULAR MATRIX, and a thickening of the glomerular capillary walls. This may appear as a primary disorder or secondary to other diseases including infections and autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Various subtypes are classified by their abnormal ultrastructures and immune deposits. Hypocomplementemia is a characteristic feature of all types of MPGN.
The capacity of a normal organism to remain unaffected by microorganisms and their toxins. It results from the presence of naturally occurring ANTI-INFECTIVE AGENTS, constitutional factors such as BODY TEMPERATURE and immediate acting immune cells such as NATURAL KILLER CELLS.
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
A condition characterized by the recurrence of HEMOGLOBINURIA caused by intravascular HEMOLYSIS. In cases occurring upon cold exposure (paroxysmal cold hemoglobinuria), usually after infections, there is a circulating antibody which is also a cold hemolysin. In cases occurring during or after sleep (paroxysmal nocturnal hemoglobinuria), the clonal hematopoietic stem cells exhibit a global deficiency of cell membrane proteins.
A metallocarboxypeptidase that removes C-terminal basic amino acid from peptides and proteins, with preference shown for lysine over arginine. It is a plasma zinc enzyme that inactivates bradykinin and anaphylatoxins.
Amyloid P component is a small, non-fibrillar glycoprotein found in normal serum and in all amyloid deposits. It has a pentagonal (pentaxin) structure. It is an acute phase protein, modulates immunologic responses, inhibits ELASTASE, and has been suggested as an indicator of LIVER DISEASE.
Solutions or mixtures of toxic and nontoxic substances elaborated by snake (Ophidia) salivary glands for the purpose of killing prey or disabling predators and delivered by grooved or hollow fangs. They usually contain enzymes, toxins, and other factors.
A biosensing technique in which biomolecules capable of binding to specific analytes or ligands are first immobilized on one side of a metallic film. Light is then focused on the opposite side of the film to excite the surface plasmons, that is, the oscillations of free electrons propagating along the film's surface. The refractive index of light reflecting off this surface is measured. When the immobilized biomolecules are bound by their ligands, an alteration in surface plasmons on the opposite side of the film is created which is directly proportional to the change in bound, or adsorbed, mass. Binding is measured by changes in the refractive index. The technique is used to study biomolecular interactions, such as antigen-antibody binding.
Proteins prepared by recombinant DNA technology.
A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
Inflammation of any part of the KIDNEY.
Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.
A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.
Swelling involving the deep DERMIS, subcutaneous, or submucosal tissues, representing localized EDEMA. Angioedema often occurs in the face, lips, tongue, and larynx.
Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.
The COOH-terminal fragment of COMPLEMENT 2, released by the action of activated COMPLEMENT C1S. It is a SERINE PROTEASE. C2a combines with COMPLEMENT C4B to form C4b2a (CLASSICAL PATHWAY C3 CONVERTASE) and subsequent C4b2a3b (CLASSICAL PATHWAY C5 CONVERTASE).
Immunoelectrophoresis in which a second electrophoretic transport is performed on the initially separated antigen fragments into an antibody-containing medium in a direction perpendicular to the first electrophoresis.
Visible accumulations of fluid within or beneath the epidermis.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
A chronic and relatively benign subepidermal blistering disease usually of the elderly and without histopathologic acantholysis.
A test used to determine whether or not complementation (compensation in the form of dominance) will occur in a cell with a given mutant phenotype when another mutant genome, encoding the same mutant phenotype, is introduced into that cell.
Inbred BALB/c mice are a strain of laboratory mice that have been selectively bred to be genetically identical to each other, making them useful for scientific research and experiments due to their consistent genetic background and predictable responses to various stimuli or treatments.
Infections with bacteria of the species NEISSERIA MENINGITIDIS.
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research.
Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses.
Glycoproteins found on the membrane or surface of cells.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Modified oligonucleotides in which one of the oxygens of the phosphate group is replaced with a sulfur atom.
A type of glomerulonephritis that is characterized by the accumulation of immune deposits (COMPLEMENT MEMBRANE ATTACK COMPLEX) on the outer aspect of the GLOMERULAR BASEMENT MEMBRANE. It progresses from subepithelial dense deposits, to basement membrane reaction and eventual thickening of the basement membrane.
Antibodies from an individual that react with ISOANTIGENS of another individual of the same species.
Transport proteins that carry specific substances in the blood or across cell membranes.
A group of antigens that includes both the major and minor histocompatibility antigens. The former are genetically determined by the major histocompatibility complex. They determine tissue type for transplantation and cause allograft rejections. The latter are systems of allelic alloantigens that can cause weak transplant rejection.
The parts of a macromolecule that directly participate in its specific combination with another molecule.
The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
A species of gram-negative, aerobic BACTERIA. It is a commensal and pathogen only of humans, and can be carried asymptomatically in the NASOPHARYNX. When found in cerebrospinal fluid it is the causative agent of cerebrospinal meningitis (MENINGITIS, MENINGOCOCCAL). It is also found in venereal discharges and blood. There are at least 13 serogroups based on antigenic differences in the capsular polysaccharides; the ones causing most meningitis infections being A, B, C, Y, and W-135. Each serogroup can be further classified by serotype, serosubtype, and immunotype.
The diffusion or accumulation of neutrophils in tissues or cells in response to a wide variety of substances released at the sites of inflammatory reactions.
Any of the ruminant mammals with curved horns in the genus Ovis, family Bovidae. They possess lachrymal grooves and interdigital glands, which are absent in GOATS.
Peptides whose amino and carboxy ends are linked together with a peptide bond forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS. Some of them are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL).
Immunoglobulins produced in a response to BACTERIAL ANTIGENS.
A method for the detection of very small quantities of antibody in which the antigen-antibody-complement complex adheres to indicator cells, usually primate erythrocytes or nonprimate blood platelets. The reaction is dependent on the number of bound C3 molecules on the C3b receptor sites of the indicator cell.
Antibodies found in adult RHEUMATOID ARTHRITIS patients that are directed against GAMMA-CHAIN IMMUNOGLOBULINS.
Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed)
Established cell cultures that have the potential to propagate indefinitely.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
An iron-binding protein that was originally characterized as a milk protein. It is widely distributed in secretory fluids and is found in the neutrophilic granules of LEUKOCYTES. The N-terminal part of lactoferrin possesses a serine protease which functions to inactivate the TYPE III SECRETION SYSTEM used by bacteria to export virulence proteins for host cell invasion.
Specific molecular sites on the surface of various cells, including B-lymphocytes and macrophages, that combine with IMMUNOGLOBULIN Gs. Three subclasses exist: Fc gamma RI (the CD64 antigen, a low affinity receptor), Fc gamma RII (the CD32 antigen, a high affinity receptor), and Fc gamma RIII (the CD16 antigen, a low affinity receptor).
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
The classes of immunoglobulins found in any species of animal. In man there are nine classes that migrate in five different groups in electrophoresis; they each consist of two light and two heavy protein chains, and each group has distinguishing structural and functional properties.
All blood proteins except albumin ( = SERUM ALBUMIN, which is not a globulin) and FIBRINOGEN (which is not in the serum). The serum globulins are subdivided into ALPHA-GLOBULINS; BETA-GLOBULINS; and GAMMA-GLOBULINS on the basis of their electrophoretic mobilities. (From Dorland, 28th ed)
Local surface sites on antibodies which react with antigen determinant sites on antigens (EPITOPES.) They are formed from parts of the variable regions of FAB FRAGMENTS.
The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.
The movement of leukocytes in response to a chemical concentration gradient or to products formed in an immunologic reaction.
Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS.
Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
Elements of limited time intervals, contributing to particular results or situations.
A technique that combines protein electrophoresis and double immunodiffusion. In this procedure proteins are first separated by gel electrophoresis (usually agarose), then made visible by immunodiffusion of specific antibodies. A distinct elliptical precipitin arc results for each protein detectable by the antisera.
Crystallizable fragments composed of the carboxy-terminal halves of both IMMUNOGLOBULIN HEAVY CHAINS linked to each other by disulfide bonds. Fc fragments contain the carboxy-terminal parts of the heavy chain constant regions that are responsible for the effector functions of an immunoglobulin (COMPLEMENT fixation, binding to the cell membrane via FC RECEPTORS, and placental transport). This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.)
Any member of the group of ENDOPEPTIDASES containing at the active site a serine residue involved in catalysis.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
Methods used by pathogenic organisms to evade a host's immune system.
Proteins found in any species of bacterium.
The single layer of pigment-containing epithelial cells in the RETINA, situated closely to the tips (outer segments) of the RETINAL PHOTORECEPTOR CELLS. These epithelial cells are macroglia that perform essential functions for the photoreceptor cells, such as in nutrient transport, phagocytosis of the shed photoreceptor membranes, and ensuring retinal attachment.
A blood plasma glycoprotein that mediates cell adhesion and interacts with proteins of the complement, coagulation, and fibrinolytic cascade. (From Segen, Dictionary of Modern Medicine, 1992)
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Synthetic or natural materials, other than DRUGS, that are used to replace or repair any body TISSUES or bodily function.
CELL LINE derived from the ovary of the Chinese hamster, Cricetulus griseus (CRICETULUS). The species is a favorite for cytogenetic studies because of its small chromosome number. The cell line has provided model systems for the study of genetic alterations in cultured mammalian cells.
White blood cells. These include granular leukocytes (BASOPHILS; EOSINOPHILS; and NEUTROPHILS) as well as non-granular leukocytes (LYMPHOCYTES and MONOCYTES).
Failure in built environment with loss of functional integrity.
An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.
Failure of the PLACENTA to deliver an adequate supply of nutrients and OXYGEN to the FETUS.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
An acute hypersensitivity reaction due to exposure to a previously encountered ANTIGEN. The reaction may include rapidly progressing URTICARIA, respiratory distress, vascular collapse, systemic SHOCK, and death.

Up-regulated production and activation of the complement system in Alzheimer's disease brain. (1/1999)

We used reverse transcriptase-polymerase chain reaction and Western blotting techniques to measure the levels of complement mRNAs and their protein products in Alzheimer's disease (AD) brain compared with non-AD brain. mRNAs for C1q, C1r, C1s, C2, C3, C4, C5, C6, C7, C8, and C9 were detected in the 11 regions of brain that were investigated. The mRNA levels were markedly up-regulated in affected areas of AD brain. In the entorhinal cortex, hippocampus, and midtemporal gyrus, which had dense accumulations of plaques and tangles, C1q mRNA was increased 11- to 80-fold over control levels, and C9 mRNA 10- to 27-fold. These levels were substantially higher than in the livers of the same cases. Western blot analysis of AD hippocampus established the presence of all of the native complement proteins as well as their activation products C4d, C3d, and the membrane attack complex. These data indicate that high levels of complement are being produced in affected areas of AD brain, that full activation of the classical complement pathway is continuously taking place, and that this activation may be contributing significantly to AD pathology.  (+info)

Capsular sialic acid limits C5a production on type III group B streptococci. (2/1999)

The majority of type III group B streptococcus (GBS) human neonatal infections are caused by a genetically related subgroup called III-3. We have proposed that a bacterial enzyme, C5a-ase, contributes to the pathogenesis of neonatal infections with GBS by rapidly inactivating C5a, a potent pro-inflammatory molecule, but many III-3 strains do not express C5a-ase. The amount of C5a produced in serum following incubation with representative type III strains was quantitated in order to better understand the relationship between C5a production and C5a-ase expression. C5a production following incubation of bacteria with serum depleted of antibody to the bacterial surface was inversely proportional to the sialic acid content of the bacterial capsule, with the more heavily sialylated III-3 strains generating less C5a than the less-virulent, less-sialylated III-2 strains. The amount of C5a produced correlated significantly with C3 deposition on each bacterial strain. Repletion with type-specific antibody caused increased C3b deposition and C5a production through alternative pathway activation, but C5a was functionally inactivated by strains that expressed C5a-ase. The increased virulence of III-3 strains compared to that of III-2 strains results at least partially from the higher sialic acid content of III-3 strains, which inhibits both opsonophagocytic killing and C5a production in the absence of type-specific antibody. We propose that C5a-ase is not necessary for III-3 strains to cause invasive disease because the high sialic acid content of III-3 strains inhibits C5a production.  (+info)

Polymerization of IgA and IgM: roles of Cys309/Cys414 and the secretory tailpiece. (3/1999)

We have investigated how the secretory tailpiece (tp), Cys414 and the amino acids flanking Cys414 or Cys309 are involved in regulating the different polymerization of IgM and IgA to pentamers and dimers/monomers, respectively. Whereas changing the tp of IgM to that of IgA has little effect on IgM polymerization, introducing the mu tp to IgA leads to the formation of larger than wild-type IgA polymers, including pentamers and hexamer. This shows that the secretory tp can differentially regulate polymerization depending on the heavy chain context. Cys414, which is engaged in intermonomeric disulfide bonds in IgM, is not crucial for the difference in IgM and IgA polymerization; IgM with a C414S mutation forms more large polymers than IgA. Also, IgA with IgM-like mutations in the five amino acids flanking Cys309, which is homologous to Cys414, oligomerize similarly as IgA wild type. Thus, IgA appears to have an inherent tendency to form monomers and dimers that is partially regulated by the tp, while the Cys309 region has only a minor effect. We also show that complement activation by IgM is sensitive to alterations in the polymeric structure, while IgA is inactive in classical complement activation even for polymers such as pentamers and hexamers.  (+info)

Two constituents of the initiation complex of the mannan-binding lectin activation pathway of complement are encoded by a single structural gene. (4/1999)

Mannan-binding lectin (MBL) forms a multimolecular complex with at least two MBL-associated serine proteases, MASP-1 and MASP-2. This complex initiates the MBL pathway of complement activation by binding to carbohydrate structures present on bacteria, yeast, and viruses. MASP-1 and MASP-2 are composed of modular structural motifs similar to those of the C1q-associated serine proteases C1r and C1s. Another protein of 19 kDa with the same N-terminal sequence as the 76-kDa MASP-2 protein is consistently detected as part of the MBL/MASP complex. In this study, we present the primary structure of this novel MBL-associated plasma protein of 19 kDa, MAp19, and demonstrate that MAp19 and MASP-2 are encoded by two different mRNA species generated by alternative splicing/polyadenylation from one structural gene.  (+info)

Role of antibody and complement in opsonization of group B streptococci. (5/1999)

A requirement for the classic complement pathway in opsonization of group B streptococci was observed by using both a chemiluminescence and a radiolabeled bacterial uptake technique. The classic pathway increased levels of opsonization for types Ia and II stock and wild strains and for some type III wild strains. In contrast, other type III wild strains and the type III stock strain had accelerated kinetics of uptake in the presence of an intact classic pathway, but the level of opsonization was unchanged from that with antibody alone. We could not demonstrate a significant role for the alternative pathway in opsonizing stock or wild strains of group B streptococci. Futhermore, electrophoretic and complement consumption analysis by hemolytic titration failed to reveal alternative pathway activation by the majority of strains of this group. Therapy aimed at supplying opsonins for these organisms will require the presence of type-specific antibody.  (+info)

Anti-endothelial cell antibodies in systemic vasculitis and systemic lupus erythematosus (SLE): effects of heat inactivation on binding and specificity. (6/1999)

Heating sera is used to inactivate complement but may affect the binding characteristics of autoantibodies. We studied the effect of heating sera from patients with systemic vasculitides and SLE on antibody binding to cultured human umbilical vein endothelial cells. Sera from 32 patients with systemic vasculitides, eight with SLE and 10 healthy controls were studied for anti-endothelial cell antibodies (AECA) using an ELISA before and after heating sera to 56 degrees C for 30 min. The median (range) AECA binding index in the patient group increased from 20% (0-153%) to 71.5% (10-259%) (P < 0.0001). The AECA binding index in the control group also increased from 14% (0-52%) to 90% (42-154%) (P < 0.0001). The increased binding was unaffected by the addition of fresh complement or removal of immune complexes and the increased binding after heating persisted even after cooling to 4 degrees C. Specificity experiments showed that after heating, the binding specificity of sera was lost. Removal of immunoglobulin with Protein A abolished the increased binding seen after heating. Heating sera increases AECA binding in both patient and control sera. The mechanism is probably non-specific damage to the immunoglobulin molecule, and heating sera should thus be avoided.  (+info)

Influence of dialysis with polyamide vs haemophan haemodialysers on monokines and complement activation during a 4-month long-term study. (7/1999)

BACKGROUND: Contact between blood and dialysis membranes activates mononuclear cells and the complement system. The extent of activation is dependent on the dialyser material used and is considered an index of biocompatibility. Polyamide dialysers consist of a synthetic membrane that claims high standards of biocompatibility. Haemophan dialysers represent membranes made of modified cellulose that are now broadly used for treatment in Europe and are already considered to be more biocompatible than the cuprophane membranes that were used as reference in most previous studies. METHODS: In a cross-over treatment study short-term as well as long-term effects of a polyamide dialyser with respect to monokine induction and complement activation were compared to a haemophan dialyser. RESULTS: Neither haemophan nor polyamide dialysers induced relevant changes in plasma monokine levels. However, in vitro challenge of mononuclear cells with lipopolysaccharide (LPS) unmasked a significantly stronger preactivation for the secretion of proinflammatory monokines during haemophan than polyamide dialysis. Unlike other monokines the production of the regulatory monokine IL-10 was mainly influenced by individual factors and correlated with the patient's immune status rather than the dialyser type used. Enhanced preactivation of monocytes in haemophan compared to polyamide dialysis was paralleled by an increased complement activation. Cellular preactivation and formation of terminal complement complex remained constant over the 4-month treatment period. CONCLUSIONS: Haemophan and polyamide dialysers do not induce changes in plasma cytokine levels both during short-term and long-term use. However, they significantly differ in complement activation as well as preactivation of monocytes. Preactivated monocytes are prone to secrete high amounts of proinflammatory cytokines when exposed to a second stimulus like endotoxin. Secretion of the regulatory cytokine IL-10 is not influenced by the dialyser type.  (+info)

Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion molecules. (8/1999)

Soluble human complement receptor type 1 (sCR1, TP10) has been expressed in Chinese hamster ovary (CHO) DUKX-B11 cells and shown to inhibit the classical and alternative complement pathways in vitro and in vivo. A truncated version of sCR1 lacking the long homologous repeat-A domain (LHR-A) containing the C4b binding site has similarly been expressed and designated sCR1[desLHR-A]. sCR1[desLHR-A] was shown to be a selective inhibitor of the alternative complement pathway in vitro and to function in vivo. In this study, sCR1 and sCR1[desLHR-A] were expressed in CHO LEC11 cells with an active alpha(1,3)-fucosyltransferase, which makes possible the biosynthesis of the sialyl-Lewisx (sLex) tetrasaccharide (NeuNAcalpha2-3Galbeta1-4(Fucalpha1-3)GlcNAc) during post-translational glycosylation. The resulting glycoproteins, designated sCR1sLex and sCR1[desLHR-A]sLex, respectively, retained the complement regulatory activities of their DUKX B11 counterparts, which lack alpha(1-3)-fucose. Carbohydrate analysis of purified sCR1sLex and sCR1[desLHR-A]sLex indicated an average incorporation of 10 and 8 mol of sLex/mol of glycoprotein, respectively. sLex is a carbohydrate ligand for the selectin adhesion molecules. sCR1sLex was shown to specifically bind CHO cells expressing cell surface E-selectin. sCR1[desLHR-A]sLex inhibited the binding of the monocytic cell line U937 to human aortic endothelial cells, which had been activated with tumor necrosis factor-alpha to up-regulate the expression of E-selectin. sCR1sLex inhibited the binding of U937 cells to surface-adsorbed P-selectin-IgG. sCR1sLex and sCR1[desLHR-A]sLex have thus demonstrated both complement regulatory activity and the capacity to bind selectins and to inhibit selectin-mediated cell adhesion in vitro.  (+info)

Complement activation is the process by which the complement system, a part of the immune system, is activated to help eliminate pathogens and damaged cells from the body. The complement system consists of a group of proteins that work together to recognize and destroy foreign substances.

Activation of the complement system can occur through three different pathways: the classical pathway, the lectin pathway, and the alternative pathway. Each pathway involves a series of proteolytic reactions that ultimately result in the formation of the membrane attack complex (MAC), which creates a pore in the membrane of the target cell, leading to its lysis and removal.

The classical pathway is typically activated by the binding of antibodies to antigens on the surface of a pathogen or damaged cell. The lectin pathway is activated by the recognition of specific carbohydrate structures on the surface of microorganisms. The alternative pathway can be spontaneously activated and serves as an amplification loop for both the classical and lectin pathways.

Complement activation plays a crucial role in the immune response, but uncontrolled or excessive activation can also lead to tissue damage and inflammation. Dysregulation of complement activation has been implicated in various diseases, including autoimmune disorders, inflammatory conditions, and neurodegenerative diseases.

Complement C3 is a protein that plays a central role in the complement system, which is a part of the immune system that helps to clear pathogens and damaged cells from the body. Complement C3 can be activated through three different pathways: the classical pathway, the lectin pathway, and the alternative pathway. Once activated, it breaks down into two fragments, C3a and C3b.

C3a is an anaphylatoxin that helps to recruit immune cells to the site of infection or injury, while C3b plays a role in opsonization, which is the process of coating pathogens or damaged cells with proteins to make them more recognizable to the immune system. Additionally, C3b can also activate the membrane attack complex (MAC), which forms a pore in the membrane of target cells leading to their lysis or destruction.

In summary, Complement C3 is an important protein in the complement system that helps to identify and eliminate pathogens and damaged cells from the body through various mechanisms.

The complement system is a group of proteins found in the blood and on the surface of cells that when activated, work together to help eliminate pathogens such as bacteria, viruses, and fungi from the body. The proteins are normally inactive in the bloodstream. When they encounter an invading microorganism or foreign substance, a series of reactions take place leading to the activation of the complement system. Activation results in the production of effector molecules that can punch holes in the cell membranes of pathogens, recruit and activate immune cells, and help remove debris and dead cells from the body.

There are three main pathways that can lead to complement activation: the classical pathway, the lectin pathway, and the alternative pathway. Each pathway involves a series of proteins that work together in a cascade-like manner to amplify the response and generate effector molecules. The three main effector molecules produced by the complement system are C3b, C4b, and C5b. These molecules can bind to the surface of pathogens, marking them for destruction by other immune cells.

Complement proteins also play a role in the regulation of the immune response. They help to prevent excessive activation of the complement system, which could damage host tissues. Dysregulation of the complement system has been implicated in a number of diseases, including autoimmune disorders and inflammatory conditions.

In summary, Complement System Proteins are a group of proteins that play a crucial role in the immune response by helping to eliminate pathogens and regulate the immune response. They can be activated through three different pathways, leading to the production of effector molecules that mark pathogens for destruction. Dysregulation of the complement system has been linked to various diseases.

Complement C4 is a protein that plays a crucial role in the complement system, which is a part of the immune system that helps to clear pathogens and damaged cells from the body. Complement C4 is involved in the early stages of the complement activation cascade, where it helps to identify and tag foreign or abnormal cells for destruction by other components of the immune system.

Specifically, Complement C4 can be cleaved into two smaller proteins, C4a and C4b, during the complement activation process. C4b then binds to the surface of the target cell and helps to initiate the formation of the membrane attack complex (MAC), which creates a pore in the cell membrane and leads to lysis or destruction of the target cell.

Deficiencies or mutations in the Complement C4 gene can lead to various immune disorders, including certain forms of autoimmune diseases and susceptibility to certain infections.

The alternative complement pathway is one of the three initiating pathways of the complement system, which is a part of the innate immune system that helps to clear pathogens and damaged cells from the body. The other two pathways are the classical and lectin pathways.

The alternative pathway is continuously activated at a low level, even in the absence of infection or injury, through the spontaneous cleavage of complement component C3 into C3a and C3b by the protease factor D in the presence of magnesium ions. The generated C3b can then bind covalently to nearby surfaces, including pathogens and host cells.

On self-surfaces, regulatory proteins like decay-accelerating factor (DAF) or complement receptor 1 (CR1) help to prevent the formation of the alternative pathway convertase and thus further activation of the complement system. However, on foreign surfaces, the C3b can recruit more complement components, forming a complex called the alternative pathway convertase (C3bBb), which cleaves additional C3 molecules into C3a and C3b.

The generated C3b can then bind to the surface and participate in the formation of the membrane attack complex (MAC), leading to the lysis of the target cell. The alternative pathway plays a crucial role in the defense against gram-negative bacteria, fungi, and parasites, as well as in the clearance of immune complexes and apoptotic cells. Dysregulation of the alternative complement pathway has been implicated in several diseases, including autoimmune disorders and atypical hemolytic uremic syndrome (aHUS).

The Complement Membrane Attack Complex (MAC), also known as the Terminal Complement Complex (TCC), is a protein structure that forms in the final stages of the complement system's immune response. The complement system is a part of the innate immune system that helps to eliminate pathogens and damaged cells from the body.

The MAC is composed of several proteins, including C5b, C6, C7, C8, and multiple subunits of C9, which assemble on the surface of target cells. The formation of the MAC creates a pore-like structure in the cell membrane, leading to disruption of the membrane's integrity and ultimately causing cell lysis or damage.

The MAC plays an important role in the immune response by helping to eliminate pathogens that have evaded other immune defenses. However, uncontrolled activation of the complement system and formation of the MAC can also contribute to tissue damage and inflammation in various diseases, such as autoimmune disorders, age-related macular degeneration, and ischemia-reperfusion injury.

The "Classical Complement Pathway" is one of the three pathways that make up the complement system, which is a part of the immune system in humans and other animals. The complement system helps to enhance the ability of antibodies and phagocytic cells to clear pathogens from the body.

The Classical Complement Pathway is initiated by the binding of the first component of the complement system, C1, to an activator surface, such as an antigen-antibody complex. Activation of C1 results in the sequential activation of other components of the complement system, including C4 and C2, which form the C3 convertase (C4b2a). The C3 convertase cleaves the third component of the complement system, C3, into C3a and C3b. C3b then binds to the activator surface and forms a complex with other components of the complement system, leading to the formation of the membrane attack complex (MAC), which creates a pore in the membrane of the target cell, causing its lysis.

The Classical Complement Pathway plays an important role in the immune response to pathogens and can also contribute to inflammation and tissue damage in certain diseases, such as autoimmune disorders and allergies.

Complement C1q is a protein that is part of the complement system, which is a group of proteins in the blood that help to eliminate pathogens and damaged cells from the body. C1q is the first component of the classical complement pathway, which is activated by the binding of C1q to antibodies that are attached to the surface of a pathogen or damaged cell.

C1q is composed of six identical polypeptide chains, each containing a collagen-like region and a globular head region. The globular heads can bind to various structures, including the Fc regions of certain antibodies, immune complexes, and some types of cells. When C1q binds to an activating surface, it triggers a series of proteolytic reactions that lead to the activation of other complement components and the formation of the membrane attack complex (MAC), which can punch holes in the membranes of pathogens or damaged cells, leading to their destruction.

In addition to its role in the immune system, C1q has also been found to have roles in various physiological processes, including tissue remodeling, angiogenesis, and the clearance of apoptotic cells. Dysregulation of the complement system, including abnormalities in C1q function, has been implicated in a variety of diseases, including autoimmune disorders, inflammatory diseases, and neurodegenerative conditions.

Complement C3b is a protein fragment that plays a crucial role in the complement system, which is a part of the immune system that helps to clear pathogens and damaged cells from the body. C3b is generated during the activation of the complement system, particularly via the classical, lectin, and alternative pathways.

Once formed, C3b can bind covalently to the surface of microbes or other target particles, marking them for destruction by other components of the immune system. Additionally, C3b can interact with other proteins in the complement system to generate the membrane attack complex (MAC), which forms pores in the membranes of targeted cells, leading to their lysis and removal.

In summary, Complement C3b is a vital protein fragment involved in the recognition, tagging, and elimination of pathogens and damaged cells during the immune response.

Complement C3a is a protein fragment that is generated during the activation of the complement system, which is a part of the immune system. The complement system helps to eliminate pathogens and damaged cells from the body by marking them for destruction and attracting immune cells to the site of infection or injury.

C3a is produced when the third component of the complement system (C3) is cleaved into two smaller fragments, C3a and C3b, during the complement activation cascade. C3a is a potent anaphylatoxin, which means it can cause the release of histamine and other mediators from mast cells and basophils, leading to inflammation, increased vascular permeability, and smooth muscle contraction.

C3a also has chemotactic properties, meaning it can attract immune cells such as neutrophils and monocytes to the site of complement activation. Additionally, C3a can modulate the activity of various immune cells, including dendritic cells, T cells, and B cells, and play a role in the regulation of the adaptive immune response.

It's important to note that while C3a has important functions in the immune response, uncontrolled or excessive activation of the complement system can lead to tissue damage and inflammation, contributing to the pathogenesis of various diseases such as autoimmune disorders, inflammatory diseases, and allergies.

Complement C5 is a protein that plays a crucial role in the complement system, which is a part of the immune system that helps to eliminate pathogens and damaged cells from the body. The complement system is a complex series of biochemical reactions that help to identify and destroy foreign substances, such as bacteria and viruses.

Complement C5 is one of several proteins in the complement system that are activated in a cascading manner in response to an activating event, such as the binding of an antibody to a pathogen. Once activated, Complement C5 can be cleaved into two smaller proteins, C5a and C5b.

C5a is a powerful anaphylatoxin, which means it can cause the release of histamine from mast cells and basophils, leading to inflammation and increased vascular permeability. It also acts as a chemoattractant, drawing immune cells to the site of infection or injury.

C5b, on the other hand, plays a role in the formation of the membrane attack complex (MAC), which is a protein structure that can punch holes in the membranes of pathogens, leading to their lysis and destruction.

Overall, Complement C5 is an important component of the immune system's response to infection and injury, helping to eliminate pathogens and damaged cells from the body.

Complement inactivator proteins are a group of regulatory proteins that help to control and limit the activation of the complement system, which is a part of the immune system. The complement system is a complex series of biochemical reactions that help to eliminate pathogens and damaged cells from the body. However, if not properly regulated, the complement system can also cause damage to healthy tissues and contribute to the development of various diseases.

Complement inactivator proteins work by inhibiting specific components of the complement system, preventing them from activating and causing an immune response. Some examples of complement inactivator proteins include:

1. C1 inhibitor (C1INH): This protein regulates the activation of the classical pathway of the complement system by inhibiting the C1 complex, which is a group of proteins that initiate this pathway.
2. Decay-accelerating factor (DAF or CD55): This protein regulates the activation of both the classical and alternative pathways of the complement system by accelerating the decay of the C3/C5 convertases, which are enzymes that activate the complement components C3 and C5.
3. Membrane cofactor protein (MCP or CD46): This protein regulates the activation of the alternative pathway of the complement system by serving as a cofactor for the cleavage and inactivation of C3b, a component of the C3 convertase.
4. Factor H: This protein also regulates the activation of the alternative pathway of the complement system by acting as a cofactor for the cleavage and inactivation of C3b, and by preventing the formation of the C3 convertase.

Deficiencies or dysfunction of complement inactivator proteins can lead to various diseases, including hereditary angioedema (C1INH deficiency), atypical hemolytic uremic syndrome (factor H deficiency or dysfunction), and age-related macular degeneration (complement component overactivation).

Complement receptors are proteins found on the surface of various cells in the human body, including immune cells and some non-immune cells. They play a crucial role in the complement system, which is a part of the innate immune response that helps to eliminate pathogens and damaged cells from the body. Complement receptors bind to complement proteins or fragments that are generated during the activation of the complement system. This binding triggers various intracellular signaling events that can lead to diverse cellular responses, such as phagocytosis, inflammation, and immune regulation.

There are several types of complement receptors, including:

1. CR1 (CD35): A receptor found on erythrocytes, B cells, neutrophils, monocytes, macrophages, and glomerular podocytes. It functions in the clearance of immune complexes and regulates complement activation.
2. CR2 (CD21): Expressed mainly on B cells and follicular dendritic cells. It facilitates antigen presentation, B-cell activation, and immune regulation.
3. CR3 (CD11b/CD18, Mac-1): Present on neutrophils, monocytes, macrophages, and some T cells. It mediates cell adhesion, phagocytosis, and intracellular signaling.
4. CR4 (CD11c/CD18, p150,95): Expressed on neutrophils, monocytes, macrophages, and dendritic cells. It is involved in cell adhesion, phagocytosis, and intracellular signaling.
5. C5aR (CD88): Found on various immune cells, including neutrophils, monocytes, macrophages, mast cells, eosinophils, and dendritic cells. It binds to the complement protein C5a and mediates chemotaxis, degranulation, and inflammation.
6. C5L2 (GPR77): Present on various cell types, including immune cells. Its function is not well understood but may involve regulating C5a-mediated responses or acting as a receptor for other ligands.

These receptors play crucial roles in the immune response and inflammation by mediating various functions such as chemotaxis, phagocytosis, cell adhesion, and intracellular signaling. Dysregulation of these receptors has been implicated in several diseases, including autoimmune disorders, infections, and cancer.

Complement Factor B is a protein that plays a crucial role in the complement system, which is a part of the immune system that helps to eliminate pathogens and damaged cells from the body. Specifically, Factor B is a component of the alternative pathway of the complement system, which provides a rapid and amplified response to microbial surfaces.

Factor B is cleaved by another protease called Factor D into two fragments, Ba and Bb. The formation of the C3 convertase (C3bBb) is essential for the activation of the alternative pathway. This complex can cleave and activate more C3 molecules, leading to a cascade of reactions that result in the formation of the membrane attack complex (MAC), which forms pores in the membranes of target cells, causing their lysis and elimination.

Deficiencies or mutations in Complement Factor B can lead to various complement-mediated diseases, such as atypical hemolytic uremic syndrome (aHUS) and age-related macular degeneration (AMD).

Complement C5a is a protein fragment that is generated during the activation of the complement system, which is a part of the immune system. The complement system helps to eliminate pathogens and damaged cells from the body by tagging them for destruction and attracting immune cells to the site of infection or injury.

C5a is formed when the fifth component of the complement system (C5) is cleaved into two smaller fragments, C5a and C5b, during the complement activation cascade. C5a is a potent pro-inflammatory mediator that can attract and activate various immune cells, such as neutrophils, monocytes, and eosinophils, to the site of infection or injury. It can also increase vascular permeability, promote the release of histamine, and induce the production of reactive oxygen species, all of which contribute to the inflammatory response.

However, excessive or uncontrolled activation of the complement system and generation of C5a can lead to tissue damage and inflammation, contributing to the pathogenesis of various diseases, such as sepsis, acute respiratory distress syndrome (ARDS), and autoimmune disorders. Therefore, targeting C5a or its receptors has been explored as a potential therapeutic strategy for these conditions.

Complement C3d is a protein fragment that is formed during the activation of the complement system, which is a part of the immune system. The complement system helps to eliminate pathogens such as bacteria and viruses from the body by tagging them for destruction and attracting immune cells to the site of infection.

C3d is a cleavage product of complement component C3, which is one of the central proteins in the complement system. When C3 is activated, it is cleaved into two fragments: C3a and C3b. C3b can then be further cleaved into C3d and C3c.

C3d plays a role in the activation of the immune system by helping to link the complement system with the adaptive immune response. It does this by binding to receptors on B cells, which are a type of white blood cell that produces antibodies. This interaction can help to stimulate the production of antibodies and enhance the immune response to pathogens.

C3d has also been implicated in the development of certain autoimmune diseases, as it can contribute to the formation of immune complexes that can cause tissue damage.

Complement C9 is a protein that plays a crucial role in the complement system, which is a part of the immune system that helps to eliminate pathogens and damaged cells from the body. Specifically, C9 is one of the components of the membrane attack complex (MAC), which is a protein structure that forms pores in the membranes of target cells, leading to their lysis or destruction.

When activated, C9 polymerizes and inserts itself into the cell membrane, forming a transmembrane pore that disrupts the membrane's integrity and causes the cell to lyse. This process is an essential part of the complement system's ability to destroy pathogens and clear damaged cells from the body.

Defects in the C9 gene can lead to a rare genetic disorder called complement component 9 deficiency, which is characterized by recurrent bacterial infections and immune complex-mediated diseases. Additionally, mutations in the C9 gene have been associated with an increased risk of age-related macular degeneration (AMD), a leading cause of blindness in older adults.

Complement Factor H is a protein involved in the regulation of the complement system, which is a part of the immune system that helps to clear pathogens and damaged cells from the body. Specifically, Complement Factor H helps to regulate the activation and deactivation of the complement component C3b, preventing excessive or unwanted activation of the complement system and protecting host tissues from damage.

Complement Factor H is a crucial protein in maintaining the balance between the protective effects of the complement system and the potential for harm to the body's own cells and tissues. Deficiencies or mutations in Complement Factor H have been associated with several diseases, including age-related macular degeneration (AMD), atypical hemolytic uremic syndrome (aHUS), and C3 glomerulopathy.

Complement C4b is a protein fragment that is formed during the activation of the complement system, which is a part of the immune system. The complement system helps to eliminate pathogens and damaged cells from the body by tagging them for destruction and attracting immune cells to the site of infection or injury.

C4b is generated when the C4 protein is cleaved into two smaller fragments, C4a and C4b, during the activation of the classical or lectin pathways of the complement system. C4b then binds covalently to the surface of the target cell or pathogen, forming a complex with other complement proteins that can create a membrane attack complex (MAC) and cause cell lysis.

C4b can also act as an opsonin, coating the surface of the target cell or pathogen and making it easier for immune cells to recognize and phagocytose them. Additionally, C4b can activate the alternative pathway of the complement system, leading to further amplification of the complement response.

Complement C2 is a protein that plays a crucial role in the complement system, which is a part of the immune system that helps to eliminate pathogens and damaged cells from the body. Specifically, C2 is a component of the classical complement pathway, which is activated by the binding of antibodies to antigens on the surface of foreign particles or cells.

When the classical pathway is activated, C2 is cleaved into two fragments: C2a and C2b. C2a then binds to C4b to form the C3 convertase (C4b2a), which cleaves C3 into C3a and C3b. C3b can then go on to form the membrane attack complex, which creates a pore in the membrane of the target cell, leading to its lysis.

In summary, Complement C2 is a protein that helps to activate the complement system and destroy foreign particles or cells through the formation of the C3 convertase and the membrane attack complex.

Complement inactivating agents are substances or drugs that inhibit the complement system, which is a part of the immune system responsible for the recognition and elimination of foreign substances and microorganisms. The complement system consists of a group of proteins that work together to help eliminate pathogens from the body.

Complement inactivating agents are used in medical settings to prevent or treat various conditions associated with excessive or unwanted activation of the complement system, such as inflammation, autoimmune diseases, and transplant rejection. These agents can inhibit different components of the complement pathway, including C1 esterase inhibitors, C3 convertase inhibitors, and C5a receptor antagonists.

Examples of complement inactivating agents include eculizumab, ravulizumab, and Alexion's Ultomiris, which are monoclonal antibodies that target C5, a protein involved in the final steps of the complement pathway. These drugs have been approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and other complement-mediated diseases.

Other complement inactivating agents include C1 esterase inhibitors, such as Berinert and Ruconest, which are used to treat hereditary angioedema (HAE). These drugs work by inhibiting the activation of the classical pathway of the complement system, thereby preventing the release of inflammatory mediators that can cause swelling and pain.

Overall, complement inactivating agents play an important role in the treatment of various complement-mediated diseases, helping to reduce inflammation, prevent tissue damage, and improve patient outcomes.

Complement C1 is a protein complex that plays a crucial role in the complement system, which is a part of the immune system that helps to eliminate pathogens and damaged cells from the body. The complement system consists of a group of proteins that work together to destroy microbes and remove debris.

Complement C1 is composed of three subunits: C1q, C1r, and C1s. When activated, C1q binds to the surface of a pathogen or damaged cell, leading to the activation of C1r and C1s. Activated C1r then cleaves and activates C1s, which in turn cleaves and activates other complement components, ultimately resulting in the formation of the membrane attack complex (MAC), a protein structure that forms a pore in the membrane of the target cell, leading to its lysis and destruction.

Defects in the complement component C1 can lead to immune disorders, such as hereditary angioedema, which is characterized by recurrent episodes of swelling in various parts of the body.

Anaphylatoxins are a group of small protein molecules that are released during an immune response, specifically as a result of the activation of the complement system. The term "anaphylatoxin" comes from their ability to induce anaphylaxis, a severe and rapid allergic reaction. There are three main anaphylatoxins, known as C3a, C4a, and C5a, which are derived from the cleavage of complement components C3, C4, and C5, respectively.

Anaphylatoxins play a crucial role in the immune response by attracting and activating various immune cells, such as neutrophils, eosinophils, and mast cells, to the site of infection or injury. They also increase vascular permeability, causing fluid to leak out of blood vessels and leading to tissue swelling. Additionally, anaphylatoxins can induce smooth muscle contraction, which can result in bronchoconstriction and hypotension.

While anaphylatoxins are important for the immune response, they can also contribute to the pathogenesis of various inflammatory diseases, such as asthma, arthritis, and sepsis. Therefore, therapies that target the complement system and anaphylatoxin production have been developed and are being investigated as potential treatments for these conditions.

Complement C3-C5 convertases are proteins that play a crucial role in the activation of the complement system, which is a part of the immune system. The complement system helps to eliminate pathogens and damaged cells from the body by marking them for destruction and attracting immune cells to the site of infection or injury.

The C3-C5 convertases are formed during the activation of the complement component 3 (C3) protein, which is a central player in the complement system. The formation of the C3-C5 convertase involves two main steps:

1. C3 convertase formation: In this step, a complex of proteins called the C3 convertase is formed by the cleavage of C3 into C3a and C3b fragments. This complex can then cleave additional C3 molecules into C3a and C3b fragments, amplifying the complement response.
2. C5 convertase formation: In this step, the C3b fragment from the C3 convertase binds to another protein called C4b2a, forming a new complex called the C5 convertase. The C5 convertase can then cleave the C5 protein into C5a and C5b fragments.

The C5b fragment goes on to form the membrane attack complex (MAC), which creates a pore in the membrane of the target cell, leading to its lysis or destruction. The C3a and C5a fragments are small proteins called anaphylatoxins that can cause inflammation and attract immune cells to the site of infection or injury.

Overall, the formation of Complement C3-C5 convertases is a critical step in the activation of the complement system and plays a key role in the body's defense against pathogens and damaged cells.

CD55, also known as Decay-accelerating factor (DAF), is a protein that acts as an inhibitor of the complement system, which is a part of the immune system. It prevents the formation of the membrane attack complex (MAC) on host cells and tissues, thereby protecting them from damage caused by the complement activation. CD55 is found on the surface of many types of cells in the body, including red blood cells, white blood cells, and cells lining the blood vessels.

As an antigen, CD55 is a molecule that can be recognized by the immune system and stimulate an immune response. However, unlike some other antigens, CD55 does not typically elicit a strong immune response because it is a self-antigen, meaning it is normally present in the body and should not be targeted by the immune system.

In certain medical conditions, such as autoimmune disorders or transplant rejection, the immune system may mistakenly attack cells expressing CD55. In these cases, measuring the levels of CD55 antigens can provide valuable diagnostic information and help guide treatment decisions.

Complement C3c is a protein component of the complement system, which is a part of the immune system that helps to clear pathogens and damaged cells from the body. Complement C3c is formed when the third component of the complement system (C3) is cleaved into two smaller proteins, C3a and C3b, during the complement activation process.

C3b can then be further cleaved into C3c and C3dg. C3c is a stable fragment that remains in the circulation and can be measured in blood tests as a marker of complement activation. It plays a role in the opsonization of pathogens, which means it coats them to make them more recognizable to immune cells, and helps to initiate the membrane attack complex (MAC), which forms a pore in the cell membrane of pathogens leading to their lysis or destruction.

Abnormal levels of C3c may indicate an underlying inflammatory or immune-mediated condition, such as infection, autoimmune disease, or cancer.

Properdin is defined as a positive regulatory protein in the complement system, which is a part of the immune system. It plays a crucial role in the alternative pathway of complement activation. Properdin stabilizes the C3 convertase (C3bBb), preventing its decay and increasing the efficiency of the alternative pathway. This results in the production of the membrane attack complex, which leads to the lysis of foreign cells or pathogens. Deficiencies in properdin can lead to an increased susceptibility to bacterial infections.

Complement receptor 3b (CR3b or CD11b/CD18) is not a medical definition itself, but I can provide you with the relevant information regarding this term.

Complement receptor 3 (CR3) is a heterodimeric receptor consisting of two subunits, CD11b (also known as Mac-1 or CR3 alpha) and CD18 (also known as beta2 integrin). There are two forms of the CD11b/CD18 heterodimer: CR3a (CD11b/CD18) and CR3b (CD11b/CD18'). The difference between these two forms lies in the conformation of the CD11b subunit.

Complement receptor 3b (CR3b or CD11b/CD18') is a less common form of the CR3 receptor, which is primarily expressed on myeloid cells such as monocytes, macrophages, and neutrophils. CR3b has a higher affinity for complement component C3b and its fragments iC3b and C3dg compared to CR3a.

CR3b plays a role in various immune functions, including:

1. Phagocytosis: Binding of C3b or its fragments to CR3b facilitates the recognition and uptake of opsonized pathogens by phagocytes.
2. Adhesion: The integrin component of CR3b mediates cell-cell and cell-matrix interactions, contributing to leukocyte migration and recruitment to sites of inflammation or infection.
3. Intracellular signaling: Activation of CR3b can lead to intracellular signaling events that modulate immune responses, such as the release of pro-inflammatory cytokines and reactive oxygen species.

In summary, Complement receptor 3b (CR3b or CD11b/CD18') is a less common form of CR3 primarily expressed on myeloid cells that binds complement component C3b and its fragments with high affinity, mediating phagocytosis, adhesion, and intracellular signaling.

A Complement Hemolytic Activity Assay is a laboratory test used to measure the functionality and activity level of the complement system, which is a part of the immune system. The complement system is a group of proteins that work together to help eliminate pathogens from the body.

The assay measures the ability of the complement system to lyse (break open) red blood cells. This is done by mixing the patient's serum (the liquid portion of the blood) with antibody-coated red blood cells and incubating them together. The complement proteins in the serum will then bind to the antibodies on the red blood cells and cause them to lyse.

The degree of hemolysis (red blood cell lysis) is directly proportional to the activity level of the complement system. By measuring the amount of hemolysis, the assay can determine whether the complement system is functioning properly and at what level of activity.

This test is often used to diagnose or monitor complement-mediated diseases such as autoimmune disorders, infections, and some types of cancer. It may also be used to evaluate the effectiveness of treatments that target the complement system.

Complement C4b-binding protein (C4bp) is a regulatory protein in the complement system, which is a part of the immune system that helps to clear pathogens and damaged cells from the body. C4bp regulates the complement system by binding to and inhibiting the activity of C4b, an activated component of the classical and lectin pathways of the complement system. By doing so, C4bp helps to prevent excessive or inappropriate activation of the complement system, which could otherwise lead to tissue damage and inflammation.

C4bp is a complex protein that consists of several subunits, including a central α-chain and multiple β-chains. It is produced by liver cells and can also be found on the surface of some cells in the body. Mutations in the genes encoding C4bp have been associated with certain immune disorders, such as systemic lupus erythematosus (SLE) and atypical hemolytic uremic syndrome (aHUS).

Mannose-Binding Lectin (MBL) is a protein that belongs to the collectin family and plays a crucial role in the innate immune system. It's primarily produced by the liver and secreted into the bloodstream. MBL binds to carbohydrate structures, such as mannose, found on the surface of various microorganisms, including bacteria, viruses, fungi, and parasites.

Once MBL binds to these microorganisms, it activates the complement system through the lectin pathway, which leads to the destruction of the pathogens by opsonization (marking for phagocytosis) or direct lysis. Additionally, MBL can also initiate other immune responses, such as inflammation and immune cell activation, helping to protect the host from infections.

Deficiencies in MBL have been associated with increased susceptibility to certain infectious diseases, autoimmune disorders, and allergies. However, more research is needed to fully understand the complex role of MBL in human health and disease.

Complement Factor D is a protein that plays a crucial role in the complement system, which is a part of the immune system that helps to clear pathogens and damaged cells from the body. Specifically, Factor D is a serine protease that is involved in the alternative pathway of the complement system.

In this pathway, Factor D helps to cleave another protein called Factor B, which then activates a complex called the C3 convertase. The C3 convertase cleaves complement component 3 (C3) into C3a and C3b, leading to the formation of the membrane attack complex (MAC), which creates a pore in the membrane of the target cell, causing its lysis and removal from the body.

Deficiencies or mutations in Complement Factor D can lead to an impaired alternative pathway and increased susceptibility to certain infections, particularly those caused by Neisseria bacteria. Additionally, abnormal regulation of the complement system has been implicated in a variety of diseases, including autoimmune disorders, inflammatory conditions, and neurodegenerative diseases.

Cobra venoms are a type of snake venom that is produced by cobras, which are members of the genus Naja in the family Elapidae. These venoms are complex mixtures of proteins and other molecules that have evolved to help the snake immobilize and digest its prey.

Cobra venoms typically contain a variety of toxic components, including neurotoxins, hemotoxins, and cytotoxins. Neurotoxins target the nervous system and can cause paralysis and respiratory failure. Hemotoxins damage blood vessels and tissues, leading to internal bleeding and organ damage. Cytotoxins destroy cells and can cause tissue necrosis.

The specific composition of cobra venoms can vary widely between different species of cobras, as well as between individual snakes of the same species. Some cobras have venoms that are primarily neurotoxic, while others have venoms that are more hemotoxic or cytotoxic. The potency and effects of cobra venoms can also be influenced by factors such as the age and size of the snake, as well as the temperature and pH of the environment.

Cobra bites can be extremely dangerous and even fatal to humans, depending on the species of cobra, the amount of venom injected, and the location of the bite. Immediate medical attention is required in the event of a cobra bite, including the administration of antivenom therapy to neutralize the effects of the venom.

Complement C6 is a protein that plays a crucial role in the complement system, which is a part of the immune system that helps to eliminate pathogens and damaged cells from the body. Specifically, C6 is a component of the membrane attack complex (MAC), which is a group of proteins that work together to form a pore in the membrane of target cells, leading to their lysis or destruction.

The complement system is activated through several different pathways, including the classical pathway, the lectin pathway, and the alternative pathway. Once activated, these pathways converge at the level of C3, which is cleaved into C3a and C3b fragments. C3b can then bind to the surface of target cells and initiate the formation of the MAC.

C6 is one of several proteins that are required for the formation of the MAC. When C6 binds to C7, it undergoes a conformational change that allows it to interact with C8 and form a stable complex. This complex then recruits additional C9 molecules, which polymerize to form the pore in the target cell membrane.

Deficiencies in complement components, including C6, can lead to increased susceptibility to certain types of infections, as well as autoimmune disorders and other medical conditions.

The Mannose-Binding Lectin (MBL) pathway is a part of the complement system, which is a group of proteins that play a crucial role in the body's immune defense against infectious agents. The MBL pathway is an alternative activation pathway of the complement system, which can be initiated without the need for antibodies.

MBL is a protein found in blood plasma and other bodily fluids. It recognizes and binds to specific sugars (mannose and fucose) found on the surface of many microorganisms, including bacteria, viruses, fungi, and parasites. When MBL binds to these sugars, it triggers a series of proteolytic cleavage events that activate the complement components C4 and C2, forming the C3 convertase (C4b2a).

The C3 convertase then cleaves the complement component C3 into C3a and C3b. C3b can bind to the surface of microorganisms, leading to their opsonization (coating) and subsequent phagocytosis by immune cells. Additionally, C3b can also trigger the formation of the membrane attack complex (MAC), which creates a pore in the membrane of microorganisms, leading to their lysis and death.

Overall, the MBL pathway plays an essential role in innate immunity, providing a rapid and effective defense against invading microorganisms.

Complement activating enzymes are proteins that play a crucial role in the activation of the complement system, which is a part of the immune system. The complement system is a complex series of biochemical reactions that help to eliminate pathogens and damaged cells from the body.

There are several types of complement activating enzymes, including:

1. Classical pathway activators: These include the C1, C4, and C2 components of the complement system. When activated, they trigger a series of reactions that lead to the formation of the membrane attack complex (MAC), which creates a pore in the membrane of the target cell, leading to its lysis.
2. Alternative pathway activators: These include factors B, D, and P. They are constantly active at low levels and can be activated by surfaces that are not normally found in the body, such as bacterial cell walls. Once activated, they also trigger the formation of the MAC.
3. Lectin pathway activators: These include mannose-binding lectin (MBL) and ficolins. They bind to carbohydrates on the surface of microbes and activate the complement system through the MBL-associated serine proteases (MASPs).

Overall, complement activating enzymes play a critical role in the immune response by helping to identify and eliminate pathogens and damaged cells from the body.

CD59 is a type of protein found on the surface of many cells in the human body, including red and white blood cells, that functions as an inhibitor of the complement system. The complement system is a part of the immune system that helps to eliminate pathogens such as bacteria and viruses from the body.

CD59 specifically inhibits the formation of the membrane attack complex (MAC), which is a protein structure that forms pores in the cell membrane and can lead to cell lysis or death. By preventing the formation of the MAC, CD59 helps to protect cells from complement-mediated damage.

As an antigen, CD59 is a molecule that can be recognized by the immune system and stimulate an immune response. However, because it is a self-protein found on normal human cells, CD59 is not typically targeted by the immune system unless there is some kind of dysregulation or abnormality.

In certain medical conditions, such as autoimmune disorders or transplant rejection, the immune system may mistakenly target CD59 or other self-proteins, leading to damage to healthy cells and tissues. In these cases, treatments may be necessary to modulate or suppress the immune response and prevent further harm.

Complement C3b inactivator proteins, also known as complement regulators or decay-accelerating factor (DAF), are a group of proteins that play a crucial role in regulating the complement system. The complement system is a part of the immune system that helps to eliminate pathogens and damaged cells from the body.

The complement C3b inactivator proteins include two main types: complement receptor 1 (CR1) and decay-accelerating factor (DAF). These proteins work by regulating the formation of the membrane attack complex (MAC), a protein structure that forms pores in the cell membrane, leading to cell lysis.

Complement C3b inactivator proteins bind to C3b and C4b components of the complement system, preventing them from forming the MAC. By doing so, they help to prevent excessive activation of the complement system, which can damage healthy cells and tissues.

Deficiencies or dysfunction of complement C3b inactivator proteins have been associated with several diseases, including autoimmune disorders, inflammatory diseases, and infectious diseases. Therefore, understanding the role of these proteins in regulating the complement system is essential for developing new therapies to treat these conditions.

Complement C3 Convertase, Alternative Pathway is a complex enzyme composed of the proteins C3b and Bb. It plays a crucial role in the alternative pathway of the complement system, which is a part of the innate immune system that helps to defend the body against invading pathogens.

The alternative pathway is continuously activated at a low level, and C3 Convertase is responsible for amplifying this activation. It does so by cleaving the complement component C3 into C3a and C3b. The C3b then binds to the surface of the pathogen and can form additional C3 Convertases, leading to a positive feedback loop that results in the rapid accumulation of complement components on the surface of the pathogen.

This accumulation of complement components helps to mark the pathogen for destruction by other immune cells, such as neutrophils and macrophages. Additionally, the cleavage products C3a and C5a generated during this process can act as anaphylatoxins, inducing inflammation and attracting more immune cells to the site of infection.

Regulation of Complement C3 Convertase is critical to prevent damage to host tissues. Several regulatory proteins, such as factor H and decay-accelerating factor (DAF), help to limit the formation and activity of C3 Convertase on host cells and tissues. Dysregulation of the complement system, including the alternative pathway and Complement C3 Convertase, has been implicated in a variety of diseases, including autoimmune disorders, inflammatory diseases, and infectious diseases.

Complement C4a is a protein fragment or cleavage product generated during the activation of the complement system, which is a part of the immune system. The complement system helps to eliminate pathogens and damaged cells by marking them for destruction and direct lysis. Complement component 4 (C4) is one of the key proteins in this cascade, and it gets cleaved into C4a and C4b during the activation process.

C4a is a small anaphylatoxin with a molecular weight of approximately 9 kDa. It has chemotactic properties, meaning it can attract immune cells like neutrophils to the site of complement activation. Additionally, C4a can induce histamine release from mast cells and basophils, contributing to local inflammation. However, its precise physiological role in the immune response is not entirely clear, and dysregulation of C4a production has been implicated in several pathological conditions, such as autoimmune diseases and allergies.

Complement receptor 3d (CR3d or CD11b/CD18) is not a medical definition in itself, but rather a specific type of integrin receptor that plays a crucial role in the immune system. Here's a breakdown of the components:

1. Complement Receptors: These are proteins found on the surface of various cells, including white blood cells (leukocytes), that recognize and bind to complement components, which are proteins involved in the immune response. The binding of complement components to their receptors helps facilitate communication between cells, enhances phagocytosis (the process by which certain cells engulf and destroy foreign particles or microorganisms), and contributes to the inflammatory response.
2. CR3 (Complement Receptor 3): Complement Receptor 3 is a heterodimeric receptor composed of two subunits, CD11b (also known as integrin alpha M) and CD18 (also known as integrin beta 2). Together, they form the integrin Mac-1 or αMβ2.
3. CR3d (CD11b/CD18): CR3d specifically refers to the CD11b subunit of the Complement Receptor 3 heterodimer. The CD11b subunit is responsible for recognizing and binding to complement component C3b, iC3b, and C4b fragments, as well as other ligands such as fibrinogen, ICAM-1 (Intercellular Adhesion Molecule 1), and factor X.

In summary, Complement Receptor 3d (CR3d or CD11b/CD18) is a type of integrin receptor found on the surface of various immune cells that recognizes and binds to complement components C3b, iC3b, and C4b fragments, as well as other ligands. This binding facilitates communication between cells, enhances phagocytosis, and contributes to the inflammatory response.

The term "Receptor, Anaphylatoxin C5a" refers to a specific type of receptor found on the surface of various cells in the human body, including immune cells and endothelial cells. This receptor binds to a molecule called C5a, which is a cleavage product of the complement component C5 and is one of the most potent anaphylatoxins.

Anaphylatoxins are inflammatory mediators that play a crucial role in the immune response, particularly in the activation of the complement system and the recruitment of immune cells to sites of infection or injury. C5a is generated during the activation of the complement system and has a wide range of biological activities, including chemotaxis (attracting immune cells to the site of inflammation), increased vascular permeability, and the activation of immune cells such as neutrophils, monocytes, and mast cells.

The C5a receptor, also known as CD88, is a G protein-coupled receptor that belongs to the superfamily of seven transmembrane domain receptors. When C5a binds to the receptor, it triggers a series of intracellular signaling events that lead to the activation of various cellular responses, such as the release of inflammatory mediators and the recruitment of immune cells to the site of inflammation.

Abnormal activation of the C5a/C5a receptor pathway has been implicated in a variety of inflammatory diseases, including sepsis, acute respiratory distress syndrome (ARDS), and autoimmune disorders. Therefore, targeting this pathway with therapeutic agents has emerged as a promising strategy for the treatment of these conditions.

Complement Factor I is a protein involved in the regulation of the complement system, which is a part of the immune system that helps to clear pathogens and damaged cells from the body. Specifically, Complement Factor I is a serine protease that regulates the complement component C3b by cleaving it into inactive fragments, thereby preventing the excessive activation of the complement system and protecting host tissues from damage.

Complement Factor I functions in conjunction with other regulatory proteins, such as complement receptor 1 (CR1) and membrane cofactor protein (MCP), to control the activity of the complement system at various stages. Deficiencies or mutations in Complement Factor I have been associated with several diseases, including atypical hemolytic uremic syndrome (aHUS), age-related macular degeneration (AMD), and systemic lupus erythematosus (SLE).

Complement C1 Inactivator proteins are a part of the complement system, which is a group of proteins in the blood that play a crucial role in the body's immune defense system. Specifically, Complement C1 Inactivator proteins are responsible for regulating the activation of the first component of the complement system, C1.

The complement system is activated in response to the presence of foreign substances such as bacteria or viruses in the body. The activation of C1 leads to a cascade of reactions that result in the destruction of the foreign substance. However, if this process is not properly regulated, it can lead to damage to the body's own cells and tissues.

Complement C1 Inactivator proteins help to prevent this by regulating the activation of C1. They do this by binding to and inhibiting the activity of C1, preventing it from initiating the complement cascade. A deficiency in Complement C1 Inactivator proteins can lead to a condition called hereditary angioedema, which is characterized by recurrent episodes of swelling in various parts of the body.

Mannose-binding protein-associated serine proteases (MASPs) are a group of enzymes that are associated with mannose-binding lectin (MBL), a protein involved in the innate immune system's response to pathogens. MASPs are responsible for activating the complement system, which is a part of the immune system that helps to eliminate pathogens and damaged cells from the body.

MASPs are proteases, meaning they cleave other proteins at specific sites. There are two main types of MASPs, MASP-1 and MASP-2, which are activated by the binding of MBL to carbohydrate structures on the surface of pathogens. Once activated, MASP-1 and MASP-2 cleave complement components C4 and C2, leading to the formation of the C3 convertase enzyme complex, which ultimately results in the activation of the complement system.

MASPs have also been shown to play a role in other physiological processes, such as tissue remodeling and inflammation. Mutations in MASP genes have been associated with various immune disorders, including recurrent infections, autoimmune diseases, and inflammatory conditions.

CD46, also known as membrane cofactor protein (MCP), is a regulatory protein that plays a role in the immune system and helps to protect cells from complement activation. It is found on the surface of many different types of cells in the body, including cells of the immune system such as T cells and B cells, as well as cells of various other tissues such as epithelial cells and endothelial cells.

As an antigen, CD46 is a molecule that can be recognized by the immune system and stimulate an immune response. It is a type I transmembrane protein that consists of four distinct domains: two short cytoplasmic domains, a transmembrane domain, and a large extracellular domain. The extracellular domain contains several binding sites for complement proteins, which helps to regulate the activation of the complement system and prevent it from damaging host cells.

CD46 has been shown to play a role in protecting cells from complement-mediated damage, modulating immune responses, and promoting the survival and proliferation of certain types of immune cells. It is also thought to be involved in the development of some autoimmune diseases and may be a target for immunotherapy in the treatment of cancer.

Complement C8 is a protein component of the complement system, which is a part of the immune system that helps to eliminate pathogens and damaged cells from the body. Specifically, C8 is a part of the membrane attack complex (MAC), which forms a pore in the membrane of target cells, leading to their lysis or destruction.

C8 is composed of three subunits: alpha, beta, and gamma. It is activated when it binds to the complement component C5b67 complex on the surface of a target cell. Once activated, C8 undergoes a conformational change that allows it to insert into the target cell membrane and form a pore, which disrupts the cell's membrane integrity and can lead to its death.

Deficiencies in complement components, including C8, can make individuals more susceptible to certain infections and autoimmune diseases. Additionally, mutations in the genes encoding complement proteins have been associated with various inherited disorders, such as atypical hemolytic uremic syndrome (aHUS), which is characterized by thrombotic microangiopathy and kidney failure.

Complement fixation tests are a type of laboratory test used in immunology and serology to detect the presence of antibodies in a patient's serum. These tests are based on the principle of complement activation, which is a part of the immune response. The complement system consists of a group of proteins that work together to help eliminate pathogens from the body.

In a complement fixation test, the patient's serum is mixed with a known antigen and complement proteins. If the patient has antibodies against the antigen, they will bind to it and activate the complement system. This results in the consumption or "fixation" of the complement proteins, which are no longer available to participate in a secondary reaction.

A second step involves adding a fresh source of complement proteins and a dye-labeled antibody that recognizes a specific component of the complement system. If complement was fixed during the first step, it will not be available for this secondary reaction, and the dye-labeled antibody will remain unbound. Conversely, if no antibodies were present in the patient's serum, the complement proteins would still be available for the second reaction, leading to the binding of the dye-labeled antibody.

The mixture is then examined under a microscope or using a spectrophotometer to determine whether the dye-labeled antibody has bound. If it has not, this indicates that the patient's serum contains antibodies specific to the antigen used in the test, and a positive result is recorded.

Complement fixation tests have been widely used for the diagnosis of various infectious diseases, such as syphilis, measles, and influenza. However, they have largely been replaced by more modern serological techniques, like enzyme-linked immunosorbent assays (ELISAs) and nucleic acid amplification tests (NAATs), due to their increased sensitivity, specificity, and ease of use.

Hemolysis is the destruction or breakdown of red blood cells, resulting in the release of hemoglobin into the surrounding fluid (plasma). This process can occur due to various reasons such as chemical agents, infections, autoimmune disorders, mechanical trauma, or genetic abnormalities. Hemolysis may lead to anemia and jaundice, among other complications. It is essential to monitor hemolysis levels in patients undergoing medical treatments that might cause this condition.

Complement C7 is a protein that plays a role in the complement system, which is a part of the immune system that helps to clear pathogens and damaged cells from the body. Specifically, C7 is a component of the membrane attack complex (MAC), which is a group of proteins that forms a pore in the membrane of target cells, leading to their lysis or destruction.

C7 is activated when it binds to the C5b-7 complex, which is formed by the cleavage of C5 and C6 by the C5 convertase. Once bound to the C5b-7 complex, C7 undergoes a conformational change that allows it to insert into the target cell membrane. This forms the basis for the formation of the MAC and subsequent lysis of the target cell.

Deficiencies in complement components, including C7, can lead to increased susceptibility to certain infections and autoimmune disorders. Additionally, abnormal regulation of the complement system has been implicated in a variety of diseases, including inflammatory and degenerative conditions.

The Complement C1 Inhibitor protein, also known as C1-INH, is a protein involved in the regulation of the complement system and the contact system, which are parts of the immune system. The complement system helps to eliminate pathogens (e.g., bacteria, viruses) from the body, while the contact system helps to regulate blood coagulation and inflammation.

C1-INH works by inhibiting the activation of C1, an enzyme complex that is the first component of the classical complement pathway. By inhibiting C1, C1-INH prevents the activation of downstream components of the complement system, thereby helping to regulate the immune response and prevent excessive inflammation.

Deficiencies or dysfunction in the C1-INH protein can lead to a group of genetic disorders known as C1 inhibitor deficiency disorders, which include hereditary angioedema (HAE) and acquired angioedema (AAE). These conditions are characterized by recurrent episodes of swelling in various parts of the body, such as the face, hands, feet, and airway, which can be painful and potentially life-threatening if they affect the airway.

An antigen-antibody complex is a type of immune complex that forms when an antibody binds to a specific antigen. An antigen is any substance that triggers an immune response, while an antibody is a protein produced by the immune system to neutralize or destroy foreign substances like antigens.

When an antibody binds to an antigen, it forms a complex that can be either soluble or insoluble. Soluble complexes are formed when the antigen is small and can move freely through the bloodstream. Insoluble complexes, on the other hand, are formed when the antigen is too large to move freely, such as when it is part of a bacterium or virus.

The formation of antigen-antibody complexes plays an important role in the immune response. Once formed, these complexes can be recognized and cleared by other components of the immune system, such as phagocytes, which help to prevent further damage to the body. However, in some cases, the formation of large numbers of antigen-antibody complexes can lead to inflammation and tissue damage, contributing to the development of certain autoimmune diseases.

Collectins are a group of proteins that belong to the collectin family, which are involved in the innate immune system. They are composed of a collagen-like region and a carbohydrate recognition domain (CRD), which allows them to bind to specific sugars on the surface of microorganisms, cells, and particles. Collectins play a crucial role in the defense against pathogens by promoting the clearance of microbes, modulating inflammation, and regulating immune responses.

Some examples of collectins include:

* Surfactant protein A (SP-A) and surfactant protein D (SP-D), which are found in the lungs and help to maintain the stability of the lung lining and protect against respiratory infections.
* Mannose-binding lectin (MBL), which is a serum protein that binds to mannose sugars on the surface of microorganisms, activating the complement system and promoting phagocytosis.
* Collectin liver 1 (CL-L1) and collectin kidney 1 (CL-K1), which are found in the liver and kidneys, respectively, and play a role in the clearance of apoptotic cells and immune complexes.

Deficiencies or mutations in collectins can lead to increased susceptibility to infections, autoimmune diseases, and other disorders.

Complement C5b is a protein complex that forms during the activation of the complement system, which is a part of the immune system. The complement system helps to eliminate pathogens and damaged cells from the body by marking them for destruction and attracting immune cells to the site of infection or injury.

The complement component C5 is cleaved into two fragments, C5a and C5b, during the activation of the complement system. C5a is a small peptide that acts as a chemoattractant, drawing immune cells to the site of inflammation. C5b, on the other hand, forms a complex with other complement components (C6, C7, C8, and C9) to create the membrane attack complex (MAC). The MAC inserts itself into the membrane of the target cell, forming a pore that disrupts the cell's integrity and leads to its lysis or destruction.

Therefore, Complement C5b is an important protein involved in the immune response, specifically in the terminal phase of complement activation, which results in the formation of the MAC and subsequent destruction of target cells.

Complement C1s is a protein that plays a crucial role in the complement system, which is a part of the immune system that helps to clear pathogens and damaged cells from the body. Specifically, C1s is a component of the first protein complex in the classical complement pathway, called C1.

C1 is composed of three subunits: C1q, C1r, and C1s. When C1 encounters an activating surface, such as an antibody-antigen complex or certain types of viruses and bacteria, it undergoes a conformational change that allows C1r to cleave and activate C1s. Activated C1s then goes on to cleave and activate other components in the complement pathway, leading to the generation of the membrane attack complex (MAC) and subsequent lysis of the target cell.

Deficiencies or mutations in the genes encoding complement proteins, including C1s, can lead to various immune disorders and increased susceptibility to infections.

Opsonins are proteins found in the blood that help enhance the immune system's response to foreign substances, such as bacteria and viruses. They do this by coating the surface of these pathogens, making them more recognizable to immune cells like neutrophils and macrophages. This process, known as opsonization, facilitates the phagocytosis (engulfing and destroying) of the pathogen by these immune cells.

There are two main types of opsonins:

1. IgG antibodies: These are a type of antibody produced by the immune system in response to an infection. They bind to specific antigens on the surface of the pathogen, marking them for destruction by phagocytic cells.
2. Complement proteins: The complement system is a group of proteins that work together to help eliminate pathogens. When activated, the complement system can produce various proteins that act as opsonins, including C3b and C4b. These proteins bind to the surface of the pathogen, making it easier for phagocytic cells to recognize and destroy them.

In summary, opsonin proteins are crucial components of the immune system's response to infections, helping to mark foreign substances for destruction by immune cells like neutrophils and macrophages.

Complement C1r is a protein that plays a crucial role in the complement system, which is a part of the immune system that helps to clear pathogens and damaged cells from the body. Specifically, C1r is one of the three proteins that make up the C1 complex, which is the first component of the classical complement pathway.

The C1 complex is composed of C1q, C1r, and C1s, and it is activated by the binding of C1q to the Fc region of an antibody that is bound to a pathogen or damaged cell. Once activated, C1r undergoes a conformational change that allows it to cleave and activate C1s. Activated C1s then goes on to cleave and activate other components of the complement system, leading to the production of the membrane attack complex (MAC), which forms a pore in the membrane of the target cell and causes lysis.

Deficiencies or mutations in the genes encoding the proteins of the C1 complex can lead to immune disorders, including hereditary angioedema, which is characterized by recurrent episodes of swelling in various parts of the body.

Immunoglobulin G (IgG) is a type of antibody, which is a protective protein produced by the immune system in response to foreign substances like bacteria or viruses. IgG is the most abundant type of antibody in human blood, making up about 75-80% of all antibodies. It is found in all body fluids and plays a crucial role in fighting infections caused by bacteria, viruses, and toxins.

IgG has several important functions:

1. Neutralization: IgG can bind to the surface of bacteria or viruses, preventing them from attaching to and infecting human cells.
2. Opsonization: IgG coats the surface of pathogens, making them more recognizable and easier for immune cells like neutrophils and macrophages to phagocytose (engulf and destroy) them.
3. Complement activation: IgG can activate the complement system, a group of proteins that work together to help eliminate pathogens from the body. Activation of the complement system leads to the formation of the membrane attack complex, which creates holes in the cell membranes of bacteria, leading to their lysis (destruction).
4. Antibody-dependent cellular cytotoxicity (ADCC): IgG can bind to immune cells like natural killer (NK) cells and trigger them to release substances that cause target cells (such as virus-infected or cancerous cells) to undergo apoptosis (programmed cell death).
5. Immune complex formation: IgG can form immune complexes with antigens, which can then be removed from the body through various mechanisms, such as phagocytosis by immune cells or excretion in urine.

IgG is a critical component of adaptive immunity and provides long-lasting protection against reinfection with many pathogens. It has four subclasses (IgG1, IgG2, IgG3, and IgG4) that differ in their structure, function, and distribution in the body.

Zymosan is a type of substance that is derived from the cell walls of yeast and some types of fungi. It's often used in laboratory research as an agent to stimulate inflammation, because it can activate certain immune cells (such as neutrophils) and cause them to release pro-inflammatory chemicals.

In medical terms, Zymosan is sometimes used as a tool for studying the immune system and inflammation in experimental settings. It's important to note that Zymosan itself is not a medical condition or disease, but rather a research reagent with potential applications in understanding human health and disease.

Complement C5a, des-Arginine is a derivative of the complement component C5a. The complement system is a group of proteins that are part of the body's immune defense against foreign invaders such as bacteria and viruses. When activated, the complement system can help to eliminate pathogens by attracting immune cells to the site of infection, promoting inflammation, and directly killing the pathogen.

C5a is a small protein that is generated when the complement component C5 is cleaved during the activation of the complement system. C5a is a potent anaphylatoxin, which means it can cause the release of histamine from mast cells and basophils, leading to increased vascular permeability, smooth muscle contraction, and recruitment of immune cells to the site of infection.

Des-Arginine refers to the removal of an arginine residue from the C-terminus of C5a. This modified form of C5a is known as C5a-desArg and has reduced pro-inflammatory activity compared to intact C5a. However, it can still contribute to the regulation of the immune response by interacting with specific receptors on immune cells.

In summary, Complement C5a, des-Arginine is a derivative of the complement component C5a that has reduced pro-inflammatory activity due to the removal of an arginine residue from its C-terminus.

Neutrophils are a type of white blood cell that are part of the immune system's response to infection. They are produced in the bone marrow and released into the bloodstream where they circulate and are able to move quickly to sites of infection or inflammation in the body. Neutrophils are capable of engulfing and destroying bacteria, viruses, and other foreign substances through a process called phagocytosis. They are also involved in the release of inflammatory mediators, which can contribute to tissue damage in some cases. Neutrophils are characterized by the presence of granules in their cytoplasm, which contain enzymes and other proteins that help them carry out their immune functions.

Phagocytosis is the process by which certain cells in the body, known as phagocytes, engulf and destroy foreign particles, bacteria, or dead cells. This mechanism plays a crucial role in the immune system's response to infection and inflammation. Phagocytes, such as neutrophils, monocytes, and macrophages, have receptors on their surface that recognize and bind to specific molecules (known as antigens) on the target particles or microorganisms.

Once attached, the phagocyte extends pseudopodia (cell extensions) around the particle, forming a vesicle called a phagosome that completely encloses it. The phagosome then fuses with a lysosome, an intracellular organelle containing digestive enzymes and other chemicals. This fusion results in the formation of a phagolysosome, where the engulfed particle is broken down by the action of these enzymes, neutralizing its harmful effects and allowing for the removal of cellular debris or pathogens.

Phagocytosis not only serves as a crucial defense mechanism against infections but also contributes to tissue homeostasis by removing dead cells and debris.

Immunoglobulin M (IgM) is a type of antibody that is primarily found in the blood and lymph fluid. It is the first antibody to be produced in response to an initial exposure to an antigen, making it an important part of the body's primary immune response. IgM antibodies are large molecules that are composed of five basic units, giving them a pentameric structure. They are primarily found on the surface of B cells as membrane-bound immunoglobulins (mlgM), where they function as receptors for antigens. Once an mlgM receptor binds to an antigen, it triggers the activation and differentiation of the B cell into a plasma cell that produces and secretes large amounts of soluble IgM antibodies.

IgM antibodies are particularly effective at agglutination (clumping) and complement activation, which makes them important in the early stages of an immune response to help clear pathogens from the bloodstream. However, they are not as stable or long-lived as other types of antibodies, such as IgG, and their levels tend to decline after the initial immune response has occurred.

In summary, Immunoglobulin M (IgM) is a type of antibody that plays a crucial role in the primary immune response to antigens by agglutination and complement activation. It is primarily found in the blood and lymph fluid, and it is produced by B cells after they are activated by an antigen.

Protein binding, in the context of medical and biological sciences, refers to the interaction between a protein and another molecule (known as the ligand) that results in a stable complex. This process is often reversible and can be influenced by various factors such as pH, temperature, and concentration of the involved molecules.

In clinical chemistry, protein binding is particularly important when it comes to drugs, as many of them bind to proteins (especially albumin) in the bloodstream. The degree of protein binding can affect a drug's distribution, metabolism, and excretion, which in turn influence its therapeutic effectiveness and potential side effects.

Protein-bound drugs may be less available for interaction with their target tissues, as only the unbound or "free" fraction of the drug is active. Therefore, understanding protein binding can help optimize dosing regimens and minimize adverse reactions.

Immune complex diseases are medical conditions that occur when the immune system produces an abnormal response to certain antigens, leading to the formation and deposition of immune complexes in various tissues and organs. These immune complexes consist of antibodies bound to antigens, which can trigger an inflammatory reaction and damage the surrounding tissue.

Immune complex diseases can be classified into two categories: acute and chronic. Acute immune complex diseases include serum sickness and hypersensitivity vasculitis, while chronic immune complex diseases include systemic lupus erythematosus (SLE), rheumatoid arthritis, and membranoproliferative glomerulonephritis.

The symptoms of immune complex diseases depend on the location and extent of tissue damage. They can range from mild to severe and may include fever, joint pain, skin rashes, kidney dysfunction, and neurological problems. Treatment typically involves medications that suppress the immune system and reduce inflammation, such as corticosteroids, immunosuppressants, and anti-inflammatory drugs.

Blood bactericidal activity refers to the ability of an individual's blood to kill or inhibit the growth of bacteria. This is an important aspect of the body's immune system, as it helps to prevent infection and maintain overall health. The bactericidal activity of blood can be influenced by various factors, including the presence of antibodies, white blood cells (such as neutrophils), and complement proteins.

In medical terms, the term "bactericidal" specifically refers to an agent or substance that is capable of killing bacteria. Therefore, when we talk about blood bactericidal activity, we are referring to the collective ability of various components in the blood to kill or inhibit the growth of bacteria. This is often measured in laboratory tests as a way to assess a person's immune function and their susceptibility to infection.

It's worth noting that not all substances in the blood are bactericidal; some may simply inhibit the growth of bacteria without killing them. These substances are referred to as bacteriostatic. Both bactericidal and bacteriostatic agents play important roles in maintaining the body's defense against infection.

Lectins are a type of proteins that bind specifically to carbohydrates and have been found in various plant and animal sources. They play important roles in biological recognition events, such as cell-cell adhesion, and can also be involved in the immune response. Some lectins can agglutinate certain types of cells or precipitate glycoproteins, while others may have a more direct effect on cellular processes. In some cases, lectins from plants can cause adverse effects in humans if ingested, such as digestive discomfort or allergic reactions.

Erythrocytes, also known as red blood cells (RBCs), are the most common type of blood cell in circulating blood in mammals. They are responsible for transporting oxygen from the lungs to the body's tissues and carbon dioxide from the tissues to the lungs.

Erythrocytes are formed in the bone marrow and have a biconcave shape, which allows them to fold and bend easily as they pass through narrow blood vessels. They do not have a nucleus or mitochondria, which makes them more flexible but also limits their ability to reproduce or repair themselves.

In humans, erythrocytes are typically disc-shaped and measure about 7 micrometers in diameter. They contain the protein hemoglobin, which binds to oxygen and gives blood its red color. The lifespan of an erythrocyte is approximately 120 days, after which it is broken down in the liver and spleen.

Abnormalities in erythrocyte count or function can lead to various medical conditions, such as anemia, polycythemia, and sickle cell disease.

C57BL/6 (C57 Black 6) is an inbred strain of laboratory mouse that is widely used in biomedical research. The term "inbred" refers to a strain of animals where matings have been carried out between siblings or other closely related individuals for many generations, resulting in a population that is highly homozygous at most genetic loci.

The C57BL/6 strain was established in 1920 by crossing a female mouse from the dilute brown (DBA) strain with a male mouse from the black strain. The resulting offspring were then interbred for many generations to create the inbred C57BL/6 strain.

C57BL/6 mice are known for their robust health, longevity, and ease of handling, making them a popular choice for researchers. They have been used in a wide range of biomedical research areas, including studies of cancer, immunology, neuroscience, cardiovascular disease, and metabolism.

One of the most notable features of the C57BL/6 strain is its sensitivity to certain genetic modifications, such as the introduction of mutations that lead to obesity or impaired glucose tolerance. This has made it a valuable tool for studying the genetic basis of complex diseases and traits.

Overall, the C57BL/6 inbred mouse strain is an important model organism in biomedical research, providing a valuable resource for understanding the genetic and molecular mechanisms underlying human health and disease.

Monoclonal antibodies are a type of antibody that are identical because they are produced by a single clone of cells. They are laboratory-produced molecules that act like human antibodies in the immune system. They can be designed to attach to specific proteins found on the surface of cancer cells, making them useful for targeting and treating cancer. Monoclonal antibodies can also be used as a therapy for other diseases, such as autoimmune disorders and inflammatory conditions.

Monoclonal antibodies are produced by fusing a single type of immune cell, called a B cell, with a tumor cell to create a hybrid cell, or hybridoma. This hybrid cell is then able to replicate indefinitely, producing a large number of identical copies of the original antibody. These antibodies can be further modified and engineered to enhance their ability to bind to specific targets, increase their stability, and improve their effectiveness as therapeutic agents.

Monoclonal antibodies have several mechanisms of action in cancer therapy. They can directly kill cancer cells by binding to them and triggering an immune response. They can also block the signals that promote cancer growth and survival. Additionally, monoclonal antibodies can be used to deliver drugs or radiation directly to cancer cells, increasing the effectiveness of these treatments while minimizing their side effects on healthy tissues.

Monoclonal antibodies have become an important tool in modern medicine, with several approved for use in cancer therapy and other diseases. They are continuing to be studied and developed as a promising approach to treating a wide range of medical conditions.

Antibodies are proteins produced by the immune system in response to the presence of a foreign substance, such as a bacterium or virus. They are capable of identifying and binding to specific antigens (foreign substances) on the surface of these invaders, marking them for destruction by other immune cells. Antibodies are also known as immunoglobulins and come in several different types, including IgA, IgD, IgE, IgG, and IgM, each with a unique function in the immune response. They are composed of four polypeptide chains, two heavy chains and two light chains, that are held together by disulfide bonds. The variable regions of the heavy and light chains form the antigen-binding site, which is specific to a particular antigen.

Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.

Hemolytic-Uremic Syndrome (HUS) is a serious condition that affects the blood and kidneys. It is characterized by three major features: the breakdown of red blood cells (hemolysis), the abnormal clotting of small blood vessels (microthrombosis), and acute kidney failure.

The breakdown of red blood cells leads to the release of hemoglobin into the bloodstream, which can cause anemia. The microthrombi can obstruct the flow of blood in the kidneys' filtering system (glomeruli), leading to damaged kidney function and potentially acute kidney failure.

HUS is often caused by a bacterial infection, most commonly Escherichia coli (E. coli) that produces Shiga toxins. This form of HUS is known as STEC-HUS or Stx-HUS. Other causes include infections with other bacteria, viruses, medications, pregnancy complications, and certain medical conditions such as autoimmune diseases.

Symptoms of HUS may include fever, fatigue, decreased urine output, blood in the stool, swelling in the face, hands, or feet, and irritability or confusion. Treatment typically involves supportive care, including dialysis for kidney failure, transfusions to replace lost red blood cells, and managing high blood pressure. In severe cases, a kidney transplant may be necessary.

An Enzyme-Linked Immunosorbent Assay (ELISA) is a type of analytical biochemistry assay used to detect and quantify the presence of a substance, typically a protein or peptide, in a liquid sample. It takes its name from the enzyme-linked antibodies used in the assay.

In an ELISA, the sample is added to a well containing a surface that has been treated to capture the target substance. If the target substance is present in the sample, it will bind to the surface. Next, an enzyme-linked antibody specific to the target substance is added. This antibody will bind to the captured target substance if it is present. After washing away any unbound material, a substrate for the enzyme is added. If the enzyme is present due to its linkage to the antibody, it will catalyze a reaction that produces a detectable signal, such as a color change or fluorescence. The intensity of this signal is proportional to the amount of target substance present in the sample, allowing for quantification.

ELISAs are widely used in research and clinical settings to detect and measure various substances, including hormones, viruses, and bacteria. They offer high sensitivity, specificity, and reproducibility, making them a reliable choice for many applications.

Cryoglobulins are immunoglobulins (a type of antibody) that precipitate or become insoluble at reduced temperatures, typically below 37°C (98.6°F), and re-dissolve when rewarmed. They can be found in various clinical conditions such as infections, inflammatory diseases, and lymphoproliferative disorders.

The presence of cryoglobulins in the blood can lead to a variety of symptoms, including purpura (a type of skin rash), arthralgias (joint pain), neuropathy (nerve damage), and glomerulonephritis (kidney inflammation). The diagnosis of cryoglobulinemia is made by detecting the presence of cryoglobulins in the serum, which requires special handling and processing of the blood sample. Treatment of cryoglobulinemia depends on the underlying cause and may include medications such as corticosteroids, immunosuppressive agents, or targeted therapies.

Macular degeneration, also known as age-related macular degeneration (AMD), is a medical condition that affects the central part of the retina, called the macula. The macula is responsible for sharp, detailed vision, which is necessary for activities such as reading, driving, and recognizing faces.

In AMD, there is a breakdown or deterioration of the macula, leading to gradual loss of central vision. There are two main types of AMD: dry (atrophic) and wet (exudative). Dry AMD is more common and progresses more slowly, while wet AMD is less common but can cause rapid and severe vision loss if left untreated.

The exact causes of AMD are not fully understood, but risk factors include age, smoking, family history, high blood pressure, obesity, and exposure to sunlight. While there is no cure for AMD, treatments such as vitamin supplements, laser therapy, and medication injections can help slow its progression and reduce the risk of vision loss.

I believe there may be some confusion in your question. "Rabbits" is a common name used to refer to the Lagomorpha species, particularly members of the family Leporidae. They are small mammals known for their long ears, strong legs, and quick reproduction.

However, if you're referring to "rabbits" in a medical context, there is a term called "rabbit syndrome," which is a rare movement disorder characterized by repetitive, involuntary movements of the fingers, resembling those of a rabbit chewing. It is also known as "finger-chewing chorea." This condition is usually associated with certain medications, particularly antipsychotics, and typically resolves when the medication is stopped or adjusted.

A "knockout" mouse is a genetically engineered mouse in which one or more genes have been deleted or "knocked out" using molecular biology techniques. This allows researchers to study the function of specific genes and their role in various biological processes, as well as potential associations with human diseases. The mice are generated by introducing targeted DNA modifications into embryonic stem cells, which are then used to create a live animal. Knockout mice have been widely used in biomedical research to investigate gene function, disease mechanisms, and potential therapeutic targets.

The Macrophage-1 Antigen (also known as Macrophage Antigen-1 or CD14) is a glycoprotein found on the surface of various cells, including monocytes, macrophages, and some dendritic cells. It functions as a receptor for complexes formed by lipopolysaccharides (LPS) and LPS-binding protein (LBP), which are involved in the immune response to gram-negative bacteria. CD14 plays a crucial role in activating immune cells and initiating the release of proinflammatory cytokines upon recognizing bacterial components.

In summary, Macrophage-1 Antigen is a cell surface receptor that contributes to the recognition and response against gram-negative bacteria by interacting with LPS-LBP complexes.

Autoantibodies are defined as antibodies that are produced by the immune system and target the body's own cells, tissues, or organs. These antibodies mistakenly identify certain proteins or molecules in the body as foreign invaders and attack them, leading to an autoimmune response. Autoantibodies can be found in various autoimmune diseases such as rheumatoid arthritis, lupus, and thyroiditis. The presence of autoantibodies can also be used as a diagnostic marker for certain conditions.

Reperfusion injury is a complex pathophysiological process that occurs when blood flow is restored to previously ischemic tissues, leading to further tissue damage. This phenomenon can occur in various clinical settings such as myocardial infarction (heart attack), stroke, or peripheral artery disease after an intervention aimed at restoring perfusion.

The restoration of blood flow leads to the generation of reactive oxygen species (ROS) and inflammatory mediators, which can cause oxidative stress, cellular damage, and activation of the immune system. This results in a cascade of events that may lead to microvascular dysfunction, capillary leakage, and tissue edema, further exacerbating the injury.

Reperfusion injury is an important consideration in the management of ischemic events, as interventions aimed at restoring blood flow must be carefully balanced with potential harm from reperfusion injury. Strategies to mitigate reperfusion injury include ischemic preconditioning (exposing the tissue to short periods of ischemia before a prolonged ischemic event), ischemic postconditioning (applying brief periods of ischemia and reperfusion after restoring blood flow), remote ischemic preconditioning (ischemia applied to a distant organ or tissue to protect the target organ), and pharmacological interventions that scavenge ROS, reduce inflammation, or improve microvascular function.

Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease that can affect almost any organ or system in the body. In SLE, the immune system produces an exaggerated response, leading to the production of autoantibodies that attack the body's own cells and tissues, causing inflammation and damage. The symptoms and severity of SLE can vary widely from person to person, but common features include fatigue, joint pain, skin rashes (particularly a "butterfly" rash across the nose and cheeks), fever, hair loss, and sensitivity to sunlight.

Systemic lupus erythematosus can also affect the kidneys, heart, lungs, brain, blood vessels, and other organs, leading to a wide range of symptoms such as kidney dysfunction, chest pain, shortness of breath, seizures, and anemia. The exact cause of SLE is not fully understood, but it is believed to involve a combination of genetic, environmental, and hormonal factors. Treatment typically involves medications to suppress the immune system and manage symptoms, and may require long-term management by a team of healthcare professionals.

Serum, in the context of clinical and medical laboratory science, refers to the fluid that is obtained after blood coagulation. It is the yellowish, straw-colored liquid fraction of whole blood that remains after the clotting factors have been removed. Serum contains various proteins, electrolytes, hormones, antibodies, antigens, and other substances, which can be analyzed to help diagnose and monitor a wide range of medical conditions. It is commonly used for various clinical tests such as chemistry panels, immunological assays, drug screening, and infectious disease testing.

An amino acid sequence is the specific order of amino acids in a protein or peptide molecule, formed by the linking of the amino group (-NH2) of one amino acid to the carboxyl group (-COOH) of another amino acid through a peptide bond. The sequence is determined by the genetic code and is unique to each type of protein or peptide. It plays a crucial role in determining the three-dimensional structure and function of proteins.

Glomerulonephritis is a medical condition that involves inflammation of the glomeruli, which are the tiny blood vessel clusters in the kidneys that filter waste and excess fluids from the blood. This inflammation can impair the kidney's ability to filter blood properly, leading to symptoms such as proteinuria (protein in the urine), hematuria (blood in the urine), edema (swelling), hypertension (high blood pressure), and eventually kidney failure.

Glomerulonephritis can be acute or chronic, and it may occur as a primary kidney disease or secondary to other medical conditions such as infections, autoimmune disorders, or vasculitis. The diagnosis of glomerulonephritis typically involves a combination of medical history, physical examination, urinalysis, blood tests, and imaging studies, with confirmation often requiring a kidney biopsy. Treatment depends on the underlying cause and severity of the disease but may include medications to suppress inflammation, control blood pressure, and manage symptoms.

Animal disease models are specialized animals, typically rodents such as mice or rats, that have been genetically engineered or exposed to certain conditions to develop symptoms and physiological changes similar to those seen in human diseases. These models are used in medical research to study the pathophysiology of diseases, identify potential therapeutic targets, test drug efficacy and safety, and understand disease mechanisms.

The genetic modifications can include knockout or knock-in mutations, transgenic expression of specific genes, or RNA interference techniques. The animals may also be exposed to environmental factors such as chemicals, radiation, or infectious agents to induce the disease state.

Examples of animal disease models include:

1. Mouse models of cancer: Genetically engineered mice that develop various types of tumors, allowing researchers to study cancer initiation, progression, and metastasis.
2. Alzheimer's disease models: Transgenic mice expressing mutant human genes associated with Alzheimer's disease, which exhibit amyloid plaque formation and cognitive decline.
3. Diabetes models: Obese and diabetic mouse strains like the NOD (non-obese diabetic) or db/db mice, used to study the development of type 1 and type 2 diabetes, respectively.
4. Cardiovascular disease models: Atherosclerosis-prone mice, such as ApoE-deficient or LDLR-deficient mice, that develop plaque buildup in their arteries when fed a high-fat diet.
5. Inflammatory bowel disease models: Mice with genetic mutations affecting intestinal barrier function and immune response, such as IL-10 knockout or SAMP1/YitFc mice, which develop colitis.

Animal disease models are essential tools in preclinical research, but it is important to recognize their limitations. Differences between species can affect the translatability of results from animal studies to human patients. Therefore, researchers must carefully consider the choice of model and interpret findings cautiously when applying them to human diseases.

Blood proteins, also known as serum proteins, are a group of complex molecules present in the blood that are essential for various physiological functions. These proteins include albumin, globulins (alpha, beta, and gamma), and fibrinogen. They play crucial roles in maintaining oncotic pressure, transporting hormones, enzymes, vitamins, and minerals, providing immune defense, and contributing to blood clotting.

Albumin is the most abundant protein in the blood, accounting for about 60% of the total protein mass. It functions as a transporter of various substances, such as hormones, fatty acids, and drugs, and helps maintain oncotic pressure, which is essential for fluid balance between the blood vessels and surrounding tissues.

Globulins are divided into three main categories: alpha, beta, and gamma globulins. Alpha and beta globulins consist of transport proteins like lipoproteins, hormone-binding proteins, and enzymes. Gamma globulins, also known as immunoglobulins or antibodies, are essential for the immune system's defense against pathogens.

Fibrinogen is a protein involved in blood clotting. When an injury occurs, fibrinogen is converted into fibrin, which forms a mesh to trap platelets and form a clot, preventing excessive bleeding.

Abnormal levels of these proteins can indicate various medical conditions, such as liver or kidney disease, malnutrition, infections, inflammation, or autoimmune disorders. Blood protein levels are typically measured through laboratory tests like serum protein electrophoresis (SPE) and immunoelectrophoresis (IEP).

Mannans are a type of complex carbohydrate, specifically a heteropolysaccharide, that are found in the cell walls of certain plants, algae, and fungi. They consist of chains of mannose sugars linked together, often with other sugar molecules such as glucose or galactose.

Mannans have various biological functions, including serving as a source of energy for microorganisms that can break them down. In some cases, mannans can also play a role in the immune response and are used as a component of vaccines to stimulate an immune response.

In the context of medicine, mannans may be relevant in certain conditions such as gut dysbiosis or allergic reactions to foods containing mannans. Additionally, some research has explored the potential use of mannans as a delivery vehicle for drugs or other therapeutic agents.

C-reactive protein (CRP) is a protein produced by the liver in response to inflammation or infection in the body. It is named after its ability to bind to the C-polysaccharide of pneumococcus, a type of bacteria. CRP levels can be measured with a simple blood test and are often used as a marker of inflammation or infection. Elevated CRP levels may indicate a variety of conditions, including infections, tissue damage, and chronic diseases such as rheumatoid arthritis and cancer. However, it is important to note that CRP is not specific to any particular condition, so additional tests are usually needed to make a definitive diagnosis.

A peptide fragment is a short chain of amino acids that is derived from a larger peptide or protein through various biological or chemical processes. These fragments can result from the natural breakdown of proteins in the body during regular physiological processes, such as digestion, or they can be produced experimentally in a laboratory setting for research or therapeutic purposes.

Peptide fragments are often used in research to map the structure and function of larger peptides and proteins, as well as to study their interactions with other molecules. In some cases, peptide fragments may also have biological activity of their own and can be developed into drugs or diagnostic tools. For example, certain peptide fragments derived from hormones or neurotransmitters may bind to receptors in the body and mimic or block the effects of the full-length molecule.

A kidney glomerulus is a functional unit in the nephron of the kidney. It is a tuft of capillaries enclosed within a structure called Bowman's capsule, which filters waste and excess fluids from the blood. The glomerulus receives blood from an afferent arteriole and drains into an efferent arteriole.

The process of filtration in the glomerulus is called ultrafiltration, where the pressure within the glomerular capillaries drives plasma fluid and small molecules (such as ions, glucose, amino acids, and waste products) through the filtration membrane into the Bowman's space. Larger molecules, like proteins and blood cells, are retained in the blood due to their larger size. The filtrate then continues down the nephron for further processing, eventually forming urine.

Membranoproliferative Glomerulonephritis (MPGN) is a type of glomerulonephritis, which is a group of kidney disorders characterized by inflammation and damage to the glomeruli, the tiny blood vessels in the kidneys responsible for filtering waste and excess fluids from the blood.

MPGN is specifically characterized by thickening of the glomerular basement membrane and proliferation (increased number) of cells in the mesangium, a region within the glomerulus. This condition can be primary or secondary to other diseases such as infections, autoimmune disorders, or monoclonal gammopathies.

MPGN is typically classified into three types based on the pattern of injury seen on electron microscopy: Type I, Type II (Dense Deposit Disease), and Type III. Each type has distinct clinical features, laboratory findings, and treatment approaches. Symptoms of MPGN may include hematuria (blood in urine), proteinuria (protein in urine), hypertension (high blood pressure), edema (swelling), and eventually progress to chronic kidney disease or end-stage renal disease if left untreated.

Innate immunity, also known as non-specific immunity or natural immunity, is the inherent defense mechanism that provides immediate protection against potentially harmful pathogens (like bacteria, viruses, fungi, and parasites) without the need for prior exposure. This type of immunity is present from birth and does not adapt to specific threats over time.

Innate immune responses involve various mechanisms such as:

1. Physical barriers: Skin and mucous membranes prevent pathogens from entering the body.
2. Chemical barriers: Enzymes, stomach acid, and lysozyme in tears, saliva, and sweat help to destroy or inhibit the growth of microorganisms.
3. Cellular responses: Phagocytic cells (neutrophils, monocytes, macrophages) recognize and engulf foreign particles and pathogens, while natural killer (NK) cells target and eliminate virus-infected or cancerous cells.
4. Inflammatory response: When an infection occurs, the innate immune system triggers inflammation to increase blood flow, recruit immune cells, and remove damaged tissue.
5. Complement system: A group of proteins that work together to recognize and destroy pathogens directly or enhance phagocytosis by coating them with complement components (opsonization).

Innate immunity plays a crucial role in initiating the adaptive immune response, which is specific to particular pathogens and provides long-term protection through memory cells. Both innate and adaptive immunity work together to maintain overall immune homeostasis and protect the body from infections and diseases.

Inflammation is a complex biological response of tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. It is characterized by the following signs: rubor (redness), tumor (swelling), calor (heat), dolor (pain), and functio laesa (loss of function). The process involves the activation of the immune system, recruitment of white blood cells, and release of inflammatory mediators, which contribute to the elimination of the injurious stimuli and initiation of the healing process. However, uncontrolled or chronic inflammation can also lead to tissue damage and diseases.

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disorder of the blood characterized by the destruction of red blood cells (hemolysis), which can cause symptoms such as fatigue, dark colored urine (especially in the morning), chest pain, shortness of breath, and an increased risk of blood clots. The hemoglobin from the lysed red blood cells appears in the urine, hence the term "hemoglobinuria."

The paroxysmal nature of the disorder refers to the sudden and recurring episodes of hemolysis that can occur at any time, although they may be more frequent at night. The condition is caused by mutations in a gene called PIG-A, which leads to the production of defective red blood cell membranes that are sensitive to destruction by complement, a component of the immune system.

PNH is a serious and potentially life-threatening condition that can lead to complications such as kidney damage, pulmonary hypertension, and thrombosis. Treatment typically involves supportive care, such as blood transfusions, and medications to manage symptoms and prevent complications. In some cases, stem cell transplantation may be considered as a curative treatment option.

Lysine carboxypeptidase is not a widely recognized or used medical term. However, in biochemistry, carboxypeptidases are enzymes that cleave peptide bonds at the carboxyl-terminal end of a protein or peptide. If there is a specific enzyme named "lysine carboxypeptidase," it would be an enzyme that selectively removes lysine residues from the carboxyl terminus of a protein or peptide.

There are several enzymes that can act as carboxypeptidases, and some of them have specificities for certain amino acids, such as arginine or lysine. These enzymes play important roles in various biological processes, including protein degradation, processing, and regulation.

It's worth noting that the term "lysine carboxypeptidase" may refer to different enzymes depending on the context, such as bacterial or mammalian enzymes, and they may have different properties and functions.

Serum Amyloid P-component (SAP) is a protein that is normally present in the blood and other bodily fluids. It is a part of the larger family of pentraxin proteins, which are involved in the innate immune response, meaning they provide immediate defense against foreign invaders without needing to adapt over time. SAP plays a role in inflammation, immune complex clearance, and complement activation.

In the context of amyloidosis, SAP binds to misfolded proteins called amyloid fibrils, which can deposit in various tissues and organs, leading to their dysfunction and failure. The accumulation of these amyloid fibrils with SAP is a hallmark of systemic amyloidosis.

It's important to note that while SAP plays a role in the pathogenesis of amyloidosis, it is not directly responsible for causing the disease. Instead, its presence can serve as a useful marker for diagnosing and monitoring the progression of amyloidosis.

Snake venoms are complex mixtures of bioactive compounds produced by specialized glands in snakes. They primarily consist of proteins and peptides, including enzymes, neurotoxins, hemotoxins, cytotoxins, and cardiotoxins. These toxins can cause a variety of pharmacological effects on the victim's body, such as disruption of the nervous system, blood coagulation, muscle function, and cell membrane integrity, ultimately leading to tissue damage and potentially death. The composition of snake venoms varies widely among different species, making each species' venom unique in its toxicity profile.

Surface Plasmon Resonance (SPR) is a physical phenomenon that occurs at the interface between a metal and a dielectric material, when electromagnetic radiation (usually light) is shone on it. It involves the collective oscillation of free electrons in the metal, known as surface plasmons, which are excited by the incident light. The resonance condition is met when the momentum and energy of the photons match those of the surface plasmons, leading to a strong absorption of light and an evanescent wave that extends into the dielectric material.

In the context of medical diagnostics and research, SPR is often used as a sensitive and label-free detection technique for biomolecular interactions. By immobilizing one binding partner (e.g., a receptor or antibody) onto the metal surface and flowing the other partner (e.g., a ligand or antigen) over it, changes in the refractive index at the interface can be measured in real-time as the plasmons are disturbed by the presence of bound molecules. This allows for the quantification of binding affinities, kinetics, and specificity with high sensitivity and selectivity.

Recombinant proteins are artificially created proteins produced through the use of recombinant DNA technology. This process involves combining DNA molecules from different sources to create a new set of genes that encode for a specific protein. The resulting recombinant protein can then be expressed, purified, and used for various applications in research, medicine, and industry.

Recombinant proteins are widely used in biomedical research to study protein function, structure, and interactions. They are also used in the development of diagnostic tests, vaccines, and therapeutic drugs. For example, recombinant insulin is a common treatment for diabetes, while recombinant human growth hormone is used to treat growth disorders.

The production of recombinant proteins typically involves the use of host cells, such as bacteria, yeast, or mammalian cells, which are engineered to express the desired protein. The host cells are transformed with a plasmid vector containing the gene of interest, along with regulatory elements that control its expression. Once the host cells are cultured and the protein is expressed, it can be purified using various chromatography techniques.

Overall, recombinant proteins have revolutionized many areas of biology and medicine, enabling researchers to study and manipulate proteins in ways that were previously impossible.

A dose-response relationship in immunology refers to the quantitative relationship between the dose or amount of an antigen (a substance that triggers an immune response) and the magnitude or strength of the resulting immune response. Generally, as the dose of an antigen increases, the intensity and/or duration of the immune response also increase, up to a certain point. This relationship helps in determining the optimal dosage for vaccines and immunotherapies, ensuring sufficient immune activation while minimizing potential adverse effects.

Nephritis is a medical term that refers to inflammation of the kidneys, specifically affecting the glomeruli - the tiny filtering units inside the kidneys. The condition can cause damage to the glomeruli, leading to impaired kidney function and the leakage of protein and blood into the urine.

Nephritis can result from a variety of causes, including infections, autoimmune disorders, and exposure to certain medications or toxins. Depending on the severity and underlying cause, nephritis may be treated with medications, dietary modifications, or other therapies aimed at reducing inflammation and preserving kidney function. In severe cases, hospitalization and more intensive treatments may be necessary.

Glycoproteins are complex proteins that contain oligosaccharide chains (glycans) covalently attached to their polypeptide backbone. These glycans are linked to the protein through asparagine residues (N-linked) or serine/threonine residues (O-linked). Glycoproteins play crucial roles in various biological processes, including cell recognition, cell-cell interactions, cell adhesion, and signal transduction. They are widely distributed in nature and can be found on the outer surface of cell membranes, in extracellular fluids, and as components of the extracellular matrix. The structure and composition of glycoproteins can vary significantly depending on their function and location within an organism.

Edetic acid, also known as ethylenediaminetetraacetic acid (EDTA), is not a medical term per se, but a chemical compound with various applications in medicine. EDTA is a synthetic amino acid that acts as a chelating agent, which means it can bind to metallic ions and form stable complexes.

In medicine, EDTA is primarily used in the treatment of heavy metal poisoning, such as lead or mercury toxicity. It works by binding to the toxic metal ions in the body, forming a stable compound that can be excreted through urine. This helps reduce the levels of harmful metals in the body and alleviate their toxic effects.

EDTA is also used in some diagnostic tests, such as the determination of calcium levels in blood. Additionally, it has been explored as a potential therapy for conditions like atherosclerosis and Alzheimer's disease, although its efficacy in these areas remains controversial and unproven.

It is important to note that EDTA should only be administered under medical supervision due to its potential side effects and the need for careful monitoring of its use.

Angioedema is a medical condition characterized by rapid swelling of the skin, mucous membranes, and submucosal tissues. The swelling typically occurs in the face, lips, tongue, larynx, and extremities, and can also affect the gastrointestinal tract. Angioedema can be caused by a variety of factors, including allergic reactions, hereditary genetic mutations, and certain medications.

In medical terms, angioedema is defined as a self-limiting episode of localized edema in the deep dermis, subcutaneous tissue, or mucous membranes, characterized by well-circumscribed, nonpitting, nondependent swelling. The swelling can occur suddenly and may persist for up to 72 hours. In severe cases, angioedema can cause airway obstruction and be life-threatening if not treated promptly.

Angioedema can be classified into two main types: allergic or non-allergic. Allergic angioedema is caused by an immune response to an allergen, such as food, medication, or insect venom. Non-allergic angioedema can be further divided into several subtypes, including hereditary angioedema (HA), acquired angioedema (AAE), and drug-induced angioedema.

Hereditary angioedema is a rare genetic disorder caused by mutations in the C1 inhibitor gene, leading to uncontrolled activation of the complement system and increased production of bradykinin, a potent vasodilator. Acquired angioedema is similar to hereditary angioedema but occurs later in life and is associated with underlying medical conditions such as lymphoproliferative disorders or autoimmune diseases. Drug-induced angioedema can be caused by a variety of medications, including ACE inhibitors, angiotensin receptor blockers (ARBs), and nonsteroidal anti-inflammatory drugs (NSAIDs).

The diagnosis of angioedema is typically based on clinical presentation, medical history, and laboratory tests. Treatment depends on the underlying cause of the condition but may include antihistamines, corticosteroids, epinephrine, and medications that target the complement system or bradykinin pathway. In severe cases, hospitalization and intensive care may be necessary to manage airway obstruction and other complications.

The Fluorescent Antibody Technique (FAT) is a type of immunofluorescence assay used in laboratory medicine and pathology for the detection and localization of specific antigens or antibodies in tissues, cells, or microorganisms. In this technique, a fluorescein-labeled antibody is used to selectively bind to the target antigen or antibody, forming an immune complex. When excited by light of a specific wavelength, the fluorescein label emits light at a longer wavelength, typically visualized as green fluorescence under a fluorescence microscope.

The FAT is widely used in diagnostic microbiology for the identification and characterization of various bacteria, viruses, fungi, and parasites. It has also been applied in the diagnosis of autoimmune diseases and certain cancers by detecting specific antibodies or antigens in patient samples. The main advantage of FAT is its high sensitivity and specificity, allowing for accurate detection and differentiation of various pathogens and disease markers. However, it requires specialized equipment and trained personnel to perform and interpret the results.

Complement C2a is a proteolytic fragment generated through the activation of the complement component C2 during the classical complement pathway. It is a serine protease that plays a crucial role in the formation of the C3 convertase (C4b2a) complex, which cleaves and activates the complement component C3 into C3a and C3b. This activation step is essential for the initiation of the immune response and elimination of pathogens through various effector mechanisms such as opsonization, phagocytosis, and formation of the membrane attack complex (MAC). Dysregulation or deficiency in complement components, including C2a, can lead to immunological disorders and increased susceptibility to infections.

Two-dimensional immunoelectrophoresis (2DE) is a specialized laboratory technique used in the field of clinical pathology and immunology. This technique is a refined version of traditional immunoelectrophoresis that adds an additional electrophoretic separation step, enhancing its resolution and allowing for more detailed analysis of complex protein mixtures.

In two-dimensional immunoelectrophoresis, proteins are first separated based on their isoelectric points (pI) in the initial dimension using isoelectric focusing (IEF). This process involves applying an electric field to a protein mixture contained within a gel matrix, where proteins will migrate and stop migrating once they reach the pH that matches their own isoelectric point.

Following IEF, the separated proteins are then subjected to a second electrophoretic separation in the perpendicular direction (second dimension) based on their molecular weights using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). SDS is a negatively charged molecule that binds to proteins, giving them a uniform negative charge and allowing for separation based solely on size.

Once the two-dimensional separation is complete, the gel is then overlaid with specific antisera to detect and identify proteins of interest. The resulting precipitin arcs formed at the intersection of the antibody and antigen are compared to known standards or patterns to determine the identity and quantity of the separated proteins.

Two-dimensional immunoelectrophoresis is particularly useful in identifying and quantifying proteins in complex mixtures, such as those found in body fluids like serum, urine, or cerebrospinal fluid (CSF). It can be applied to various clinical scenarios, including diagnosis and monitoring of monoclonal gammopathies, autoimmune disorders, and certain infectious diseases.

A blister is a small fluid-filled bubble that forms on the skin due to friction, burns, or contact with certain chemicals or irritants. Blisters are typically filled with a clear fluid called serum, which is a component of blood. They can also be filled with blood (known as blood blisters) if the blister is caused by a more severe injury.

Blisters act as a natural protective barrier for the underlying skin and tissues, preventing infection and promoting healing. It's generally recommended to leave blisters intact and avoid breaking them, as doing so can increase the risk of infection and delay healing. If a blister is particularly large or painful, medical attention may be necessary to prevent complications.

"Cells, cultured" is a medical term that refers to cells that have been removed from an organism and grown in controlled laboratory conditions outside of the body. This process is called cell culture and it allows scientists to study cells in a more controlled and accessible environment than they would have inside the body. Cultured cells can be derived from a variety of sources, including tissues, organs, or fluids from humans, animals, or cell lines that have been previously established in the laboratory.

Cell culture involves several steps, including isolation of the cells from the tissue, purification and characterization of the cells, and maintenance of the cells in appropriate growth conditions. The cells are typically grown in specialized media that contain nutrients, growth factors, and other components necessary for their survival and proliferation. Cultured cells can be used for a variety of purposes, including basic research, drug development and testing, and production of biological products such as vaccines and gene therapies.

It is important to note that cultured cells may behave differently than they do in the body, and results obtained from cell culture studies may not always translate directly to human physiology or disease. Therefore, it is essential to validate findings from cell culture experiments using additional models and ultimately in clinical trials involving human subjects.

Flow cytometry is a medical and research technique used to measure physical and chemical characteristics of cells or particles, one cell at a time, as they flow in a fluid stream through a beam of light. The properties measured include:

* Cell size (light scatter)
* Cell internal complexity (granularity, also light scatter)
* Presence or absence of specific proteins or other molecules on the cell surface or inside the cell (using fluorescent antibodies or other fluorescent probes)

The technique is widely used in cell counting, cell sorting, protein engineering, biomarker discovery and monitoring disease progression, particularly in hematology, immunology, and cancer research.

According to the American Academy of Ophthalmology and the National Organization for Rare Disorders, bullous pemphigoid is an autoimmune blistering disorder characterized by the formation of large, fluid-filled blisters (bullae) on the skin and mucous membranes. This condition primarily affects older adults, with most cases occurring in individuals over 60 years of age.

In bullous pemphigoid, the immune system mistakenly produces antibodies against proteins called BP230 and BP180, which are found in the basement membrane zone – a layer that separates the epidermis (outer skin layer) from the dermis (inner skin layer). This autoimmune response leads to the formation of blisters, causing significant discomfort and potential complications if left untreated.

The symptoms of bullous pemphigoid typically include:

1. Large, fluid-filled blisters on the skin, often appearing on the trunk, arms, or legs. These blisters may be itchy or painful.
2. Blisters that rupture easily, leading to raw, open sores.
3. Mucous membrane involvement, such as blisters in the mouth, nose, eyes, or genital area.
4. Skin redness and irritation.
5. Fluid-filled bumps (papules) or pus-filled bumps (pustules).
6. Scarring and skin discoloration after blisters heal.

Treatment for bullous pemphigoid usually involves a combination of medications to control the immune response, reduce inflammation, and promote healing. These may include corticosteroids, immunosuppressants, or other targeted therapies. In some cases, antibiotics may also be prescribed to help manage secondary infections that can occur due to blister formation.

It is essential to consult with a healthcare professional for an accurate diagnosis and treatment plan if you suspect you have bullous pemphigoid or are experiencing related symptoms.

A genetic complementation test is a laboratory procedure used in molecular genetics to determine whether two mutated genes can complement each other's function, indicating that they are located at different loci and represent separate alleles. This test involves introducing a normal or wild-type copy of one gene into a cell containing a mutant version of the same gene, and then observing whether the presence of the normal gene restores the normal function of the mutated gene. If the introduction of the normal gene results in the restoration of the normal phenotype, it suggests that the two genes are located at different loci and can complement each other's function. However, if the introduction of the normal gene does not restore the normal phenotype, it suggests that the two genes are located at the same locus and represent different alleles of the same gene. This test is commonly used to map genes and identify genetic interactions in a variety of organisms, including bacteria, yeast, and animals.

BALB/c is an inbred strain of laboratory mouse that is widely used in biomedical research. The strain was developed at the Institute of Cancer Research in London by Henry Baldwin and his colleagues in the 1920s, and it has since become one of the most commonly used inbred strains in the world.

BALB/c mice are characterized by their black coat color, which is determined by a recessive allele at the tyrosinase locus. They are also known for their docile and friendly temperament, making them easy to handle and work with in the laboratory.

One of the key features of BALB/c mice that makes them useful for research is their susceptibility to certain types of tumors and immune responses. For example, they are highly susceptible to developing mammary tumors, which can be induced by chemical carcinogens or viral infection. They also have a strong Th2-biased immune response, which makes them useful models for studying allergic diseases and asthma.

BALB/c mice are also commonly used in studies of genetics, neuroscience, behavior, and infectious diseases. Because they are an inbred strain, they have a uniform genetic background, which makes it easier to control for genetic factors in experiments. Additionally, because they have been bred in the laboratory for many generations, they are highly standardized and reproducible, making them ideal subjects for scientific research.

Meningococcal infections are caused by the bacterium Neisseria meningitidis, also known as meningococcus. These infections can take several forms, but the most common are meningitis (inflammation of the membranes surrounding the brain and spinal cord) and septicemia (bloodstream infection). Meningococcal infections are contagious and can spread through respiratory droplets or close contact with an infected person. They can be serious and potentially life-threatening, requiring prompt medical attention and treatment with antibiotics. Symptoms of meningococcal meningitis may include fever, headache, stiff neck, and sensitivity to light, while symptoms of septicemia may include fever, chills, rash, and severe muscle pain. Vaccination is available to prevent certain strains of meningococcal disease.

Sepsis is a life-threatening condition that arises when the body's response to an infection injures its own tissues and organs. It is characterized by a whole-body inflammatory state (systemic inflammation) that can lead to blood clotting issues, tissue damage, and multiple organ failure.

Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Infections that lead to sepsis most often start in the lungs, urinary tract, skin, or gastrointestinal tract.

Sepsis is a medical emergency. If you suspect sepsis, seek immediate medical attention. Early recognition and treatment of sepsis are crucial to improve outcomes. Treatment usually involves antibiotics, intravenous fluids, and may require oxygen, medication to raise blood pressure, and corticosteroids. In severe cases, surgery may be required to clear the infection.

I must clarify that the term "Guinea Pigs" is not typically used in medical definitions. However, in colloquial or informal language, it may refer to people who are used as the first to try out a new medical treatment or drug. This is known as being a "test subject" or "in a clinical trial."

In the field of scientific research, particularly in studies involving animals, guinea pigs are small rodents that are often used as experimental subjects due to their size, cost-effectiveness, and ease of handling. They are not actually pigs from Guinea, despite their name's origins being unclear. However, they do not exactly fit the description of being used in human medical experiments.

Immunoglobulins (Igs), also known as antibodies, are glycoprotein molecules produced by the immune system's B cells in response to the presence of foreign substances, such as bacteria, viruses, and toxins. These Y-shaped proteins play a crucial role in identifying and neutralizing pathogens and other antigens, thereby protecting the body against infection and disease.

Immunoglobulins are composed of four polypeptide chains: two identical heavy chains and two identical light chains, held together by disulfide bonds. The variable regions of these chains form the antigen-binding sites, which recognize and bind to specific epitopes on antigens. Based on their heavy chain type, immunoglobulins are classified into five main isotypes or classes: IgA, IgD, IgE, IgG, and IgM. Each class has distinct functions in the immune response, such as providing protection in different body fluids and tissues, mediating hypersensitivity reactions, and aiding in the development of immunological memory.

In medical settings, immunoglobulins can be administered therapeutically to provide passive immunity against certain diseases or to treat immune deficiencies, autoimmune disorders, and other conditions that may benefit from immunomodulation.

Membrane glycoproteins are proteins that contain oligosaccharide chains (glycans) covalently attached to their polypeptide backbone. They are integral components of biological membranes, spanning the lipid bilayer and playing crucial roles in various cellular processes.

The glycosylation of these proteins occurs in the endoplasmic reticulum (ER) and Golgi apparatus during protein folding and trafficking. The attached glycans can vary in structure, length, and composition, which contributes to the diversity of membrane glycoproteins.

Membrane glycoproteins can be classified into two main types based on their orientation within the lipid bilayer:

1. Type I (N-linked): These glycoproteins have a single transmembrane domain and an extracellular N-terminus, where the oligosaccharides are predominantly attached via asparagine residues (Asn-X-Ser/Thr sequon).
2. Type II (C-linked): These glycoproteins possess two transmembrane domains and an intracellular C-terminus, with the oligosaccharides linked to tryptophan residues via a mannose moiety.

Membrane glycoproteins are involved in various cellular functions, such as:

* Cell adhesion and recognition
* Receptor-mediated signal transduction
* Enzymatic catalysis
* Transport of molecules across membranes
* Cell-cell communication
* Immunological responses

Some examples of membrane glycoproteins include cell surface receptors (e.g., growth factor receptors, cytokine receptors), adhesion molecules (e.g., integrins, cadherins), and transporters (e.g., ion channels, ABC transporters).

CD (cluster of differentiation) antigens are cell-surface proteins that are expressed on leukocytes (white blood cells) and can be used to identify and distinguish different subsets of these cells. They are important markers in the field of immunology and hematology, and are commonly used to diagnose and monitor various diseases, including cancer, autoimmune disorders, and infectious diseases.

CD antigens are designated by numbers, such as CD4, CD8, CD19, etc., which refer to specific proteins found on the surface of different types of leukocytes. For example, CD4 is a protein found on the surface of helper T cells, while CD8 is found on cytotoxic T cells.

CD antigens can be used as targets for immunotherapy, such as monoclonal antibody therapy, in which antibodies are designed to bind to specific CD antigens and trigger an immune response against cancer cells or infected cells. They can also be used as markers to monitor the effectiveness of treatments and to detect minimal residual disease (MRD) after treatment.

It's important to note that not all CD antigens are exclusive to leukocytes, some can be found on other cell types as well, and their expression can vary depending on the activation state or differentiation stage of the cells.

Phosphorothioate oligonucleotides are a type of synthetic oligonucleotide (a short chain of nucleotides) in which one of the non-bridging oxygen atoms in the phosphate group is replaced by a sulfur atom. This modification, known as phosphorothioation, confers increased resistance to degradation by endonucleases and exonucleases, thereby increasing the stability and half-life of the oligonucleotide in biological systems.

Phosphorothioate oligonucleotides have been widely used as antisense molecules, which can bind to complementary RNA sequences and inhibit gene expression through various mechanisms, such as RNase H-mediated degradation or steric hindrance of translation. They have also been explored for use in other applications, including aptamer development, vaccine adjuvants, and drug delivery systems.

However, it is important to note that phosphorothioate oligonucleotides can exhibit off-target effects, such as binding to proteins and activating the immune system, which may lead to undesirable side effects. Therefore, their use must be carefully evaluated in preclinical and clinical studies to ensure safety and efficacy.

Membranous glomerulonephritis (MGN) is a kidney disorder that leads to the inflammation and damage of the glomeruli, which are the tiny blood vessels in the kidneys responsible for filtering waste and excess fluids from the blood. In MGN, the membrane that surrounds the glomerular capillaries becomes thickened and damaged due to the deposit of immune complexes, primarily composed of antibodies and antigens.

The onset of membranous glomerulonephritis can be either primary (idiopathic) or secondary to various underlying conditions such as autoimmune diseases (like systemic lupus erythematosus), infections (hepatitis B or C, syphilis, endocarditis), medications, or malignancies.

The symptoms of membranous glomerulonephritis may include:

1. Proteinuria - the presence of excess protein, specifically albumin, in the urine. This can lead to nephrotic syndrome, characterized by heavy protein loss in urine, edema (swelling), hypoalbuminemia (low blood albumin levels), and hyperlipidemia (high blood lipid levels).
2. Hematuria - the presence of red blood cells in the urine, which can be visible or microscopic.
3. Hypertension - high blood pressure.
4. Edema - swelling in various body parts due to fluid retention.
5. Nephrotic range proteinuria (protein loss greater than 3.5 grams per day) and/or nephritic syndrome (a combination of hematuria, proteinuria, hypertension, and kidney dysfunction) can be observed in some cases.

The diagnosis of membranous glomerulonephritis typically involves a thorough medical history, physical examination, urinalysis, blood tests, and imaging studies. A definitive diagnosis often requires a kidney biopsy to assess the glomerular structure and the nature of the immune complex deposits. Treatment depends on the underlying cause and severity of the disease and may include corticosteroids, immunosuppressants, blood pressure management, and supportive care for symptoms like edema and proteinuria.

Isoantibodies are antibodies produced by the immune system that recognize and react to antigens (markers) found on the cells or tissues of another individual of the same species. These antigens are typically proteins or carbohydrates present on the surface of red blood cells, but they can also be found on other cell types.

Isoantibodies are formed when an individual is exposed to foreign antigens, usually through blood transfusions, pregnancy, or tissue transplantation. The exposure triggers the immune system to produce specific antibodies against these antigens, which can cause a harmful immune response if the individual receives another transfusion or transplant from the same donor in the future.

There are two main types of isoantibodies:

1. Agglutinins: These are IgM antibodies that cause red blood cells to clump together (agglutinate) when mixed with the corresponding antigen. They develop rapidly after exposure and can cause immediate transfusion reactions or hemolytic disease of the newborn in pregnant women.
2. Hemolysins: These are IgG antibodies that destroy red blood cells by causing their membranes to become more permeable, leading to lysis (bursting) of the cells and release of hemoglobin into the plasma. They take longer to develop but can cause delayed transfusion reactions or hemolytic disease of the newborn in pregnant women.

Isoantibodies are detected through blood tests, such as the crossmatch test, which determines compatibility between a donor's and recipient's blood before transfusions or transplants.

Carrier proteins, also known as transport proteins, are a type of protein that facilitates the movement of molecules across cell membranes. They are responsible for the selective and active transport of ions, sugars, amino acids, and other molecules from one side of the membrane to the other, against their concentration gradient. This process requires energy, usually in the form of ATP (adenosine triphosphate).

Carrier proteins have a specific binding site for the molecule they transport, and undergo conformational changes upon binding, which allows them to move the molecule across the membrane. Once the molecule has been transported, the carrier protein returns to its original conformation, ready to bind and transport another molecule.

Carrier proteins play a crucial role in maintaining the balance of ions and other molecules inside and outside of cells, and are essential for many physiological processes, including nerve impulse transmission, muscle contraction, and nutrient uptake.

Histocompatibility antigens, also known as human leukocyte antigens (HLAs), are proteins found on the surface of most cells in the body. They play a critical role in the immune system's ability to differentiate between "self" and "non-self" cells. Histocompatibility antigens are encoded by a group of genes called the major histocompatibility complex (MHC).

There are two main types of histocompatibility antigens: class I and class II. Class I antigens are found on almost all nucleated cells, while class II antigens are primarily expressed on immune cells such as B cells, macrophages, and dendritic cells. These antigens present pieces of proteins (peptides) from both inside and outside the cell to T-cells, a type of white blood cell that plays a central role in the immune response.

When foreign peptides are presented to T-cells by histocompatibility antigens, it triggers an immune response aimed at eliminating the threat. This is why histocompatibility antigens are so important in organ transplantation - if the donor's and recipient's antigens do not match closely enough, the recipient's immune system may recognize the transplanted organ as foreign and attack it.

Understanding the role of histocompatibility antigens has been crucial in developing techniques for matching donors and recipients in organ transplantation, as well as in diagnosing and treating various autoimmune diseases and cancers.

In the context of medical and biological sciences, a "binding site" refers to a specific location on a protein, molecule, or cell where another molecule can attach or bind. This binding interaction can lead to various functional changes in the original protein or molecule. The other molecule that binds to the binding site is often referred to as a ligand, which can be a small molecule, ion, or even another protein.

The binding between a ligand and its target binding site can be specific and selective, meaning that only certain ligands can bind to particular binding sites with high affinity. This specificity plays a crucial role in various biological processes, such as signal transduction, enzyme catalysis, or drug action.

In the case of drug development, understanding the location and properties of binding sites on target proteins is essential for designing drugs that can selectively bind to these sites and modulate protein function. This knowledge can help create more effective and safer therapeutic options for various diseases.

Antibody specificity refers to the ability of an antibody to bind to a specific epitope or antigenic determinant on an antigen. Each antibody has a unique structure that allows it to recognize and bind to a specific region of an antigen, typically a small portion of the antigen's surface made up of amino acids or sugar residues. This highly specific binding is mediated by the variable regions of the antibody's heavy and light chains, which form a pocket that recognizes and binds to the epitope.

The specificity of an antibody is determined by its unique complementarity-determining regions (CDRs), which are loops of amino acids located in the variable domains of both the heavy and light chains. The CDRs form a binding site that recognizes and interacts with the epitope on the antigen. The precise fit between the antibody's binding site and the epitope is critical for specificity, as even small changes in the structure of either can prevent binding.

Antibody specificity is important in immune responses because it allows the immune system to distinguish between self and non-self antigens. This helps to prevent autoimmune reactions where the immune system attacks the body's own cells and tissues. Antibody specificity also plays a crucial role in diagnostic tests, such as ELISA assays, where antibodies are used to detect the presence of specific antigens in biological samples.

Neisseria meningitidis is a Gram-negative, aerobic, bean-shaped diplococcus bacterium. It is one of the leading causes of bacterial meningitis and sepsis (known as meningococcal disease) worldwide. The bacteria can be found in the back of the nose and throat of approximately 10-25% of the general population, particularly in children, teenagers, and young adults, without causing any symptoms or illness. However, when the bacterium invades the bloodstream and spreads to the brain or spinal cord, it can lead to life-threatening infections such as meningitis (inflammation of the membranes surrounding the brain and spinal cord) and septicemia (blood poisoning).

Neisseria meningitidis is classified into 12 serogroups based on the chemical structure of their capsular polysaccharides. The six major serogroups that cause most meningococcal disease worldwide are A, B, C, W, X, and Y. Vaccines are available to protect against some or all of these serogroups.

Meningococcal disease can progress rapidly, leading to severe symptoms such as high fever, headache, stiff neck, confusion, nausea, vomiting, and a rash consisting of purple or red spots. Immediate medical attention is required if someone experiences these symptoms, as meningococcal disease can cause permanent disabilities or death within hours if left untreated.

Neutrophil infiltration is a pathological process characterized by the accumulation of neutrophils, a type of white blood cell, in tissue. It is a common feature of inflammation and occurs in response to infection, injury, or other stimuli that trigger an immune response. Neutrophils are attracted to the site of tissue damage by chemical signals called chemokines, which are released by damaged cells and activated immune cells. Once they reach the site of inflammation, neutrophils help to clear away damaged tissue and microorganisms through a process called phagocytosis. However, excessive or prolonged neutrophil infiltration can also contribute to tissue damage and may be associated with various disease states, including cancer, autoimmune disorders, and ischemia-reperfusion injury.

I apologize, but "sheep" is not a term that has a medical definition. It is a common animal with the scientific name Ovis aries. If you have any medical or health-related questions, I would be happy to try and help answer those for you.

Cyclic peptides are a type of peptides in which the N-terminus and C-terminus of the peptide chain are linked to form a circular structure. This is in contrast to linear peptides, which have a straight peptide backbone with a free N-terminus and C-terminus. The cyclization of peptides can occur through various mechanisms, including the formation of an amide bond between the N-terminal amino group and the C-terminal carboxylic acid group (head-to-tail cyclization), or through the formation of a bond between side chain functional groups.

Cyclic peptides have unique structural and chemical properties that make them valuable in medical and therapeutic applications. For example, they are more resistant to degradation by enzymes compared to linear peptides, which can increase their stability and half-life in the body. Additionally, the cyclic structure allows for greater conformational rigidity, which can enhance their binding affinity and specificity to target molecules.

Cyclic peptides have been explored as potential therapeutics for a variety of diseases, including cancer, infectious diseases, and neurological disorders. They have also been used as tools in basic research to study protein-protein interactions and cell signaling pathways.

Bacterial antibodies are a type of antibodies produced by the immune system in response to an infection caused by bacteria. These antibodies are proteins that recognize and bind to specific antigens on the surface of the bacterial cells, marking them for destruction by other immune cells. Bacterial antibodies can be classified into several types based on their structure and function, including IgG, IgM, IgA, and IgE. They play a crucial role in the body's defense against bacterial infections and provide immunity to future infections with the same bacteria.

The term "Immune Adherence Reaction" is not widely used in modern immunology or medicine. It appears to be an outdated concept that refers to the attachment of immune complexes (consisting of antigens, antibodies, and complement components) to Fc receptors on phagocytic cells, such as neutrophils and monocytes. This interaction facilitates the clearance of immune complexes from circulation and helps to prevent tissue damage caused by their deposition.

However, it is important to note that this term is not commonly used in current scientific literature or clinical settings. Instead, the processes it describes are typically discussed within the broader context of immune complex-mediated inflammation, complement activation, and phagocytosis.

Rheumatoid factor (RF) is an autoantibody, specifically an immunoglobulin M (IgM) antibody, that can be detected in the blood serum of some people with rheumatoid arthritis (RA), other inflammatory conditions, and infectious diseases. RF targets the Fc portion of IgG, leading to immune complex formation and subsequent inflammation, which contributes to the pathogenesis of RA. However, not all patients with RA test positive for RF, and its presence does not necessarily confirm a diagnosis of RA. Other conditions can also lead to elevated RF levels, such as infections, liver diseases, and certain malignancies. Therefore, the interpretation of RF results should be considered alongside other clinical, laboratory, and imaging findings for an accurate diagnosis and appropriate management.

Lipopolysaccharides (LPS) are large molecules found in the outer membrane of Gram-negative bacteria. They consist of a hydrophilic polysaccharide called the O-antigen, a core oligosaccharide, and a lipid portion known as Lipid A. The Lipid A component is responsible for the endotoxic activity of LPS, which can trigger a powerful immune response in animals, including humans. This response can lead to symptoms such as fever, inflammation, and septic shock, especially when large amounts of LPS are introduced into the bloodstream.

A cell line is a culture of cells that are grown in a laboratory for use in research. These cells are usually taken from a single cell or group of cells, and they are able to divide and grow continuously in the lab. Cell lines can come from many different sources, including animals, plants, and humans. They are often used in scientific research to study cellular processes, disease mechanisms, and to test new drugs or treatments. Some common types of human cell lines include HeLa cells (which come from a cancer patient named Henrietta Lacks), HEK293 cells (which come from embryonic kidney cells), and HUVEC cells (which come from umbilical vein endothelial cells). It is important to note that cell lines are not the same as primary cells, which are cells that are taken directly from a living organism and have not been grown in the lab.

A mutation is a permanent change in the DNA sequence of an organism's genome. Mutations can occur spontaneously or be caused by environmental factors such as exposure to radiation, chemicals, or viruses. They may have various effects on the organism, ranging from benign to harmful, depending on where they occur and whether they alter the function of essential proteins. In some cases, mutations can increase an individual's susceptibility to certain diseases or disorders, while in others, they may confer a survival advantage. Mutations are the driving force behind evolution, as they introduce new genetic variability into populations, which can then be acted upon by natural selection.

Lactoferrin is a glycoprotein that belongs to the transferrin family. It is an iron-binding protein found in various exocrine secretions such as milk, tears, and saliva, as well as in neutrophils, which are a type of white blood cell involved in immune response. Lactoferrin plays a role in iron homeostasis, antimicrobial activity, and anti-inflammatory responses. It has the ability to bind free iron, which can help prevent bacterial growth by depriving them of an essential nutrient. Additionally, lactoferrin has been shown to have direct antimicrobial effects against various bacteria, viruses, and fungi. Its role in the immune system also includes modulating the activity of immune cells and regulating inflammation.

IgG receptors, also known as Fcγ receptors (Fc gamma receptors), are specialized protein molecules found on the surface of various immune cells, such as neutrophils, monocytes, macrophages, and some lymphocytes. These receptors recognize and bind to the Fc region of IgG antibodies, one of the five classes of immunoglobulins in the human body.

IgG receptors play a crucial role in immune responses by mediating different effector functions, including:

1. Antibody-dependent cellular cytotoxicity (ADCC): IgG receptors on natural killer (NK) cells and other immune cells bind to IgG antibodies coated on the surface of virus-infected or cancer cells, leading to their destruction.
2. Phagocytosis: When IgG antibodies tag pathogens or foreign particles, phagocytes like neutrophils and macrophages recognize and bind to these immune complexes via IgG receptors, facilitating the engulfment and removal of the targeted particles.
3. Antigen presentation: IgG receptors on antigen-presenting cells (APCs) can internalize immune complexes, process the antigens, and present them to T cells, thereby initiating adaptive immune responses.
4. Inflammatory response regulation: IgG receptors can modulate inflammation by activating or inhibiting downstream signaling pathways in immune cells, depending on the specific type of Fcγ receptor and its activation state.

There are several types of IgG receptors (FcγRI, FcγRII, FcγRIII, and FcγRIV) with varying affinities for different subclasses of IgG antibodies (IgG1, IgG2, IgG3, and IgG4). The distinct functions and expression patterns of these receptors contribute to the complexity and fine-tuning of immune responses in the human body.

A base sequence in the context of molecular biology refers to the specific order of nucleotides in a DNA or RNA molecule. In DNA, these nucleotides are adenine (A), guanine (G), cytosine (C), and thymine (T). In RNA, uracil (U) takes the place of thymine. The base sequence contains genetic information that is transcribed into RNA and ultimately translated into proteins. It is the exact order of these bases that determines the genetic code and thus the function of the DNA or RNA molecule.

Immunoglobulins, also known as antibodies, are proteins produced by the immune system to recognize and neutralize foreign substances like pathogens or antigens. The term "immunoglobulin isotypes" refers to the different classes of immunoglobulins that share a similar structure but have distinct functions and properties.

There are five main isotypes of immunoglobulins in humans, namely IgA, IgD, IgE, IgG, and IgM. Each isotype has a unique heavy chain constant region (CH) that determines its effector functions, such as binding to Fc receptors, complement activation, or protection against pathogens.

IgA is primarily found in external secretions like tears, saliva, and breast milk, providing localized immunity at mucosal surfaces. IgD is expressed on the surface of B cells and plays a role in their activation and differentiation. IgE is associated with allergic responses and binds to mast cells and basophils, triggering the release of histamine and other mediators of inflammation.

IgG is the most abundant isotype in serum and has several subclasses (IgG1, IgG2, IgG3, and IgG4) that differ in their effector functions. IgG can cross the placenta, providing passive immunity to the fetus. IgM is the first antibody produced during an immune response and is primarily found in the bloodstream, where it forms large pentameric complexes that are effective at agglutination and complement activation.

Overall, immunoglobulin isotypes play a crucial role in the adaptive immune response, providing specific and diverse mechanisms for recognizing and neutralizing foreign substances.

Serum globulins are a group of proteins present in the liquid portion of blood, known as serum. They are produced by the immune system in response to foreign substances such as bacteria, viruses, and allergens. Serum globulins include several types of immunoglobulins (antibodies), complement components, and other proteins involved in the immune response.

The serum globulin level is often measured as part of a complete blood count (CBC) or a protein electrophoresis test. An elevated serum globulin level may indicate an ongoing infection, inflammation, or an autoimmune disorder. Conversely, a decreased level may suggest a liver or kidney disease, or a malnutrition condition. It is important to note that the interpretation of serum globulin levels should be done in conjunction with other laboratory and clinical findings.

A binding site on an antibody refers to the specific region on the surface of the antibody molecule that can recognize and bind to a specific antigen. Antibodies are proteins produced by the immune system in response to the presence of foreign substances called antigens. They have two main functions: to neutralize the harmful effects of antigens and to help eliminate them from the body.

The binding site of an antibody is located at the tips of its Y-shaped structure, formed by the variable regions of the heavy and light chains of the antibody molecule. These regions contain unique amino acid sequences that determine the specificity of the antibody for a particular antigen. The binding site can recognize and bind to a specific epitope or region on the antigen, forming an antigen-antibody complex.

The binding between the antibody and antigen is highly specific and depends on non-covalent interactions such as hydrogen bonds, van der Waals forces, and electrostatic attractions. This interaction plays a crucial role in the immune response, as it allows the immune system to recognize and eliminate pathogens and other foreign substances from the body.

Antibody-Dependent Cell Cytotoxicity (ADCC) is a type of immune response in which the effector cells of the immune system, such as natural killer (NK) cells, cytotoxic T-cells or macrophages, recognize and destroy virus-infected or cancer cells that are coated with antibodies.

In this process, an antibody produced by B-cells binds specifically to an antigen on the surface of a target cell. The other end of the antibody then interacts with Fc receptors found on the surface of effector cells. This interaction triggers the effector cells to release cytotoxic substances, such as perforins and granzymes, which create pores in the target cell membrane and induce apoptosis (programmed cell death).

ADCC plays an important role in the immune defense against viral infections and cancer. It is also a mechanism of action for some monoclonal antibody therapies used in cancer treatment.

Chemotaxis, Leukocyte is the movement of leukocytes (white blood cells) towards a higher concentration of a particular chemical substance, known as a chemotactic factor. This process plays a crucial role in the immune system's response to infection and injury.

When there is an infection or tissue damage, certain cells release chemotactic factors, which are small molecules or proteins that can attract leukocytes to the site of inflammation. Leukocytes have receptors on their surface that can detect these chemotactic factors and move towards them through a process called chemotaxis.

Once they reach the site of inflammation, leukocytes can help eliminate pathogens or damaged cells by phagocytosis (engulfing and destroying) or releasing toxic substances that kill the invading microorganisms. Chemotaxis is an essential part of the immune system's defense mechanisms and helps to maintain tissue homeostasis and prevent the spread of infection.

Phosphorylcholine is not a medical condition or disease, but rather a chemical compound. It is the choline ester of phosphoric acid, and it plays an important role in the structure and function of cell membranes. Phosphorylcholine is also found in certain types of lipoproteins, including low-density lipoprotein (LDL) or "bad" cholesterol.

In the context of medical research and therapy, phosphorylcholine has been studied for its potential role in various diseases, such as atherosclerosis, Alzheimer's disease, and other inflammatory conditions. Some studies have suggested that phosphorylcholine may contribute to the development of these diseases by promoting inflammation and immune responses. However, more research is needed to fully understand the role of phosphorylcholine in human health and disease.

Cricetinae is a subfamily of rodents that includes hamsters, gerbils, and relatives. These small mammals are characterized by having short limbs, compact bodies, and cheek pouches for storing food. They are native to various parts of the world, particularly in Europe, Asia, and Africa. Some species are popular pets due to their small size, easy care, and friendly nature. In a medical context, understanding the biology and behavior of Cricetinae species can be important for individuals who keep them as pets or for researchers studying their physiology.

Immunoglobulin A (IgA) is a type of antibody that plays a crucial role in the immune function of the human body. It is primarily found in external secretions, such as saliva, tears, breast milk, and sweat, as well as in mucous membranes lining the respiratory and gastrointestinal tracts. IgA exists in two forms: a monomeric form found in serum and a polymeric form found in secretions.

The primary function of IgA is to provide immune protection at mucosal surfaces, which are exposed to various environmental antigens, such as bacteria, viruses, parasites, and allergens. By doing so, it helps prevent the entry and colonization of pathogens into the body, reducing the risk of infections and inflammation.

IgA functions by binding to antigens present on the surface of pathogens or allergens, forming immune complexes that can neutralize their activity. These complexes are then transported across the epithelial cells lining mucosal surfaces and released into the lumen, where they prevent the adherence and invasion of pathogens.

In summary, Immunoglobulin A (IgA) is a vital antibody that provides immune defense at mucosal surfaces by neutralizing and preventing the entry of harmful antigens into the body.

Heparin is defined as a highly sulfated glycosaminoglycan (a type of polysaccharide) that is widely present in many tissues, but is most commonly derived from the mucosal tissues of mammalian lungs or intestinal mucosa. It is an anticoagulant that acts as an inhibitor of several enzymes involved in the blood coagulation cascade, primarily by activating antithrombin III which then neutralizes thrombin and other clotting factors.

Heparin is used medically to prevent and treat thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, and certain types of heart attacks. It can also be used during hemodialysis, cardiac bypass surgery, and other medical procedures to prevent the formation of blood clots.

It's important to note that while heparin is a powerful anticoagulant, it does not have any fibrinolytic activity, meaning it cannot dissolve existing blood clots. Instead, it prevents new clots from forming and stops existing clots from growing larger.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

Immunoelectrophoresis (IEP) is a laboratory technique used in the field of clinical pathology and immunology. It is a method for separating and identifying proteins, particularly immunoglobulins or antibodies, in a sample. This technique combines the principles of electrophoresis, which separates proteins based on their electric charge and size, with immunological reactions, which detect specific proteins using antigen-antibody interactions.

In IEP, a protein sample is first separated by electrophoresis in an agarose or agar gel matrix on a glass slide or in a test tube. After separation, an antibody specific to the protein of interest is layered on top of the gel and allowed to diffuse towards the separated proteins. This creates a reaction between the antigen (protein) and the antibody, forming a visible precipitate at the point where they meet. The precipitate line's position and intensity can then be analyzed to identify and quantify the protein of interest.

Immunoelectrophoresis is particularly useful in diagnosing various medical conditions, such as immunodeficiency disorders, monoclonal gammopathies (like multiple myeloma), and other plasma cell dyscrasias. It can help detect abnormal protein patterns, quantify specific immunoglobulins, and identify the presence of M-proteins or Bence Jones proteins, which are indicative of monoclonal gammopathies.

Immunoglobulin Fc fragments are the crystallizable fragment of an antibody that is responsible for effector functions such as engagement with Fc receptors on immune cells, activation of the complement system, and neutralization of toxins. The Fc region is located at the tail end of the Y-shaped immunoglobulin molecule, and it is made up of constant regions of the heavy chains of the antibody.

When an antibody binds to its target antigen, the Fc region can interact with other proteins in the immune system, leading to a variety of responses such as phagocytosis, antibody-dependent cellular cytotoxicity (ADCC), and complement activation. These effector functions help to eliminate pathogens and infected cells from the body.

Immunoglobulin Fc fragments can be produced artificially through enzymatic digestion of intact antibodies, resulting in a fragment that retains the ability to interact with Fc receptors and other proteins involved in immune responses. These fragments have potential therapeutic applications in a variety of diseases, including autoimmune disorders, inflammatory conditions, and cancer.

Macrophages are a type of white blood cell that are an essential part of the immune system. They are large, specialized cells that engulf and destroy foreign substances, such as bacteria, viruses, parasites, and fungi, as well as damaged or dead cells. Macrophages are found throughout the body, including in the bloodstream, lymph nodes, spleen, liver, lungs, and connective tissues. They play a critical role in inflammation, immune response, and tissue repair and remodeling.

Macrophages originate from monocytes, which are a type of white blood cell produced in the bone marrow. When monocytes enter the tissues, they differentiate into macrophages, which have a larger size and more specialized functions than monocytes. Macrophages can change their shape and move through tissues to reach sites of infection or injury. They also produce cytokines, chemokines, and other signaling molecules that help coordinate the immune response and recruit other immune cells to the site of infection or injury.

Macrophages have a variety of surface receptors that allow them to recognize and respond to different types of foreign substances and signals from other cells. They can engulf and digest foreign particles, bacteria, and viruses through a process called phagocytosis. Macrophages also play a role in presenting antigens to T cells, which are another type of immune cell that helps coordinate the immune response.

Overall, macrophages are crucial for maintaining tissue homeostasis, defending against infection, and promoting wound healing and tissue repair. Dysregulation of macrophage function has been implicated in a variety of diseases, including cancer, autoimmune disorders, and chronic inflammatory conditions.

Serine endopeptidases are a type of enzymes that cleave peptide bonds within proteins (endopeptidases) and utilize serine as the nucleophilic amino acid in their active site for catalysis. These enzymes play crucial roles in various biological processes, including digestion, blood coagulation, and programmed cell death (apoptosis). Examples of serine endopeptidases include trypsin, chymotrypsin, thrombin, and elastase.

Immunologic cytotoxicity refers to the damage or destruction of cells that occurs as a result of an immune response. This process involves the activation of immune cells, such as cytotoxic T cells and natural killer (NK) cells, which release toxic substances, such as perforins and granzymes, that can kill target cells.

In addition, antibodies produced by B cells can also contribute to immunologic cytotoxicity by binding to antigens on the surface of target cells and triggering complement-mediated lysis or antibody-dependent cellular cytotoxicity (ADCC) by activating immune effector cells.

Immunologic cytotoxicity plays an important role in the body's defense against viral infections, cancer cells, and other foreign substances. However, it can also contribute to tissue damage and autoimmune diseases if the immune system mistakenly targets healthy cells or tissues.

Immune evasion is a term used in immunology to describe the various strategies employed by pathogens (such as viruses, bacteria, parasites) to avoid or subvert the host's immune system. This can include mechanisms that allow the pathogen to directly inhibit or escape the actions of immune cells, like T cells and neutrophils, or to prevent the detection of their presence by masking themselves from the immune system.

For example, some viruses may change their surface proteins to avoid recognition by antibodies, while others may block the presentation of their antigens to T cells. Similarly, some bacteria can produce enzymes that degrade or modify components of the immune system, allowing them to evade detection and destruction.

Immune evasion is a major challenge in the development of effective vaccines and therapies for infectious diseases, as it allows pathogens to persist and cause chronic infections. Understanding the mechanisms of immune evasion can help researchers develop strategies to overcome these challenges and improve outcomes for patients.

Bacterial proteins are a type of protein that are produced by bacteria as part of their structural or functional components. These proteins can be involved in various cellular processes, such as metabolism, DNA replication, transcription, and translation. They can also play a role in bacterial pathogenesis, helping the bacteria to evade the host's immune system, acquire nutrients, and multiply within the host.

Bacterial proteins can be classified into different categories based on their function, such as:

1. Enzymes: Proteins that catalyze chemical reactions in the bacterial cell.
2. Structural proteins: Proteins that provide structural support and maintain the shape of the bacterial cell.
3. Signaling proteins: Proteins that help bacteria to communicate with each other and coordinate their behavior.
4. Transport proteins: Proteins that facilitate the movement of molecules across the bacterial cell membrane.
5. Toxins: Proteins that are produced by pathogenic bacteria to damage host cells and promote infection.
6. Surface proteins: Proteins that are located on the surface of the bacterial cell and interact with the environment or host cells.

Understanding the structure and function of bacterial proteins is important for developing new antibiotics, vaccines, and other therapeutic strategies to combat bacterial infections.

The retinal pigment epithelium (RPE) is a single layer of cells located between the photoreceptor cells of the retina and the choroid, which is a part of the eye containing blood vessels. The RPE plays a crucial role in maintaining the health and function of the photoreceptors by providing them with nutrients, removing waste products, and helping to regulate the light-sensitive visual pigments within the photoreceptors.

The RPE cells contain pigment granules that absorb excess light to prevent scattering within the eye and improve visual acuity. They also help to form the blood-retina barrier, which restricts the movement of certain molecules between the retina and the choroid, providing an important protective function for the retina.

Damage to the RPE can lead to a variety of eye conditions, including age-related macular degeneration (AMD), which is a leading cause of vision loss in older adults.

Vitronectin is a glycoprotein found in various biological fluids, including blood plasma. It has multiple functions in the body, such as participating in blood clotting (as a cofactor for the protease thrombin), inhibiting the complement system, and binding to cell surfaces and the extracellular matrix. Vitronectin can also interact with several other molecules, including heparin, collagen, and the cytoskeleton. It is involved in various biological processes, such as cell adhesion, migration, and protection against apoptosis (programmed cell death).

Immunohistochemistry (IHC) is a technique used in pathology and laboratory medicine to identify specific proteins or antigens in tissue sections. It combines the principles of immunology and histology to detect the presence and location of these target molecules within cells and tissues. This technique utilizes antibodies that are specific to the protein or antigen of interest, which are then tagged with a detection system such as a chromogen or fluorophore. The stained tissue sections can be examined under a microscope, allowing for the visualization and analysis of the distribution and expression patterns of the target molecule in the context of the tissue architecture. Immunohistochemistry is widely used in diagnostic pathology to help identify various diseases, including cancer, infectious diseases, and immune-mediated disorders.

Biocompatible materials are non-toxic and non-reacting substances that can be used in medical devices, tissue engineering, and drug delivery systems without causing harm or adverse reactions to living tissues or organs. These materials are designed to mimic the properties of natural tissues and are able to integrate with biological systems without being rejected by the body's immune system.

Biocompatible materials can be made from a variety of substances, including metals, ceramics, polymers, and composites. The specific properties of these materials, such as their mechanical strength, flexibility, and biodegradability, are carefully selected to meet the requirements of their intended medical application.

Examples of biocompatible materials include titanium used in dental implants and joint replacements, polyethylene used in artificial hips, and hydrogels used in contact lenses and drug delivery systems. The use of biocompatible materials has revolutionized modern medicine by enabling the development of advanced medical technologies that can improve patient outcomes and quality of life.

CHO cells, or Chinese Hamster Ovary cells, are a type of immortalized cell line that are commonly used in scientific research and biotechnology. They were originally derived from the ovaries of a female Chinese hamster (Cricetulus griseus) in the 1950s.

CHO cells have several characteristics that make them useful for laboratory experiments. They can grow and divide indefinitely under appropriate conditions, which allows researchers to culture large quantities of them for study. Additionally, CHO cells are capable of expressing high levels of recombinant proteins, making them a popular choice for the production of therapeutic drugs, vaccines, and other biologics.

In particular, CHO cells have become a workhorse in the field of biotherapeutics, with many approved monoclonal antibody-based therapies being produced using these cells. The ability to genetically modify CHO cells through various methods has further expanded their utility in research and industrial applications.

It is important to note that while CHO cells are widely used in scientific research, they may not always accurately represent human cell behavior or respond to drugs and other compounds in the same way as human cells do. Therefore, results obtained using CHO cells should be validated in more relevant systems when possible.

Leukocytes, also known as white blood cells (WBCs), are a crucial component of the human immune system. They are responsible for protecting the body against infections and foreign substances. Leukocytes are produced in the bone marrow and circulate throughout the body in the bloodstream and lymphatic system.

There are several types of leukocytes, including:

1. Neutrophils - These are the most abundant type of leukocyte and are primarily responsible for fighting bacterial infections. They contain enzymes that can destroy bacteria.
2. Lymphocytes - These are responsible for producing antibodies and destroying virus-infected cells, as well as cancer cells. There are two main types of lymphocytes: B-lymphocytes and T-lymphocytes.
3. Monocytes - These are the largest type of leukocyte and help to break down and remove dead or damaged tissues, as well as microorganisms.
4. Eosinophils - These play a role in fighting parasitic infections and are also involved in allergic reactions and inflammation.
5. Basophils - These release histamine and other chemicals that cause inflammation in response to allergens or irritants.

An abnormal increase or decrease in the number of leukocytes can indicate an underlying medical condition, such as an infection, inflammation, or a blood disorder.

I'm happy to help! However, I must clarify that the term "structure collapse" is not typically used in medical definitions. It is more commonly used in fields like engineering and construction to describe the failure or complete breakdown of a building or other structure.

In the context of medical terminology, a similar concept might be referred to as "structural collapse of bodily tissues or organs," which could be defined as the partial or total loss of structural integrity in bodily tissues or organs, leading to their malfunction or failure. This can occur due to various reasons such as trauma, disease, infection, or aging.

Examples of structural collapse in the body include:

* Aortic dissection: a serious condition where the inner layer of the aorta tears, causing blood to flow between the layers and potentially leading to rupture or aneurysm.
* Spinal cord injury: damage to the spinal cord due to trauma, which can result in partial or complete loss of sensory and motor function below the level of injury.
* Osteoporosis: a condition characterized by weak and brittle bones, leading to an increased risk of fractures and structural collapse of the vertebrae in the spine.

Graft rejection is an immune response that occurs when transplanted tissue or organ (the graft) is recognized as foreign by the recipient's immune system, leading to the activation of immune cells to attack and destroy the graft. This results in the failure of the transplant and the need for additional medical intervention or another transplant. There are three types of graft rejection: hyperacute, acute, and chronic. Hyperacute rejection occurs immediately or soon after transplantation due to pre-existing antibodies against the graft. Acute rejection typically occurs within weeks to months post-transplant and is characterized by the infiltration of T-cells into the graft. Chronic rejection, which can occur months to years after transplantation, is a slow and progressive process characterized by fibrosis and tissue damage due to ongoing immune responses against the graft.

Placental insufficiency is a condition in which the placenta does not provide adequate nutrients and oxygen to the developing fetus. This can occur due to various reasons, such as poor placental development, damage to the placenta, or problems with the blood flow to the placenta. As a result, the fetus may receive less oxygen and nutrients than it needs for proper growth and development, which can lead to a range of complications, including low birth weight, preterm birth, and developmental delays.

The medical definition of placental insufficiency is: "a condition in which the placenta fails to provide adequate support to the developing fetus, resulting in impaired fetal growth and development." This condition can be diagnosed through various tests, such as ultrasound, fetal monitoring, and blood tests, and may require close monitoring and management throughout pregnancy to ensure the best possible outcomes for both the mother and the baby.

A biological marker, often referred to as a biomarker, is a measurable indicator that reflects the presence or severity of a disease state, or a response to a therapeutic intervention. Biomarkers can be found in various materials such as blood, tissues, or bodily fluids, and they can take many forms, including molecular, histologic, radiographic, or physiological measurements.

In the context of medical research and clinical practice, biomarkers are used for a variety of purposes, such as:

1. Diagnosis: Biomarkers can help diagnose a disease by indicating the presence or absence of a particular condition. For example, prostate-specific antigen (PSA) is a biomarker used to detect prostate cancer.
2. Monitoring: Biomarkers can be used to monitor the progression or regression of a disease over time. For instance, hemoglobin A1c (HbA1c) levels are monitored in diabetes patients to assess long-term blood glucose control.
3. Predicting: Biomarkers can help predict the likelihood of developing a particular disease or the risk of a negative outcome. For example, the presence of certain genetic mutations can indicate an increased risk for breast cancer.
4. Response to treatment: Biomarkers can be used to evaluate the effectiveness of a specific treatment by measuring changes in the biomarker levels before and after the intervention. This is particularly useful in personalized medicine, where treatments are tailored to individual patients based on their unique biomarker profiles.

It's important to note that for a biomarker to be considered clinically valid and useful, it must undergo rigorous validation through well-designed studies, including demonstrating sensitivity, specificity, reproducibility, and clinical relevance.

Anaphylaxis is a severe, life-threatening systemic allergic reaction that occurs suddenly after exposure to an allergen (a substance that triggers an allergic reaction) to which the person has previously been sensitized. The symptoms of anaphylaxis include rapid onset of symptoms such as itching, hives, swelling of the throat and tongue, difficulty breathing, wheezing, cough, chest tightness, rapid heartbeat, hypotension (low blood pressure), shock, and in severe cases, loss of consciousness and death. Anaphylaxis is a medical emergency that requires immediate treatment with epinephrine (adrenaline) and other supportive measures to stabilize the patient's condition.

... (CB-CAPs) or complement split products, refers to complement activation fragments, ... Ahearn, Joseph M.; Liu, Chau-Ching; Manzi, Susan (6 November 2017). "Cell-bound complement activation products as lupus ... "Cell-bound complement activation products in SLE". Lupus Science & Medicine. 4 (1): e000236. doi:10.1136/lupus-2017-000236. PMC ... C4d, that are bound covalently to somatic cells, as a result of activation of the classical complement pathway. They appear ...
16, 301-310 Versey, J.M.B., Slater, L., Hobbs, J.R. Activation of complement in relation to disease, (1975) J.Clin.Path. 28, ... Complement activation. Mixed lymphocyte reaction T-cell receptors. Phagocyte function. First to fully describe IgA deficiency. ... Target cell death without added complement after cooperation of 7S-antibodies with non-immune lymphocytes. (1972) Nature New ...
"Complement Activation in Inflammatory Skin Diseases". Frontiers in Immunology. 9: 639. doi:10.3389/fimmu.2018.00639. ISSN 1664- ...
"Complement Activation in Inflammatory Skin Diseases". Frontiers in Immunology. 9: 639. doi:10.3389/fimmu.2018.00639. ISSN 1664- ... immune complexes deposit in vessel walls leading to activation of the complement system. C3a and C5a, proteins produced from ... the complement system, attract neutrophils to the vessels. Once activated, neutrophils then release preformed substances, ...
"Complement Activation in Inflammatory Skin Diseases". Frontiers in Immunology. 9: 639. doi:10.3389/fimmu.2018.00639. ISSN 1664- ...
Activation of the complement pathway through the classical, lectin or alternative complement pathway is followed by a cascade ... Alternative complement pathway - another complement system pathway Lectin pathway - another complement system pathway Noris, ... Classical complement activation has also been shown to combat Methicillin-resistant Staphylococcus aureus. Certain variants of ... Obesity in turn results in an abnormally high level of complement activation via production of the C1 component of the ...
Giang J, Seelen MA, van Doorn MB, Rissmann R, Prens EP, Damman J (2018). "Complement Activation in Inflammatory Skin Diseases ... The mechanism of action of PUVA is unknown, but probably involves activation of psoralen by UVA light, which inhibits the ... leads to activation of the immune system and then the maintenance phase consisting of chronic progression of the disease. Skin ...
When complement is activated on a cell surface, the activation is limited by endogenous complement regulatory proteins, which ... Polymorphisms of complement component 3, complement factor B, and complement factor I, as well as deletion of complement factor ... The end result of this complement activation or complement fixation cascade is stimulation of phagocytes to clear foreign and ... Bajic G, Degn SE, Thiel S, Andersen GR (November 2015). "Complement activation, regulation, and molecular basis for complement- ...
"Complement Activation in Inflammatory Skin Diseases". Frontiers in Immunology. 9: 639. doi:10.3389/fimmu.2018.00639. ISSN 1664- ...
"Complement Activation in Inflammatory Skin Diseases". Frontiers in Immunology. 9: 639. doi:10.3389/fimmu.2018.00639. ISSN 1664- ... "Complement Activation in Inflammatory Skin Diseases". Frontiers in Immunology. 9: 639. doi:10.3389/fimmu.2018.00639. ISSN 1664- ...
Kirschfink, M; Knoblauch, K; Roelcke, D (1994). "Activation of complement by cold agglutinins". Infusionstherapie und ... Binding of CA causes agglutination of erythrocytes and the antigen-antibody complex induces complement (C) activation and ... Binding of antibodies to red blood cells activates the classical pathway of the complement system. If the complement response ... Jaffe, C J; Atkinson, J P; Frank, M M (1976-10-01). "The role of complement in the clearance of cold agglutinin-sensitized ...
This prevents activation of complement. Sialic acid in the form of polysialic acid is an unusual posttranslational modification ...
Complement (C3)-activation phagocytosis by lung macrophages. J Immunol. 1978; 120:1305-1312. 40. Handin RI, Stossel TP. Effect ... Genetic defects affecting complement and host resistance to infection. In: Dayton DH, Bellanti JA, eds. The Phagocytic Cell in ... The opsonic fragment of third component of human complement (C3). J Exp Med. 1975; 141:1329-1347. 28. Hartwig JH, Stossel TP. ... Alveolar macrophage myosin Mg2+- adenosine triphosphatase requires a cofactor for activation by actin. J Biol Chem. 1975; 250: ...
Corrocher R, Tedesco F, Rabusin P, De Sandre G (1975). "Effect of human erythrocyte stromata on complement activation". Br. J. ... Lin B, Morris DW, Chou JY (1997). "The role of HNF1alpha, HNF3gamma, and cyclic AMP in glucose-6-phosphatase gene activation". ... "Analysis of hepatocyte nuclear factor-3 beta protein domains required for transcriptional activation and nuclear targeting". ...
Corrocher R, Tedesco F, Rabusin P, De Sandre G (February 1975). "Effect of human erythrocyte stromata on complement activation ... "Modulation of T-cell activation by malignant melanoma initiating cells". Cancer Research. 70 (2): 697-708. doi:10.1158/0008- ...
Corrocher, R.; Tedesco, F.; Rabusin, P.; De Sandre, G. (1975). "Effect of human erythrocyte stromata on complement activation ...
There is no complement activation or MAG loss. These differences are noticeable only in early lesions and the heterogeneity was ... but also signs of complement system activation can be found. This pattern has been considered similar to damage seen in NMO, ... but no signs of complement system activation. Pattern II The scar presents T-cells and macrophages around blood vessels, with ... Activation of macrophages and lymphocytes and their migration across the barrier may result in direct attacks on myelin sheaths ...
There is no complement activation or MAG loss. The meaning of this fact is controversial. For some investigation teams it means ... but also signs of complement system activation can be found. Though this pattern could be considered similar to damage seen in ... but no signs of complement system activation. Pattern II The scar presents T-cells and macrophages around blood vessels, with ... which was associated with internalization of AQP4 and AQP1 and astrocyte apoptosis in the absence of complement activation. ...
Hourcade D, Holers VM, Atkinson JP (1989). "The regulators of complement activation (RCA) gene cluster". Adv Immunol. Advances ... Properdin (Factor P) is the only known positive regulator of complement activation that stabilizes the alternative C3 ... "C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface ... "Formation of classical C3 convertase during the alternative pathway of human complement activation". Biokhimiia (Moscow, Russia ...
There is no complement activation or MAG loss. These differences are noticeable only in early lesions and the heterogeneity was ... but also signs of complement system activation can be found. This pattern has been considered similar to damage seen in NMO, ... but no signs of complement system activation. Pattern II The scar presents T-cells and macrophages around blood vessels, with ... The complement system infiltration in these cases convert this pattern into a candidate for research into autoimmune ...
The classical pathway of complement activation is initiated when the C1 complex, made up of C1r and C1s serine proteases, ... The alternative pathway of complement activation is typically always active at low levels in blood plasma through a process ... C3a formation occurs through activation and cleavage of complement component 3 in a reaction catalyzed by C3-convertase. There ... Coulthard, LG; Woodruff, TM (15 April 2015). "Is the complement activation product C3a a proinflammatory molecule? Re- ...
1994). "Complement activation by recombinant HIV-1 glycoprotein gp120". J. Immunol. 152 (12): 6028-34. PMID 7911492. Arribas J ... 1996). "Identification of complement activation sites in human immunodeficiency virus type-1 glycoprotein gp120". Blood. 87 (6 ... Complement component 5 is involved in the complement system. It is cleaved into C5a and C5b: C5a plays an important role in ... Complement component 5 is the fifth component of complement, which plays an important role in inflammatory and cell killing ...
Increased expression of surface molecules that inhibit complement activation. Local production of immunosuppressive cytokines, ... 2001). "Activation of RhoA and ROCK are essential for detachment of migrating leukocytes". Mol. Biol. Cell. 12 (7): 2137-2145. ... The chemorepellent 8CPT-cAMP inhibits PLC activity and thereby increases Ptds(3,4,5)P3 accumulation and activation of PTEN. In ... Kotwal, GJ (2000). "Poxviral mimicry of complement and chemokine system components: what's the end game?". Immunol Today. 21 (5 ...
September 2009). "Complement protease MASP-1 activates human endothelial cells: PAR4 activation is a link between complement ... MASP-1 is a serine protease that functions as a component of the lectin pathway of complement activation. The complement ... "The role of MASP-1/3 in complement activation". In Lambris JD, Holers VM, Ricklin D (eds.). Complement Therapeutics. Advances ... This protein is directly involved in complement activation because MASP-1 activates MASP-2 by cleaving (cutting off a piece) a ...
Complement fixation causes the generation of additional inflammatory mediators. Complement activation is very important in ... Complement regulatory proteins (FH and FHL-1), may be removed by SpeB, and therefore restrain FH and FHL-1 recruitment in the ... As soon as binding occurs to the glomerulus, via interaction with properdin, the complement is activated. ... The following diagnostic methods can be used for acute proliferative glomerulonephritis: Kidney biopsy Complement profile ...
"The complement and contact activation systems: partnership in pathogenesis beyond angioedema". Immunological Reviews. 274 (1): ... The contact activation system's physiological role in the kinin-kallikrein system is more clear. Here, after activation of PK ... in which artificial materials act as a surface for contact activation. This test is used to measure the contact activation ... In the contact activation system or CAS, three proteins in the blood, factor XII (FXII), prekallikrein (PK) and high molecular ...
April 2023). "Mechanism of activation and biased signaling in complement receptor C5aR1". Cell Research. 33 (4): 312-324. doi: ... Wu KC, Condon ND, Hill TA, Reid RC, Fairlie D, Lim J (March 2023). "Ras related protein Rab5a regulates complement C5a receptor ... Complement peptide C5a, C4a, and C3a receptors". Pharmacological Reviews. 65 (1): 500-543. doi:10.1124/pr.111.005223. PMID ... April 2015). "The Complement Receptor C5aR Controls Acute Inflammation and Astrogliosis following Spinal Cord Injury". The ...
Serine proteases then cleave a number of soluble complement proteins leading to complement activation, opsonisation, generation ... "Complement System Part I - Molecular Mechanisms of Activation and Regulation". Frontiers in Immunology. 6: 262. doi:10.3389/ ... acetyl groups present in the carbohydrates of bacterial surfaces and mediate activation of the lectin pathway of the complement ... When ficolins bind to their PAMP ligands by their C-terminal fibrinogen-like domain, they initiate the proteolytic complement ...
Activation of the C1 complex initiates the classical complement pathway. This occurs when C1q binds to antigen-antibody ... The C1 complex (complement component 1, C1) is a protein complex involved in the complement system. It is the first component ... Deciphering the fine details of C1 assembly and activation mechanisms: "mission impossible"? Complement+C1 at the U.S. National ... 2001). "The complement system and innate immunity". Immunobiology: The Immune System in Health and Disease. New York: Garland ...
Complement activation is involved and the effect is usually profound. Hyperacute rejection happens within minutes to hours ...
Videm, Vibeke (1991). Biocompatibility of cardiopulmonary bypass: measures to reduce complement activation (Thesis). Oslo. OCLC ...
Its activation is required for both classical and alternative complement activation pathways. People with C3 deficiency are ... "Entrez Gene: C3 complement component 3". Sahu A, Lambris JD (Apr 2001). "Structure and biology of complement protein C3, a ... C3 plays a central role in the activation of the complement system. ... "Structure of C3b in complex with CRIg gives insights into regulation of complement activation". Nature. 444 (7116): 217-20. ...
... - Download as a PDF or view online for free ... Similar to Complement activation pathway.pptx. Complement proteins by Complement proteinsMintah Dadzie Francis. 3.4K. views•29 ... Complement activation pathway.pptx. *1. Complement activation pathway PRESENTED BY Mr.Karthick J. ... complement and complement deficiency by complement and complement deficiencyChulalongkorn Allergy and Clinical Immunology ...
Cell-Bound Complement Activation Products (CB-CAPs) or complement split products, refers to complement activation fragments, ... Ahearn, Joseph M.; Liu, Chau-Ching; Manzi, Susan (6 November 2017). "Cell-bound complement activation products as lupus ... "Cell-bound complement activation products in SLE". Lupus Science & Medicine. 4 (1): e000236. doi:10.1136/lupus-2017-000236. PMC ... C4d, that are bound covalently to somatic cells, as a result of activation of the classical complement pathway. They appear ...
Activation. The complement system functions as an interactive sequence, with one reaction leading to another in the form of a ... Inhibitory effect of free sialic acid on complement activation and its significance in hypocomplementemic glomerulonephritis. J ... Table 3. Proteins of the Human Complement (C) System, Lectin Pathway *Table 4. Proteins of the Human Complement (C) System, C3 ... encoded search term (Complement-Related Disorders) and Complement-Related Disorders What to Read Next on Medscape ...
Figure 1 Complement activation pathways. Complement activation is triggered via activation of either the alternative, classical ... ACTIVATION OF THE COMPLEMENT SYSTEM. Activation of the complement cascade is triggered by one of three distinct pathways: the ... COMPLEMENT ACTIVATION IN RENAL DISEASE. Complement activation is known to occur in immune mediated glomerular diseases (lupus ... complement activation products can be found in diseases where glomerular complement activation is not a major feature, for ...
E-LDL is recognised by the C1q subunit of C1 and triggers direct C1 activation, suggesting that complement activation by E-LDL ... Final Report Summary - COMPLEMENT AND LDL (Complement and atherosclerosis: molecular mechanism of C1 activation by ... complement activation, and formation of the terminal C5b-9 membrane attack complex of complement were shown to occur in ... COMPLEMENT AND ATHEROSCLEROSIS: MOLECULAR MECHANISM OF C1 ACTIVATION BY ENZYMATICALLY MODIFIED LOW-DENSITY LIPOPROTEINS. ...
Complement Activation by Giardia duodenalis Parasites through the Lectin Pathway Contributes to Mast Cell Responses and ... We explored the role of complement in immunity to Giardia using mice deficient in mannose-binding lectin (Mbl2) or complement ... suggest that complement is a key factor in the innate recognition of Giardia and that recruitment of mast cells and activation ...
Complement Activation Products - C3d. Clinical use:. In any disease state where complement consumption is considered to be ... In patients with low concentrations of complement components, or very low CH50, this test can indicate the likelihood of active ...
... inhibiting thrombin activation may serve as a feasible strategy for preventing and/or reducing ... These findings provide new insights into the crosstalk between the coagulation and complement systems in the pathogenesis of ... Επιστημονικά Επιτεύγματα :Crosstalk between coagulation and complement activation promotes cardiac dysfunction in ... Crosstalk between coagulation and complement activation promotes cardiac dysfunction in arrhythmogenic right ventricular ...
Complement factor B (FB) mutant variants are associated with excessive complement activation in kidney diseases such as ... Complement factor B (FB) mutant variants are associated with excessive complement activation in kidney diseases such as ... Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome ... Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome ...
To evaluate the association between lupus severity and cell-bound complement activation products (CB-CAPs) or low complement ... Abnormalities in complement activation as measured by CB-CAPs are associated with increased LSI. ... Abnormal CB-CAPs (erythrocyte-bound C4d or B-lymphocyte-bound C4d levels >99th percentile of healthy) and complement ... Abnormal CB-CAPs were more prevalent than low complement values irrespective of LSI levels (62% vs 38%, respectively, p< ...
... an innovative complement activation array was developed.. Characterized antibodies detecting the complement activation specific ... Human serum from a healthy (n = 46) and OSCC patient (n = 57) cohort were used to investigate the role of complement activation ... This study aimed to investigate the activation of the complement system in OSCC patients as potential biomarker. Therefore, ... Our study suggests that systemic complement activation levels in OSCC patients may be useful to assess disease progression. ...
The purpose of this review is to provide a latest summary of biomarkers associated with endothelial cell activation in COVID-19 ... and offer mechanistic insights into the molecular basis of endothelial activation/dysfunction in macro- and micro-vasculature ... Complement activation. Recent studies have demonstrated that complement activation is associated with SARS-CoV-2 infection ... Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Sci Immunol. 2021;6:eabh2259. ...
Dive into the research topics of Human complement activation by smooth and rough Proteus mirabilis lipopolysaccharides. ...
... complement: …occurs by three pathways: the classical pathway, the lectin pathway, and the alternative pathway (or properdin ... complement activation. *. In complement. …occurs by three pathways: the classical pathway, the lectin pathway, and the ... In immune system: Activation of the complement system. …one to be discovered, the classical pathway, which is initiated by ...
... ... Objective: To determine the impact of genetic variability in complement activation on early development of the systemic ... Measurements and Main results: A total of 299 children were genotyped for functional polymorphisms in the complement activation ... Conclusions: Functional polymorphisms in the complement activation cascade modify the risk for early SIRS/sepsis in general ...
... Publication , Journal ... "Fleeting activation of ionotropic glutamate receptors sensitizes cortical neurons to complement attack." Neuron, vol. 36, no. 3 ... "Fleeting activation of ionotropic glutamate receptors sensitizes cortical neurons to complement attack." Neuron 36, no. 3 ( ... Fleeting activation of ionotropic glutamate receptors sensitizes cortical neurons to complement attack. Neuron. 2002 Oct 24;36( ...
Mice lacking complement components do not develop RA and blocking of complement activation prevents arthritis. Traditionally, ... is a complex process also involving complement activation. Thus, complement is consumed and deposited in the joints during the ... Misguided or excessive complement activation is involved in many common diseases such as rheumatoid arthritis, systemic lupus ... We aim to identify further molecules involved in the activation of complement in joints in RA with the goal of developing ...
Interestingly, the most primordial defense responses employed by myeloid cells against pathogens, such as complement activation ... Interestingly, the most primordial defense responses employed by myeloid cells against pathogens, such as complement activation ... Complement Activation as Tumor Promoter. Complement is an innate defense mechanism that detects and eliminates pathogens from ... Complement Anaphylatoxins as Tumor Promoters. Complement activation has been reported to promote tumor progression through the ...
... activation. Our aim was to evaluate possible associations between C activation capacity and prednisolone treatment. Plasma from ... The decreases observed after prednisolone treatment reflect a general down-regulation in immune activation. ... concentration and MBL-C4-activation capacity (AC) values compared to UC patients (p < 0.02). Before treatment, plasma from ... Our findings indicate that C activation capacity is up-regulated significantly in plasma from CD patients. ...
Start Over You searched for: Subjects Complement Activation -- physiology ✖Remove constraint Subjects: Complement Activation ... 1. Anatomy of the immune system: complement cascade Publication: E. Hanover, N.J. : Sandoz Pharmaceuticals Corp., c1988 Subject ...
... Hamad, Osama Rudbeck Laboratory ... 12th European Meeting on Complement in Human Disease 12th European Meeting on CHD, Visegrad, Hungary 5-8 September 2009 ...
Terminal complement pathway activation drives synaptic Loss in Alzheimers disease models. Acta Neuropathologica Communications ... We demonstrate that complement dysregulation occurs in Alzheimers disease mice involving the activation (C1q; C3b/iC3b) and ... It is posited that C1 binding initiates complement activation on synapses; C3 fragments then tag them for microglial ... We here address several knowledge gaps: (i) is complement activated through to MAC at the synapse? (ii) does MAC contribute to ...
View article titled, Myeloperoxidase Directs Properdin-Mediated Complement Activation Open the PDF for Myeloperoxidase Directs ... The alternative pathway (AP) of complement consists of C3, factor B, factor D and properdin, which amplifies AP activation. AP ... Joseph OFlynn; Karen O. Dixon; Maria C. Faber Krol; Mohamed R. Daha; Cees van Kooten Neutrophils and complement are key ...
Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and ... Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and ...
The classical pathway triggers pathogenic complement activation in membranous nephropathy.. Seifert L, Zahner G, Meyer- ... However, both the initiation pathways and the pathogenic significance of complement activation in MN are poorly understood. ... Proximity ligation assays to directly visualize complement assembly in the tissue reveal dominant activation via the classical ... Our study shows that, in MN, complement is primarily activated via the classical pathway and targeting complement components ...
... ... The aim for this dissertation is to provide a novel molecular link connecting complement activation with retinal vascular ... A number of studies imply that there is a link between progression of DR and complement dysregulation (3). ... studies revealed that extracellular vesicles such as exosomes associate with immunoglobulins in plasma and activate complement ...
3615905..3661108 complement Download. GenBank, FASTA, Sequence Viewer (Graphics). mRNA and Protein(s) * XM_006516463.3 → XP_ ... Tasor2 transcription activation suppressor family member 2 [Mus musculus] Tasor2 transcription activation suppressor family ... transcription activation suppressor family member 2provided by MGI. Primary source. MGI:MGI:2145274 See related. Ensembl: ... Tasor2 transcription activation suppressor family member 2 [ Mus musculus (house mouse) ] Gene ID: 105203, updated on 23-Nov- ...
Further insights into modulation of complement activation by the factor H-related family of proteins ... Further insights into modulation of complement activation by the factor H-related family of proteins ...
Measurement of complement activation. The BD® CBA Human Anaphylatoxin Kit can be used to quantitatively measure anaphylatoxin ... C4 and C5 during complement activation) protein levels in a single EDTA plasma or serum research sample. ... The complement system is also activated, and chemo-attracted neutrophils cause local inflammation and tissue damage. This type ... is characterized by Ig-M and Ig-G antibodies that bind to cell surface antigens inducing activation of complement cascades and ...
... thus providing a platform for de novo convertase assembly and complement activation. These studies, with some contradictory ... that the physiological forms of human properdin can selectively recognize surfaces and enhance or promote complement activation ... Properdin, a positive regulator of the complement system, has recently been reported to bind to certain pathogenic ... which is in agreement with the reported role for properdin as a complement initiator. ...
  • Activation of the complement pathways. (medscape.com)
  • However, both the initiation pathways and the pathogenic significance of complement activation in MN are poorly understood. (leibniz-hki.de)
  • Here, we show that components from all three complement pathways (alternative, classical and lectin) are found in renal biopsies from patients with MN. (leibniz-hki.de)
  • Complement can be triggered by one of three distinct pathways: the classical pathway (CP), alternative pathway (AP), or lectin (LP) pathway. (ashpublications.org)
  • Activation of the different pathways is mediated by pathway-specific proteins that recognize molecular patterns on pathogens. (ashpublications.org)
  • Although complement is one of the first lines of defense against infection, hyperactivity of specific pathways has been described in numerous autoimmune and inflammatory disease settings. (ashpublications.org)
  • In particular, we demonstrated a significant PTX3-mediated activation of classical (C1q-mediated) and lectin (MBL-mediated) pathways of Complement. (unicatt.it)
  • The complement system is the first line of defence against pathogen infection and can be activated by the classic, alternative and lectin pathways. (herts.ac.uk)
  • Learn about the three pathways lead to complement activation and some of their key inhibitors. (abcam.com)
  • the classical pathway initiated by antibodies bound to the surface of foreign bodies and the alternative and lectin pathways that provide an antibody-independent mechanism for complement activation, induced by the presence of bacteria and other micro-organisms. (abcam.com)
  • Complement activation , triggered by neuraminidase , and the participation of different activation pathways were analyzed by Western blot . (bvsalud.org)
  • Pulmonary findings were consistent with significant deposits of terminal complement C5b-9, C4d, and MBL associated serum protease in the microvasculature consistent with sustained systemic activation of complement pathways [7] . (acquaintpublications.com)
  • A further complicating factor is the cross-talk between complement, neutrophils, and coagulation pathways in the pathophysiology of TMA. (jrheum.org)
  • Activation of the complement system occurs through the classical (CP), lectin (LP), or alternative (AP) pathways. (jrheum.org)
  • The complement system as understood today is a multimolecular system composed of more than 32 proteins and consisting of serum proteins, serosal proteins, and cell membrane receptors that bind to complement fragments. (medscape.com)
  • The complement system consists of 7 serum and 9 membrane regulatory proteins, 1 serosal regulatory protein, and 8 cell membrane receptors that bind complement fragments. (medscape.com)
  • To evaluate the association between lupus severity and cell-bound complement activation products (CB-CAPs) or low complement proteins C3 and C4. (escholarship.org)
  • 99th percentile of healthy) and complement proteins C3 and C4 were determined using flow cytometry and turbidimetry, respectively. (escholarship.org)
  • Therefore, we are investigating the possible modulatory effects that cartilage proteins may have on complement. (lu.se)
  • A certain level of complement activation is a prerequisite for efficient and 'silent' disposal of dying cell debris, since complement proteins function as strong opsonins, but a tight balance must be maintained to prevent full-blown activation against self-antigens. (lu.se)
  • The complement system is a family of plasma proteins that mediates humoral immune surveillance. (ashpublications.org)
  • The article mentions, "Complement activation may occur early during SARS-CoV-2 infection by the direct interaction of viral proteins with mannose- binding lectin and ficolin pathway. (acquaintpublications.com)
  • 10 This distinction is not absolute because genetic defects in complement proteins have been identified in secondary TMA. (jrheum.org)
  • Most of these genes provide instructions for making proteins that help regulate a part of the body's immune response known as the complement system. (medlineplus.gov)
  • Autoantibodies cause the condition by altering the activity of proteins involved in regulating the complement system. (medlineplus.gov)
  • Unlocking the Mysteries of the Immune System: new Roles of complement proteins in Diabetes and Cancer. (lu.se)
  • Recent evidence and clinical similarities suggest a link to atypical hemolytic uremic syndrome, a disease of excessive activation of the alternative complement pathway effectively treated with a complement inhibitor, eculizumab. (johnshopkins.edu)
  • Here, we report in vitro testing of peptide inhibitor of complement C1 (PIC1) in assays of immune complex-mediated complement activation in human sera and assays for NET formation by human neutrophils. (realtalifesciences.com)
  • Peptide Inhibitor of Complement C1 (PIC1) Rapidly Inhibits Complement. (realtalifesciences.com)
  • In addition, we demonstrate that the infectious stage of T. cruzi inhibits the lectin pathway activation and complement killing expressing the complement C2 receptor inhibitor trispanning (CRIT) protein. (herts.ac.uk)
  • We found very high levels of expression of the central complement protein, C3, and complement inhibitor CD59 in human pancreatic islets. (lu.se)
  • In this review we discuss current evidence that complement activation contributes to progression of CKD, how complement could cause renal inflammation and whether complement inhibition would slow progression of renal disease. (wjgnet.com)
  • Mutagenesis was performed to study the effect of factor D (FD) inhibition on C3 convertase-induced FB cleavage, complement-mediated. (lu.se)
  • These results suggest that FD inhibition can effectively block complement overactivation induced by FB gain-of-function mutations. (lu.se)
  • Homozygosity for the complement factor H Y402H polymorphism, which is thought to reduce complement inhibition, was associated with less frequent SIRS/sepsis (the adjusted odds ratio for the homozygous variant complement factor H Y402H [CC] carriers was 0.3, 95% confidence interval, 0.1-0.7, p = .005). (figshare.com)
  • In several instances, PA-dPEG24 achieved complete inhibition with complement effector levels equivalent to background. (realtalifesciences.com)
  • Inhibition of Complement Activation, Myeloperoxidase, NET Formation And Oxidant. (realtalifesciences.com)
  • The role of complement in ependymal damage induced by neuraminidase was analyzed in vivo in two rat models of complement blockade systemic inhibition of C5 by using a function blocking antibody and testing in C6-deficient rats . (bvsalud.org)
  • We know that uncontrolled activation of the complement pathway is responsible for many devastating diseases, and through the development of the first two complement inhibitors - SOLIRIS and ULTOMIRIS - we have shown the transformative impact of C5 inhibition on several of these diseases," said John Orloff, M.D., Executive Vice President and Head of Research & Development at Alexion. (businesswire.com)
  • Complement factor B (FB) mutant variants are associated with excessive complement activation in kidney diseases such as atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy and membranoproliferative glomerulonephritis (MPGN). (lu.se)
  • The role of complement dysregulation on vascular endothelial cells has been well established in atypical hemolytic uremic syndrome (aHUS), a thrombotic microangiopathy (TMA) characterized by microangiopathic hemolytic anemia, thrombocytopenia, and target organ injury. (jrheum.org)
  • 7 - 9 A TMA is called "primary" when a genetic or acquired defect in a complement protein is identified (as in atypical hemolytic uremic syndrome [aHUS]) or "secondary" when occurring in the context of another disease process or factor such as infection, autoimmune disease, malignancy, or drugs. (jrheum.org)
  • Our study suggests that systemic complement activation levels in OSCC patients may be useful to assess disease progression. (oncotarget.com)
  • Objective: To determine the impact of genetic variability in complement activation on early development of the systemic inflammatory response syndrome (SIRS) in general pediatric critical care. (figshare.com)
  • A genotype that permits vigorous complement activation to an infectious or inflammatory insult may offer protection from development of systemic inflammation. (figshare.com)
  • Misguided or excessive complement activation is involved in many common diseases such as rheumatoid arthritis, systemic lupus erythematosus, vasculitis and age-related macula degeneration. (lu.se)
  • Abstract: Two major aspects of systemic lupus erythematosus (SLE) pathogenesis that have yet to be targeted therapeutically are immune complex-initiated complement activation and neutrophil extracellular trap (NET) formation by neutrophils. (realtalifesciences.com)
  • This review aims to provide an assessment of the nature and extent of complement involvement in TMA associated with autoimmune diseases such as systemic lupus erythematosus, antiphospholipid syndrome, and scleroderma renal crisis. (jrheum.org)
  • We are studying how apoptotic cells are recognized by C1q and complement inhibitors and what are functional consequences of these interactions. (lu.se)
  • Advancements in the understanding of the etiopathogenesis of aHUS paved the way for the successful development of anticomplement therapies (complement C5 inhibitors), which have revolutionized the treatment of aHUS. (jrheum.org)
  • Interestingly, the most primordial defense responses employed by myeloid cells against pathogens, such as complement activation, antibody-dependent cell cytotoxicity and phagocytosis, actually seem to favor cancer progression. (frontiersin.org)
  • Type II hypersensitivity is characterized by Ig-M and Ig-G antibodies that bind to cell surface antigens inducing activation of complement cascades and phagocytosis. (bdbiosciences.com)
  • We collected 40 individual CAD patient samples and showed that TNT003 prevented cold agglutinin-mediated deposition of complement opsonins that promote phagocytosis of RBCs. (ashpublications.org)
  • The functions of complement include the attraction of inflammatory cells, opsonization to promote phagocytosis, immune complex clearance and direct microbial killing through the formation of the membrane attack complex (MAC). (abcam.com)
  • It is involved in the activation of complement, enhancement of phagocytosis, and detoxification of substances released from damaged tissue. (cdc.gov)
  • The complement system functions as an interactive sequence, with one reaction leading to another in the form of a cascade. (medscape.com)
  • The complement system is an integral part of the innate immune system but also augments adaptive immune responses. (wjgnet.com)
  • Complement, a complex system of enzymes and regulators endowed with multiple biological activities (opsonisation, chemoattraction of leukocytes, cell lysis, cell activation), is a major component of innate defence against pathogens. (europa.eu)
  • This study aimed to investigate the activation of the complement system in OSCC patients as potential biomarker. (oncotarget.com)
  • The complement system is also activated, and chemo-attracted neutrophils cause local inflammation and tissue damage. (bdbiosciences.com)
  • Properdin, a positive regulator of the complement system, has recently been reported to bind to certain pathogenic microorganisms, to early or late apoptotic and necrotic cells, and to particular live human cell lines, thus providing a platform for de novo convertase assembly and complement activation. (utoledo.edu)
  • Together these results demonstrate that PA-dPEG24 can inhibit immune complex activation of the complement system and NET formation. (realtalifesciences.com)
  • The complement system has been increasingly recognized to play a pivotal role in a variety of inflammatory and autoimmune diseases. (realtalifesciences.com)
  • Trypanosoma cruzi, the causative agent of Chagas disease, has to evade complement system killing and invade the host cells to progress in infection. (herts.ac.uk)
  • Our findings establish that the complement lectin pathway recognizes T. cruzi and provide molecular insights into how the infectious stage inhibits this activation to resist complement system killing. (herts.ac.uk)
  • The complement system is a heat-labile component of blood that confers bactericidal properties. (abcam.com)
  • Complement system activation contributes to the ependymal damage induced by microbial neuraminidase. (bvsalud.org)
  • some reports implicate the complement system as a cause of these injuries . (bvsalud.org)
  • These results demonstrate that the complement system contributes to ependymal damage and death caused by neuraminidase . (bvsalud.org)
  • The complement system is an agent pro-inflammatory host defense mechanism that is part of both the night and adaptive immunity. (acquaintpublications.com)
  • Per Richard Stienm [1] , on UpToDate, the complement system plays a vital role in instructing the adaptive immune response and removal of damaged cells, tissue regeneration, and angiogenesis. (acquaintpublications.com)
  • According to an article in the American Journal of medicine and critical care by Marcus Bossman, MD at Boston University school of medicine, the complement system is suspected to have a critical role during the development of COVID-19. (acquaintpublications.com)
  • The viral nucleocapsid protein binds to a mannose-binding protein-associated serine protease 2 (MASP-2), a key protease of the MBL pathway leading to overactivation of the complement system and worsening of lung injury. (acquaintpublications.com)
  • The production of SARS-CoV-2 specific IgM and IgG during approximately the second week of the disease may further activate the complement system via the classical pathway whereas IgA can trigger the MBL pathway per Dr. Marcus Bossman's article [4] . (acquaintpublications.com)
  • SC5b-9 (terminal complement complex) is a measurement of complement system activation. (cdc.gov)
  • The complement system is an enzyme cascade that helps defend against infection. (msdmanuals.com)
  • C3 cleavage may result in formation of the membrane attack complex (MAC), the cytotoxic component of the complement system. (msdmanuals.com)
  • The complement system is a tightly regulated, cascading protein network representing a key component linking the innate and humoral immune systems. (jrheum.org)
  • Therefore, a clearer understanding of the role of the complement system in TMA associated with other conditions will help to identify patients who would benefit from these therapies. (jrheum.org)
  • The complement system is a tightly regulated, cascading protein network that performs multiple roles in homeostasis and disease prevention and is a key component of both the innate and the humoral immune systems. (jrheum.org)
  • 8 , 11 - 14 Numerous stimuli can drive the activation of the complement system, including apoptotic debris, pathogens, and antibody-antigen complexes, in addition to ischemia-reperfusion injuries associated with organ transplantation. (jrheum.org)
  • Repeated LPS injections induced an up-regulation of complement system protein c1q and distinct microglial phenotype with an enrichment of the complement-phagosome pathway. (imperial.ac.uk)
  • Our work implicates that complement system may be a therapeutic target for developing therapies to prevent or treat cognitive disorders related to neuroinflammation or other disease conditions including neurodegenerative disease per se. (imperial.ac.uk)
  • Acidosis activates complement system in vitro. (nih.gov)
  • The complement system must be carefully regulated so it targets only unwanted materials and does not damage the body's healthy cells. (medlineplus.gov)
  • A specific mutation in one of the complement system-related genes, CFHR5 , has been found to cause C3 glomerulopathy in people from the Mediterranean island of Cyprus. (medlineplus.gov)
  • Mutation in the C3 and CFH genes, as well as other complement system-related genes, have been found to cause the condition in other populations. (medlineplus.gov)
  • Several normal variants (polymorphisms) in complement system-related genes are associated with an increased likelihood of developing C3 glomerulopathy. (medlineplus.gov)
  • The genetic changes related to C3 glomerulopathy "turn up," or increase the activation of, the complement system. (medlineplus.gov)
  • Studies suggest that uncontrolled activation of the complement system also causes the other health problems that can occur with dense deposit disease, including acquired partial lipodystrophy and a buildup of drusen in the retina. (medlineplus.gov)
  • Researchers are working to determine how these associated health problems are related to overactivity of the complement system. (medlineplus.gov)
  • C-reactive protein (CRP, not shown) leads to classic pathway activation analogous to lectin pathway activation by MBL and ficolins. (medscape.com)
  • We found already that fibromodulin and cartilage oligomeric matrix protein (COMP) are potent activators of complement. (lu.se)
  • Affected individuals may have particularly low levels of a protein called complement component 3 (or C3) in the blood. (medlineplus.gov)
  • 2019) Cartilage Oligomeric Matrix Protein initiates cancer stem cells through activation of Jagged1-Notch3 signaling. (lu.se)
  • In the first phase, a series of specific interactions leads to formation of intrinsic complement proteinase, termed C3 convertase. (medscape.com)
  • Depending on the nature of complement activators, the classic pathway, the alternative pathway, or the more recently discovered lectin pathway is activated predominantly to produce C3 convertase. (medscape.com)
  • T. cruzi infectious stages resist complement-mediated killing by expressing surface receptors, which dissociate or prevent C3 convertase formation. (herts.ac.uk)
  • We explored the role of complement in immunity to Giardia using mice deficient in mannose-binding lectin (Mbl2) or complement factor 3a receptor (C3aR). (nih.gov)
  • Human serum from a healthy ( n = 46) and OSCC patient ( n = 57) cohort were used to investigate the role of complement activation in oral tumor progression. (oncotarget.com)
  • Here, we set out to test the role of complement . (bvsalud.org)
  • Yet, a great deal of complexity exists around the role of complement in TMA associated with other diseases. (jrheum.org)
  • Defining the role of complement in TMA in these conditions will help to guide timely diagnosis and management. (jrheum.org)
  • This is a case of saddle pulmonary embolism in a healthy 20 years old COVID-19 patient who had significant elevation of 50 % complement hemolytic Assay with negative COVID-19 testing by PCR and positive SARS-CoV-2 antibody. (acquaintpublications.com)
  • Based on an article by Maurizio Costabile, the classical complement activation is measured by the 50 % complement hemolytic assay ( CH 50) which tests the functional capacity of serum complement components of the classical pathway to lyse sheep red blood cells pre- coated with rabbit anti-sheep red blood cell antibody [3] . (acquaintpublications.com)
  • Measurements and Main results: A total of 299 children were genotyped for functional polymorphisms in the complement activation cascade. (figshare.com)
  • Conclusions: Functional polymorphisms in the complement activation cascade modify the risk for early SIRS/sepsis in general pediatric critical care. (figshare.com)
  • The site within the complement cascade at which sensitization was effected was the membrane attack pathway. (duke.edu)
  • Finally, we provide evidence that CP activity in CAD patients terminates prior to activation of the terminal cascade, supporting the hypothesis that the primary route of RBC destruction in these patients occurs via extravascular hemolysis. (ashpublications.org)
  • Complement activation results in an enzymatic cascade leading to the production of opsonins and anaphylatoxins responsible for clearing pathogens and initiating inflammation. (ashpublications.org)
  • C1 is the first molecule in the classical complement cascade and comprises C1q and two molecules of C1r and C1s respectively. (abcam.com)
  • Why is it important that complement activation always takes place after physical association of the target with early components in the complement cascade? (assignment-writer.com)
  • Collectively, our data provide evidence that activated microglia and complement cascade c1q signaling in the hippocampus may account for synaptic loss and cognitive impairments in a mouse model of neuroinflammation induced by repeated LPS injections. (imperial.ac.uk)
  • Furthermore, lectin pathway activation by T. cruzi required the MBL-associated serine protease 2 (MASP2) activity resulting in C2 factor cleavage. (herts.ac.uk)
  • Following these cleavage events, complement pathway activation continues as in the classical pathway. (abcam.com)
  • Alternate pathway activation occurs when components of microbial cell surfaces (eg, yeast walls, bacterial cell wall lipopolysaccharide [endotoxin]) or immunoglobulin (eg, nephritic factor, aggregated IgA) cleave small amounts of C3. (msdmanuals.com)
  • It is also emerging as an important factor in atherosclerosis: complement activation, and formation of the terminal C5b-9 membrane attack complex of complement were shown to occur in atherosclerotic lesions. (europa.eu)
  • The complement molecule effecting cytotoxicity was the membrane attack complex. (duke.edu)
  • However, the precise mechanisms of complement-mediated synaptic loss remain unclear, and the role of the lytic membrane attack complex (MAC) is unexplored. (cardiff.ac.uk)
  • By inhibiting cold agglutinin-mediated complement deposition on the cellular membrane, TNT003 prevents RBCs from being phagocytosed. (ashpublications.org)
  • The lead PIC1 derivative, PA-dPEG24, was able to dose-dependently inhibit complement activation initiated by multiple types of immune complexes (IC), including C1-anti-C1q IC, limiting the generation of pro-inflammatory complement effectors, including C5a and membrane attack complex (sC5b-9). (realtalifesciences.com)
  • The assembly of the complement membrane attack complex on the ependymal epithelium of rats injected with neuraminidase was analyzed by immunohistochemistry . (bvsalud.org)
  • The complement membrane attack complex immunolocalized on the ependymal surface in rats injected intracerebroventricularly with neuraminidase . (bvsalud.org)
  • Characterized antibodies detecting the complement activation specific epitopes C3a, C5a and sC5b-9 along with control antibodies were implemented into a suspension bead array. (oncotarget.com)
  • PRR on myeloid cells can be triggered by pathogen-associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs), but also indirectly by secondary mechanisms such as complement activation and circulating antibodies (Abs), resulting in cytolytic and phagocytic effector mechanisms. (frontiersin.org)
  • In the case of the CP, activation is driven by immune complexes containing complement-fixing antibodies. (ashpublications.org)
  • C1q attaches to antibodies bound on the pathogen surface, leading to the activation of C1s. (abcam.com)
  • 0.0001) and sC5b-9 ( p = 0.01) concentrations in OSCC patients were determined using the validated multiplex complement assay. (oncotarget.com)
  • Therefore, we used a functional complement assay, the modified Ham test, to analyze sera of women with classic or atypical HELLP syndrome, pre-eclampsia with severe features, normal pregnancies, and healthy nonpregnant women. (johnshopkins.edu)
  • Background Cell-bound complement activation products (CB-CAPs), including erythrocyte-bound C4d (EC4d) and B-lymphocyte-bound C4d (BC4d), in a multi-analyte assay with algorithm (MAP) represent an important addition to the diagnostic armamentarium of SLE. (bmj.com)
  • A number of studies imply that there is a link between progression of DR and complement dysregulation (3). (msu.edu)
  • Cees van Kooten Neutrophils and complement are key members of innate immunity. (karger.com)
  • Thus, in SLE complement acts as a double edge sword and while its genetic deficiency leads to SLE, complement also contributes to development of symptoms since there are immune complexes deposited in tissues and these activate complement. (lu.se)
  • Our studies revealed that extracellular vesicles such as exosomes associate with immunoglobulins in plasma and activate complement pathway, which contributes to the increase in retinal vascular permeability in diabetes. (msu.edu)
  • Scholars@Duke publication: Fleeting activation of ionotropic glutamate receptors sensitizes cortical neurons to complement attack. (duke.edu)
  • Excitotoxicity, triggered by excessive activation of glutamate receptors, has been implicated in neuronal death following diverse insults, including ischemia and seizures. (duke.edu)
  • We found that fleeting activation of ionotropic glutamate receptors sensitizes neurons but not astrocytes to complement attack. (duke.edu)
  • We tested the in vitro ability of eculizumab to inhibit complement activation in HELLP serum. (johnshopkins.edu)
  • C3 activation fragments were found in serum and cerebrospinal fluid of rats treated with neuraminidase , suggesting that neuraminidase itself activates complement . (bvsalud.org)
  • Serum serine proteases which participate in COMPLEMENT ACTIVATION. (bvsalud.org)
  • The alternative pathway of complement activation is in a constant state of low-level activation (known as tickover). (abcam.com)
  • These data suggest that complement is a key factor in the innate recognition of Giardia and that recruitment of mast cells and activation of T cell immunity through C3a are important for parasite control. (nih.gov)
  • Interestingly, PTX3 deposits co-localized with activation of the terminal Complement complex (C5b-9) on endothelial cells, indicating that PTX3-mediated Complement activation occurred mainly at the renal vascular level. (unicatt.it)
  • Model depicting the putative crosstalk between the complement and coagulation systems as a new pathogenetic mechanism that exacerbates myocardial injury in ARVC. (bioacademy.gr)
  • Per Wolfeam Ruf on his publication on 'the blood', complement and coagulation systems play a role in eliminating perivascular and intravascular microorganisms in the process of cold Immuno- thrombosis [2] . (acquaintpublications.com)
  • Here, we present the first evidence that T. cruzi activates the complement lectin pathway. (herts.ac.uk)
  • Mice lacking complement components do not develop RA and blocking of complement activation prevents arthritis. (lu.se)
  • Complement activation occurs in progressive chronic kidney disease and may contribute to the chronic inflammation that is characteristically found in the kidney. (wjgnet.com)
  • Anemia occurs as a result of autoantibody-mediated CP activation on the surface of the erythrocyte, leading to the deposition of complement opsonins that drive extravascular hemolysis in the liver. (ashpublications.org)
  • Further we aim to study handling of apoptotic cells and DNA from various sources by complement, in relation to autoimmune diseases . (lu.se)
  • Binding of factor H to C3b increases its inactivation by factor I. Properdin stabilizes it, preventing its inactivation by factors H and I. The alternate pathway does not result in a truly nonspecific activation of complement because it requires specific types of compounds for activation. (medscape.com)
  • The alternative pathway (AP) of complement consists of C3, factor B, factor D and properdin, which amplifies AP activation. (karger.com)
  • Finally, we have determined for the first time that the physiological forms of human properdin can selectively recognize surfaces and enhance or promote complement activation, which is in agreement with the reported role for properdin as a complement initiator. (utoledo.edu)
  • Cell-Bound Complement Activation Products (CB-CAPs) or complement split products, refers to complement activation fragments, C4d, that are bound covalently to somatic cells, as a result of activation of the classical complement pathway. (wikipedia.org)
  • It is therefore possible that inhibiting complement activation would reduce inflammation, lead to reduced fibrosis and preservation of renal function. (wjgnet.com)
  • Joint inflammation in rheumatoid arthritis (RA), a common chronic inflammatory disease that causes long-term suffering and disability in 1% of our population, is a complex process also involving complement activation. (lu.se)
  • Ig-E-mediated food allergy involves the binding of food allergens to Ig-E molecules leading to the activation of effector cells releasing histamine (immediate response) followed by allergic inflammation with increased leukotrienes, platelet activating factor (PAF), and IL-4, IL-5 and IL-13 cytokines. (bdbiosciences.com)
  • The inflammation, thrombin activation, and erythrocyte lysis caused by primary injury could promote the formation of brain edema, which is associated with poor outcome, and could cause more severe and durable injury [ 3 ]. (karger.com)
  • During classical complement is activation by antigen-antibody complex, CH 50 will be high while complement component deficiencies result in low CH 50. (acquaintpublications.com)
  • [ 2 ] However, complete complement deficiencies are quite rare and account for only a tiny percentage of SLE cases. (medscape.com)
  • Many molecules including complement are involved in the recognition of dying cells as shown by phenotype displayed by patients lacking complement component, for example deficiency of C1q leads in 95% cases to SLE. (lu.se)
  • Mannan-binding lectin (MBL) and MBL-associated serine proteases (MASPs) are involved in the initial step of the lectin pathway of complement activation. (abcam.com)
  • Complete deficiency of the early complement components C2, C4, and C1q results in SLE in 75%, 10%, and 90% of cases, respectively. (medscape.com)
  • In an antigen-specific autoimmune mouse model of MN, glomerular damage and proteinuria are reduced in complement-deficient mice compared with wild-type littermates. (leibniz-hki.de)
  • Moreover, in a study using virus-infected C3 -/- mice, by Gralinski and colleagues, complement activation was assessed in SARS-CoV infection with C3 activation products in the lung as early as one day after SARS-CoV infection. (acquaintpublications.com)
  • BOSTON & COPENHAGEN, Denmark--( BUSINESS WIRE )-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Zealand Pharma A/S (NASDAQ:ZEAL) today announced a collaboration to discover and develop novel peptide therapies for complement-mediated diseases. (businesswire.com)
  • We are excited by the potential to explore different targets in the complement pathway and look forward to building on Alexion's more than 20 years of complement expertise with the development of next-generation peptide therapies in collaboration with Zealand Pharma, which may provide the opportunity to treat many additional diseases. (businesswire.com)
  • We believe that peptide-based therapies hold great promise in inhibiting complement activation. (businesswire.com)
  • Alexion's demonstrated expertise in treating rare and complement-mediated diseases makes this the ideal collaboration to advance Zealand's complement-focused peptide programs. (businesswire.com)
  • Under the terms of the agreement, Alexion and Zealand will enter into an exclusive collaboration for the discovery and development of subcutaneously delivered peptide therapies directed to up to four complement pathway targets. (businesswire.com)
  • Activation of the classical complement pathway by therapeutic anti-thymocyte globulin preparations rapidly enhances monocyte tissue factor procoagulant activity, according to the article. (acquaintpublications.com)
  • We aim to identify further molecules involved in the activation of complement in joints in RA with the goal of developing diagnostic assays for diagnosis, prognosis and follow up of treatment. (lu.se)
  • One application of our research are improved diagnostic assays such as recently commercialized test measuring complement activations products C4d. (lu.se)
  • Proximity ligation assays to directly visualize complement assembly in the tissue reveal dominant activation via the classical pathway, with a close correlation to the degree of glomerular C1q-binding IgG subclasses. (leibniz-hki.de)
  • 4 , 13 Complement plays a crucial role in host defense against foreign bodies by promoting phagocyte-mediated clearance of cell debris through activation of an inflammatory response, opsonization of pathogens, and lysis of susceptible bacteria and cells. (jrheum.org)
  • Complement activation is known to occur in many diverse renal diseases, including glomerulonephritis, thrombotic microangiopathies and transplant rejection. (wjgnet.com)
  • Patients with aHUS are currently treated with eculizumab while there is no specific treatment for other complement-mediated renal diseases. (lu.se)
  • Insidious attack of cortical neurons by complement has been implicated in Alzheimer's and other neurodegenerative diseases. (duke.edu)
  • In collaboration with clinicians we are studying molecular mechanisms of complement involvement in these diseases. (lu.se)
  • Peptides offer a number of advantages, including being highly selective and potent, allowing low dosage volumes for ease of administration, and having the potential to treat a broad range of complement-mediated diseases. (businesswire.com)
  • 10 This review aims to provide an assessment of the nature and extent of complement involvement in the underlying pathophysiology of TMA associated with autoimmune diseases that will help to stratify patients for targeted therapy. (jrheum.org)
  • These in vitro findings predict that a fleeting excitotoxic insult could act synergistically with complement to destroy cortical neurons and accelerate neurological deterioration. (duke.edu)
  • The purpose of this review is to provide a latest summary of biomarkers associated with endothelial cell activation in COVID-19 and offer mechanistic insights into the molecular basis of endothelial activation/dysfunction in macro- and micro-vasculature of COVID-19 patients. (nature.com)
  • This process includes diffuse activation of inflammatory and coagulation cascades, vasodilation and vascular maldistribution, capillary endothelial leakage, and dysfunctional utilization of oxygen and nutrients at the cellular level. (medscape.com)
  • Mechanisms leading to T-cell activation in drug hypersensitivity. (bdbiosciences.com)
  • Membranous nephropathy (MN) is an antibody-mediated autoimmune disease characterized by glomerular immune complexes containing complement components. (leibniz-hki.de)
  • Activation of the classical pathway (CP) of complement is often associated with autoimmune disorders in which disease pathology is linked to the presence of an autoantibody. (ashpublications.org)
  • We identified complement factor H as an important independent genetic modifier of SIRS/sepsis. (figshare.com)
  • Recently we have studied the ability of an enzymatically modified form of LDL (E-LDL), obtained by treatment with trypsin and then cholesterol esterase, to activate C1, the complex that triggers activation of the classical pathway of complement. (europa.eu)
  • In conclusion, these data indicate that PTX3 might be a potential therapeutic target to prevent Complement-induced I/R injury. (unicatt.it)
  • The binding of MBL to mannose and N-acetyl glucosamine in micro-organisms leads to the activation of MASPs, which subsequently cleave C4 and C2. (abcam.com)